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Z U S A M M E N FA S S U N G
Anfang 2011 wurde am Heidelberger Ionenstrahl-Therapiezentrum HIT die ex-
trakranielle Stereotaxie zur Behandlung des Hepatozellulären Karzinoms einge-
führt. Zunächst wurden dreizehn Patienten behandelt, einschließlich des ersten
Patienten mit atemgesteuerter Bestrahlung (Gating). In dieser Arbeit werden der
neu eingeführte Behandlungsablauf und die Datenerfassung für die Behandlung
bewegter Organe vorgestellt. Aufgrund der Patientendatensätze sind simulierte
und rekonstruierte zeitabhängige 4D-Dosisverteilungen der Bestrahlungen ver-
fügbar.
Simulationen von 4D-Dosisverteilungen erfordern genaue Kenntnis der Or-
ganbewegung und korrekte Vorhersagen des Zeitverhaltens des Beschleunigers.
Um die Vorhersage zu verbessern, wurden die Eigenschaften des HIT-Synchro-
tron-Zyklus untersucht; bei dieser Untersuchung wurden energieabhängige und
stochastische Aspekte sowie tägliche Schwankungen der Strahlintensität fest-
gestellt. Eine Simulation-Software wurde implementiert, die auf einem realis-
tischen Modell des Beschleunigers beruht. Die Genauigkeit der errechneten Be-
strahlungsabläufe wurde mit Bestrahlungsaufzeichnungen überprüft. Eine ex-
perimentelle Überprüfung des Algorithmus wurde anhand eines Patienten-Be-
handlungsplans in einem bewegten Wasserphantom durchgeführt. Hierbei wur-
de eine Dosisabweichung von (1.0± 7.3)% ermittelt.
Seit Ende 2012 eröffnet die HIT-Schwerionen-Gantry neue Bestrahlungsmög-
lichkeiten. In einer Planungsstudie wurden die optimalen Plangeometrien für
die Behandlung von Ösophagus-Karzinomen ermittelt. Grundlage der Studie
waren vier Patientendatensätze und dreizehn vorgeschlagene Plangeometrien.
Über eine quasi-statische Dosisberechnung wurden die Effekte von intrafraktio-
neller Organbewegung berücksichtigt. Die berechneten Dosisverteilungen kön-
nen als Grundlage für die Definition von Sicherheitssäumen und Gatingfenster-
größen dienen.
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A B S T R A C T
In 2011, stereotactic body radiotherapy was introduced for the treatment of hepa-
tocellular carcinoma at the Heidelberg Ion-Beam Therapy Center (HIT). Initially,
thirteen patients were treated, including the first patient treated using respira-
tory beam gating. This thesis presents the work flow and data acquisition for
the treatment of moving organs. Based on the acquired patient data, simulated
and reconstructed 4D dose distributions are now available.
Simulations of 4D dose distributions require precise knowledge of the organ
motion and accelerator timing. To improve the prediction, the properties of
the HIT synchrotron cycle were investigated, revealing energy-dependent and
stochastic aspects and day-to-day beam intensity fluctuations. A simulation was
implemented based on a realistic model of the accelerator. The accuracy of calcu-
lated irradiation sequences was verified using treatment records. Experimental
verification using a patient treatment plan was performed in a moving water
phantom, where a total dose deviation of (1.0± 7.3)% was determined.
Since 2012, the HIT heavy-ion gantry offers new treatment options. In a treat-
ment planning study, optimal plan geometries for the treatment of esophageal
carcinoma were determined. Effects of intrafractional organ motion were ac-
counted for in a quasi-static dose calculation. Results can potentially be used for
margin and gating window definition.
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I N T R O D U C T I O N
Tumor diseases are the second most common cause of death in the developed
countries, surpassed only by diseases of the cardio-vascular system. In 2015,
39% of all deaths in Germany were attributed to cardio-vascular diseases, 25% to
tumor diseases1. Furthermore, 44% of women and 50% of men can be expected
to develop cancer in their lifetime2.
In this thesis, the focus is on two tumor localizations: Cancer of the liver, which
is responsible for 2% of cancer related deaths in women and 4% in men, and can-
cer of the esophagus, responsible for 1% of cancer related deaths in women and
3% in men. In 2014, 13, 000 patients died from cancer of the liver and esophagus
in Germany, with increasing numbers expected in the upcoming years. Viable
treatment options for liver and esophageal cancer are limited, which is reflected
by low five-year-survival rates. Only 11% of women and 14% of men diagnosed
with liver cancer, and 21% of patients diagnosed with esophageal cancer survive
five years after the diagnosis.
Studies at the National Institute of Radiological Sciences, Chiba, Japan (NIRS)
suggest carbon ion therapy may be a viable treatment option for hepatocellular
carcinoma, with five-year-survival rates increased to 33% (Kamada et al. (2015)).
Studies on the efficacy of treating esophageal carcinoma with carbon ions have
not been published yet, but carbon ion therapy has been shown to be beneficial
in treating adenoid cystic carcinoma (Jensen et al. (2015)) and highly conformal
irradiations have been shown to be beneficial in esophageal carcinoma (Carring-
ton et al. (2016)). Hence, highly conformal carbon ion boosts could increase local
control and survival rates.
Particle therapy has been pioneered in the Lawrence Berkeley National Lab-
oratory, USA. Here, the first patients were treated with proton beams in 1954.
In 1974, the first patients received treatment with heavy ions. To offer particle
therapy to an increasing number of patients, the first dedicated proton therapy
facility started operation in 1990 at the Loma Linda University Medical Center,
USA. The first dedicated carbon ion therapy facility followed in 1994, when the
Heavy-Ion Medical Accelerator Complex in Chiba, Japan, started its operation.
In Germany, carbon ion therapy has been pioneered at the GSI Helmholtz Centre
for Heavy Ion Research in Darmstadt, where patients were treated in a dedicated
clinical treatment room. From 1997 to 2008, over 440 patients were irradiated us-
ing carbon ions with an active raster scanning technique. After the success of
this pilot project, the Heidelberg Ion-Beam Therapy Center (HIT) was built as
a dedicated clinical ion beam facility, which began patient operation in Novem-
ber 2009. In October 2012, the first patients were irradiated using the heavy ion
gantry.
Organ motion is an issue when treating tumors of the thorax and abdomen,
where daily variations of the patient anatomy may require plan adaptations. Ad-
ditionally, the liver moves by 1 to 2 centimeters due to breathing motion and
1 See: Statistisches Bundesamt (Destatis) (2017)
2 See: Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in
Deutschland e.V. (Hrsg.) (2017)
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heart palpitation (Langen and Jones (2001); Liang et al. (2018)). In combination
with fluence-modulated radiotherapy (IMRT or IMPT), the interference between
the fluence pattern and the organ motion can negatively impact the resulting
dose distribution (Phillips et al. (1992); Bert and Durante (2011)). This can have
a detrimental effect on the treatment outcome. Several mitigation strategies are
available, including passive techniques like motion reduction, rescanning, and
margin concepts; and active techniques like beam gating and beam tracking.
Further, 4D treatment planning systems are being developed which include or-
gan motion in the dose calculation and can be used to simulate or reconstruct
doses delivered to patients (Richter et al. (2013a,b)).
Most research relevant to this thesis has been performed in close collaboration
with the GSI biophysics research group. Because of the similarities between the
techniques used in the pilot project and the HIT facility, results and new devel-
opments from GSI can be directly integrated into clinical research at HIT. The
cooperation between Heidelberg University Hospital, German Cancer Research
Center (DKFZ), National Center for Tumor Diseases (NCT) and GSI has led to
the creation of a German Research Foundation (DFG) founded clinical research
group, which started in 2009. Research topics include the therapy of gastro-
intestinal tumors including beam gating (Richter et al. (2014)), adaptive planning
for prostate and pancreatic cancer (Rucin´ski (2013); Batista (2016); Batista et al.
(2018)), and 4D treatment plan optimization (Richter et al. (2013b)). This work
was funded by the German Research Foundation as part of the clinical research
group KFO 214 Heavy Ion Therapy.
scope of this thesis
The integration of new therapy concepts, developed in collaboration with the
GSI biophysics research group, into the clinical routine of patient therapy at HIT
is the main focus of the work done in this thesis. It is presented in three main
parts:
• Adaptation of the treatment work flow for the treatment of patients suffer-
ing from hepatocellular carcinoma. From May 2011 to July 2013, thirteen
patients were treated using this work flow, including the first beam gat-
ing patient at HIT. Here, the data acquisition necessary to simulate and
reconstruct dose distributions is presented.
• Development and introduction of an improved simulation of the HIT accel-
erator timing structure, necessary for accurate predictions of dose distribu-
tions and variability. The model is verified using irradiation records and
measurements in a moving water phantom.
• Presentation of a treatment planning study for esophageal cancer, using
the newly available heavy ion gantry at HIT. Organ motion is taken into
account using a simplified quasi-static dose calculation approach.
Chapter 2 is dedicated to the research fundamentals relevant to this thesis.
Chapter 3 describes the improved treatment work flow introduced for the treat-
ment of hepatocellular carcinoma. Chapter 4 covers the improved accelerator
timing simulation necessary for 4D dose calculation. Chapter 5 presents an
esophagus treatment planning study which aims to find the optimal treatment
geometry for the new heavy ion gantry.
2
M AT E R I A L S A N D M E T H O D S
In this chapter, the fundamentals of ion beam therapy will be described. This
encompasses the physical and radiobiological properties of ion beams, an outline
of the Heidelberg Ion Therapy Center (HIT), the properties of the treatment
planning software used in this thesis and the basic principles of treating moving
organs.
2.1 fundamentals of ion beam therapy
Megavoltage photon beams from linear accelerators or radioactive sources are
widely used in radiotherapy. In comparison, beams of high-energy ions such
as protons or heavier elements offer advantages beneficial to the treatment of
tumors: While the entrance dose in tissue is low, the depth-dose distribution
exhibits a distinct maximum and steep fall-off (Bragg peak) with a well-defined
range. Ion beams have a small lateral spread and especially heavier particles
have an increased biological effectiveness in the Bragg peak region due to higher
density ionization. These properties make ion beams well suited for the treat-
ment of radio-resistant tumors located near organs at risk.
2.1.1 Physical Properties of Ion Beams
absorbed dose One of the fundamental quantities of radiation therapy is
the absorbed dose D. All biological effects of radiotherapy (like cell death and
tumor control) are linked to the energy dose deposited in tissue. It is defined
in the ICRU report 90 (Seltzer et al. (2014)) as the mean energy imparted by
ionizing radiation dε¯ in a given volume to a mass element dm:
D =
dε¯
dm
[1Gy = 1 J/kg] (1)
The imparted energy ε is defined as the sum of all energy deposits εi in the
volume:
ε =
X
i
εi, with εi = εin − εout +Q (2)
Each energy deposit εi is the result of a single interaction of an incoming
particle. εin is the energy of the incident particle and εout is the sum of the
energies of all particles leaving the interaction. Q is the change in rest energies
of all involved particles.
mass stopping power The mean energy loss dE of a particle traversing a
distance dl in a material of density ρ is described by the mass stopping power S/ρ:
S
ρ
=
1
ρ
dE
dl
, with S =
dE
dl
(3)
as the linear stopping power.
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In general, the mass stopping power is described by three components:
S
ρ
=
1
ρ
dE
dl el
+
1
ρ
dE
dl rad
+
1
ρ
dE
dl nuc
, (4)
where the first term is the mass electronic stopping power due to ionization or
excitation of atomic electrons, the second term is the mass radiative stopping power
due to emission of bremsstrahlung and the third term is the mass nuclear stopping
power due to elastic Coulomb interactions with the nucleus of an atom.
The typical range requirement for radiotherapy using charged particles is
30 cm, which translates to particle energies of 220 MeV for protons and 430 MeV/u
for carbon ions. At this energy, the energy loss is dominated by inelastic colli-
sions with target electrons, described by the electronic stopping power term. Ra-
diative stopping power is relevant for interactions of electron or positron beams,
but is reduced by a factor of (me/M)
2 for ions, where me is the rest mass of the
electron and M is the rest mass of the incident ion. Nuclear stopping power is
only relevant for ions of low kinetic energy.
A calculation of the electronic stopping power for charged particles has been
performed by Bethe, using the first Born approximation (Bethe (1930); Fano
(1963)). For the interaction of heavy ion beams with electrons, the assumption
me << M can be used to arrive at the modified Bethe-Bloch formula:
1
ρ
Sel =
1
ρ
dE
dl el
=
4πr2emec
2
β2
Z
uA
z2 · B (β) , (5)
where B(β) is the stopping number per electron:
B (β) = ln
2mec
2β2
(1−β2) I
−β2 −
δ
2
−
C
Z
+ zB1 + z
2B2. (6)
Here, re is the classical electron radius, c is the speed of light in vacuum, β is
the velocity of the particle v divided by c, Z is the charge of the target nucleus, z
is the charge of the projectile, u is the atomic mass constant and A is the relative
atomic weight. I is the mean excitation energy of the medium. This formula
contains the Barkas correction zB1, Bloch correction z2B2, shell correction C/Z
and density-effect correction δ (Bloch (1933a,b); Seltzer et al. (2014)).
particle range Assuming a continuous loss of energy for a particle travers-
ing through matter, its path length can be calculated from the initial energy using
the mass stopping power. The approach is called continuous-slowing-down approx-
imation (CSDA) and the mass CSDA range is defined as:
ρ r0 (E0 → Efin) = ρ
ZE0
Efin
1
S(E 0)
dE 0, (7)
with the initial particle energy E0 and a final particle energy Efin, which is usually
the lowest ionization potential of the medium (Seltzer et al. (2014)). Note that,
due to angular deflections in the medium, the CSDA range is not the same as
the penetration depth.
energy loss and range straggling The Bethe-Bloch formula only de-
scribes the mean energy loss of a charged particle. Taking only the Bethe formula
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into account, the energy loss of an ion beam would result in an extremely sharp
dose peak towards the end of its path. In reality, the energy loss is a stochastic
process and the energy loss and range is different for each individual ion, an
effect known as energy loss straggling. This leads to a broadening of the peak.
For particles traversing a thin layer, these fluctuations are described by the
Vavilov distribution (Vavilov (1957)). For practical reasons, the energy loss can
be approximated as a Gaussian distribution (Bohr (1940); Ahlen (1980)). The
ratio of the straggling width σR and mean range R can be expressed as
σR
R
=
1√
M
f E/Mc2 , (8)
where E is the energy and M is the mass of the ion. f is a slowly varying
function of particle energy and mass. For light ions stopping in water, σR/R
is approximately 1 : 1000. Due to the difference in mass, range straggling of
protons is approximately 3.5 times larger than of carbon ions of similar range.
In practice, range straggling is also introduced by inhomogeneities in the tar-
get tissue. For practical reasons, a broadened peak is desired in spot- and raster-
scanning techniques and may be enhanced using a ripple filter. This reduces the
number of planes to be irradiated and increases the speed of irradiation.
lateral beam spread In general, ion beams show a small lateral deflection
in comparison with electron or positron beams. While the stopping of an ion
beam is mainly due to electronic interactions, the lateral spread of an ion beam
is the result of elastic Coulomb interactions with the target nuclei. Physically, this
effect is well described by Molière scatter theory (Molière (1948)) and has been
confirmed by high energy proton beam experiments (Gottschalk et al. (1993)).
One result of the theory, relevant for particle therapy, is that lighter particles
are deflected more at similar ranges. A proton beam at a mean range of R =
15.6 cm shows an angular beam spread more than three times larger than a
carbon ion beam of the same range (Schardt and Elsässer (2010)).
nuclear fragmentation While nuclear interactions have almost no effect
on the energy loss of an ion beam, they have other effects which are significant at
larger penetration depths. At high beam energies, collisions between projectile
and target nuclei lead to the beam particles losing one or more nucleons. This
is described in the abrasion-ablation model (Serber (1947)). In this model, parts
of the nuclei are sheared off, creating lighter (low-Z) fragments of the projectile
and target nucleus.
In carbon ion therapy, this means a loss of primary beam particles and build-
up of lighter fragments. At higher beam energies, lighter fragments can comprise
a significant fraction of the particles in the peak region. Usually, the lighter
fragments have a longer range, creating a dose tail behind the Bragg peak.
One advantage of this effect is the creation of PET-active 10C, 11C, and 15O
fragments. This is useful in PET imaging for in-vivo range verification (Parodi
(2004); Parodi et al. (2007, 2008); Bauer et al. (2013b)).
bragg peak A prominent reason to use charged particles for radiotherapy is
its inverted dose profile with the Bragg peak, named after Sir William Henry Bragg,
who discovered the effect when he investigated the stopping of alpha particles in
air (Bragg and Kleeman (1905)). Robert Wilson proposed the use of protons and
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Figure 1: Mass Stopping Power S/ρ of a carbon ion beam used at HIT as a function of
depth in water. Five beam energies have been selected: 109 MeV/u, 204 MeV/u,
276 MeV/u, 340 MeV/u and 423 MeV/u. With increasing beam energy, the range
increases. At the same time, range straggling increases, increasing peak width
and the plateau-to-peak ratio. Beam data taken from TRiP depth-dose tables.
heavy ions for precision radiotherapy (Wilson (1946)) due to the distinct narrow
peak of the dose distribution. This specific form of the Bragg peak is explained
by the 1/β2 dependence in the Bethe formula: With decreasing particle velocity,
the energy loss increases.
In Fig. 1, examples of the dose profile are shown for carbon ions used for ther-
apy at the HIT Heidelberg Ion-Beam Therapy Center. As can be seen from the
figure, the range of the beam can be precisely adjusted by changing the kinetic
energy of the ion beam. Also, the effects of range straggling and fragmentation,
which increase with the mean range R, can be observed.
2.1.2 Radiobiology
In addition to the advantageous depth-dose profile, beams of heavy ions offer ra-
diobiological benefits (Suit et al. (2010)). The increased stopping power of heavy
ions compared to photon beams results in a larger energy deposition and more
severe cell damage. This effect is larger in the peak region than in the entrance
channel, leading to an increased biological effect inside the target volume (Kraft
(2000)).
relative biological effectiveness To account for the biological effects,
the relative biological effectiveness (RBE) has been introduced. It is defined as the
ratio of the dose of X-ray irradiation DRefγ divided by the dose of ion irradiation
DIon resulting in the same biological effect (Schardt and Elsässer (2010)):
RBE =
DRefγ
DIon Isoeffect
(9)
The value of the RBE depends on several factors, including the desired effect
level (usually 1% or 10% cell survival), tissue properties and beam quality. For
proton beams, the RBE is usually assumed to be a fixed value (RBE = 1.1), except
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for the distal 1-2 mm of the Bragg peak, where an increased linear energy transfer
(LET) may cause an increased RBE (Paganetti et al. (2002)). For beams of heavy
ions, the RBE depends on the dose level (Weyrather et al. (1999); Furusawa et al.
(2000)), linear energy transfer (Belli et al. (1998); Furusawa et al. (2000)), particle
type and tissue type (Weyrather et al. (1999); Suzuki et al. (2000)).
For patient treatment, the RBE is calculated from biophysical models inte-
grated into the treatment planning software. In this study, the local effect model
(LEM), developed at GSI and integrated into the treatment planning software
TRiP, was used for all dose calculations (Scholz and Kraft (1996); Krämer and
Scholz (2000)).
photon-equivalent dose In order to facilitate the transfer of knowledge
from conventional radiotherapy, the absorbed (physical) dose D is weighted with
the RBE factor:
DBiol. (~x) = RBE (~x) ·DPhys. (~x) (10)
To distinguish this photon-equivalent dose from the absorbed dose, the weighted
dose is usually indicated as Gray-equivalent dose, abbreviated Gy (RBE).
Based on the photon-equivalent dose, results can be compared to data from
conventional radiotherapy, like tumor control probability (TCP) and normal tissue
complication probability (NTCP).
cell survival Survival probabilities of cells subject to irradiation are an
important property in the characterization of tissues and irradiation qualities.
Usually, cell survival is measured following the procedure proposed by Puck
(Puck and Marcus (1956)): One to two weeks after an irradiation with dose D, the
proliferation of cells is analyzed. Colonies with at least 50 cells are considered
as surviving and are counted. The fraction of surviving cells S is then usually
parametrized by the linear-quadratic (LQ) model (Hall (2000)):
S(D) = exp −αD−βD2 (11)
The parameters α and β are experimentally determined. The property α/β is
an important quantity in conventional radiotherapy and is also used as a basis
in the local effect model.
2.2 ion beam therapy at hit
The Heidelberg Ion-Beam Therapy Center (HIT) is a dedicated facility for proton and
heavy ion beam therapy. Patients at HIT were initially mainly treated for chor-
doma, chondrosarcoma and adenoidcystic carcinoma using active raster scan-
ning of carbon ion and proton beams. This section describes the history and
technical properties of HIT and its accelerator facility.
2.2.1 The Heidelberg Ion-Beam Therapy Center
Based on the experience gained from the experimental cancer treatment pro-
gram at GSI, the creation of a dedicated ion beam therapy facility was proposed
as early as 1998 (Debus et al. (1998); Eickhoff et al. (2000)). Initial proposals
included the installation of two heavy ion gantries, which was later changed to
two treatment rooms with fixed beam lines and one heavy ion gantry.
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Figure 2: Illustrated Overview of the HIT Facility: Starting on the lower left, low-energy
ion beams are created in ECR ion sources, accelerated by a linear accelerator
and injected into the synchrotron (upper left). After acceleration and extraction,
the beam is transferred to one of two horizontal fixed beam patient treatment
rooms (center) or to the heavy ion gantry treatment room (right).
Image: Courtesy of Universitätsklinikum Heidelberg.
Apart from this major change, most properties have been implemented as
in the early proposals (Haberer et al. (2004); Heeg et al. (2004); Eickhoff et al.
(2004)): Patients are treated using an intensity controlled raster scan method,
and both low LET ion species (protons, helium ions) and high LET ions (carbon
and oxygen) are available. Three patient treatment rooms are available, two
with a horizontal fixed beam line and one heavy ion gantry. Fig. 2 presents an
overview of the HIT facility, showing the two horizontal fixed beam treatment
rooms in the center and the heavy ion gantry on the right.
Construction of HIT started in November 2003; in June 2006, construction of
the HIT building and accelerator were completed. Beam commissioning was
finished in April 2008 (Ondreka and Weinrich (2008)) and the first patient was
treated in November 2009. In October 2012, the first patient was treated using
the heavy ion gantry (Galonska et al. (2013)). By the end of 2016, more than
3, 900 patients had been treated at HIT (PTCOG and Jermann (2017)); by July
2019, a total of 5, 725 patients1.
The HIT accelerator offers a large variation of beam parameters. Both proton
and carbon ion beams have a maximum penetration depth of up to 30 cms and
variable beam diameters and intensities. Part of the specifications was a beam
range between 20 and 300 mm in water and a dose rate of 2 Gy/min. The energy
can be varied in 255 discrete steps, each step amounting to a range difference
of approximately one millimeter. Table 1 gives an overview over the available
parameter space.
For the irradiation, a slow knock-out (KO) extraction with an extraction time
of five seconds is used. The extraction can be interrupted up to five times and
stored for up to 30 seconds for complex irradiation fields or for gated irradia-
1 Prof. Dr. Oliver Jäkel, private communication
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Parameter Steps Proton Beam Carbon Ion Beam
Energy 255 48− 221 MeV/u 88− 430 MeV/u
Penetration Depth 255 20− 300 mm 20− 300 mm
Beam Size (FWHM) 4 8− 20 mm 4− 12 mm
Intensity 10 8 · 107 − 2 · 109 1/s 2 · 106 − 8 · 107 1/s
Ions per Spill 10 4 · 108 − 1 · 1010 1 · 107 − 4 · 108
Table 1: HIT Beam Parameters (taken from Ondreka and Weinrich (2008))
tions. Further, the system has been designed to allow for fast switching of beam
properties and treatment rooms.
2.2.2 Composition of the HICAT Accelerator Facility
At the heart of HIT, the Heavy Ion Cancer Therapy (HICAT) accelerator facility
generates the ion beams necessary for patient treatment. It has been specifically
designed for clinical use, offering proton and carbon ion beams for clinical op-
eration. Because the properties and working principles of the accelerator are
crucial in understanding the work done in Chapter 4, they are presented more
detailed in the next section.
2.2.2.1 Overview
The HICAT accelerator was designed as a therapy accelerator for proton and
carbon ion beams. To be usable in a clinical setting, a compact design, highly
reliable beam operation, and a low number of critical components were part of
the design criteria (Dolinskii et al. (2000)). Further, the accelerator should be ca-
pable of quickly switching ion species and treatment rooms, making a combined
treatment with protons and carbon ions possible.
Each step of the acceleration is shown in Fig. 2. An ion beam is generated in
one of three ECR ion sources. This low-energy beam is transferred to the linear
accelerator, where it is accelerated to 7 MeV/u for injection into the synchrotron.
In the synchrotron, the beam is accelerated to the desired energy. Using slow
knock-out extraction, the beam is removed from the synchrotron over the period
of five seconds. The extracted beam is transfered to one of the treatment rooms,
including the heavy ion gantry. In the treatment room, the beam delivery system
uses active beam scanning to irradiate the correct position inside the patient.
2.2.2.2 ECR Ion Sources
At HIT, all ion beams are generated in one of three electron cyclotron resonance
ECR ion sources. Proton beams are generated from hydrogen gas; carbon and
oxygen ions from carbon dioxide gas and helium ions from helium gas (Winkel-
mann et al. (2014)). ECR ion sources offer stable ion beams, reliable long term
operation and are easily maintained (Tinschert et al. (2008)).
Inside an ECR ion source, a plasma of the source gas is confined in a magnetic
bottle. This plasma is further ionized using microwaves in a process called elec-
tron cyclotron resonance heating (Xie (1998)). Electrons are heated in a thin layer in
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which the microwave frequency ωf matches the electron cyclotron frequency ωc
ωf = ωc =
eB
me
, (12)
where e and me are the charge and mass of the electron and B is the local
magnetic field. The heated electrons collide with gas molecules, ionizing them
in the process and creating more plasma.
Using an electric field created by a set of extraction electrodes, a constant
stream of generated ions is extracted out of the source. At HIT, the extracted
ions have a kinetic energy of 8 keV/u.
The ion beam enters the low energy beam transport (LEBT) via an analyzing 90◦
dipole magnet. In the case of the combined carbon-oxygen source, the correct
ion species is selected here. Also, contamination of ions with different charge-to-
mass ratio are removed.
In the LEBT, the desired intensity of the ion beam is selected using an aperture
and a focusing magnet. To decrease the intensity, the beam is defocused and
more particles are stopped by the aperture. If more intensity is required, the
beam is focused and more particles enter the linear accelerator.
2.2.2.3 Linear Accelerator
Between the sources and the synchrotron, an injector linac accelerates the parti-
cles from 8 keV/u to 7 MeV/u. At this energy, ion beams can be injected into the
synchrotron more efficiently, increasing beam intensity and stability (Schlitt et al.
(2004); Maier et al. (2007)).
The linear accelerator operates at 216 MHz and consists of two stages, a ra-
dio frequency quadrupole (RFQ) and an IH-type drift tube linac (DTL). The RFQ
accelerates the ion beam to 400 keV/u. It also focuses the beam into bunches of
200 µs length, necessary for operation of the DTL. In the DTL, the ion beam is
accelerated to 7 MeV/u and enters the medium energy beam transport (MEBT).
In the MEBT, the remaining electrons are removed from the ions using a strip-
per foil, a thin layer of graphite. Here, the proton charge state changes from H1+3
to 3H1+, the carbon ions from C4+ to C6+. Again, an analyzing dipole mag-
net removes contaminating ions with differing charge-to-mass ratios. Finally, a
chopper system cuts the ion beam to 30 µs pulses, containing enough particles
for five seconds of extraction.
2.2.2.4 Synchrotron
The synchrotron is responsible for the main part of the acceleration. An injected
7 MeV/u beam is accelerated to energies of up to 430 MeV/u, which is then
extracted and transferred to the treatment rooms. This energy is equivalent to a
range of 30 cm in water (Dolinskii et al. (2000)).
It has a circumference of 65 m and consists of six dipole bending magnets with
a bending angle of 60◦ each. At the highest beam energy, the dipole magnets
operate at a flux density of 1.53 T, with ramping rates of 1.5 T/s, allowing for
acceleration within one second.
In order to increase the ion beam intensity, a multi-turn injection is used, which
uses 15 turns of the synchrotron to distribute the 30 µs pulse from the linear
accelerator in the horizontal phase plane. This increases the beam intensity by a
factor of 15 compared to the MEBT.
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The ions are accelerated using two radio frequency (RF) acceleration cavities.
In these cavities, a standing electromagnetic wave bunches and accelerates the
ion beam with each pass. To keep up with the increasing magnetic rigidity
B · ρ of the beam, the magnetic flux density of the dipole magnets is increased
synchronously to keep the beam in orbit. Depending on the requested energy,
acceleration takes 0.5 to 0.9 seconds.
2.2.2.5 Beam Extraction
When the beam reaches the requested particle energy, it can be stored for up to
30 seconds, or extracted. Due to the limited speed of the beam delivery system,
a slow beam extraction is required. At HIT, a transverse RF knock-out extraction
has been implemented (Tomizawa et al. (1993); Dolinskii et al. (2000)).
For the extraction, the ion beam is excited using a transverse electromagnetic
field. As a consequence, excited fractions of the beam leave the stable orbits
of the phase space and can be extracted from the synchrotron. By controlling
the amplitude and frequency of the excitation field, the beam extraction can be
halted and resumed later.
At HIT, the extraction lasts for up to five seconds, after which the synchrotron
is reset and prepared for the next injection of ions. Extraction can be interrupted
for up to five times, which is favourable when irradiating complex treatment
plans or for gated irradiations.
Ideally, the extracted beam intensity is characterized by a fast increase up to
the nominal intensity, which is maintained until the end of the extraction. Ini-
tially, this was not the case, leading to interlocks in the beam delivery system
and a decision to reduce the beam intensity (Peters et al. (2008)). Improvements
were made when the intensity feedback system was installed in 2013, which
increased stability and intensity (Schömers et al. (2011); Schömers (2013)). On-
going improvements are made to provide patient-specific intensity modulation
(Schömers et al. (2013)).
2.2.2.6 High Energy Beam Transport
From the synchrotron, the extracted ion beam is transported to its destination
via the high energy beam transport (HEBT). In addition to the three treatment
rooms, a quality assurance room is available for beam diagnostics and research
purposes. If the beam is not required in any room, it can be safely disposed of
using a beam dump in the HEBT.
All treatment rooms are using the same synchrotron and treatment can only
be performed in one room at a time. If one treatment room is currently using
the beam, the other rooms have to wait until the treatment is finished.
2.2.2.7 Treatment Rooms
Patient treatments are performed in each of three available treatment rooms. Two
treatment rooms are equipped with a fixed horizontal beam line, one is equipped
with the isocentric heavy ion gantry. All beam lines, including the quality assur-
ance room, are equipped for intensity controlled rasterscanning (Haberer et al.
(1993)).
The beam position is controlled by horizontal and vertical dipole scanner mag-
nets. In the fixed beam line, the scanner magnets are located in a backroom, five
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meters from the isocenter; on the heavy ion gantry, the scanner magnets are
positioned on the gantry in front of the final 90◦ dipole magnet.
During treatment, the ion beam is monitored at all times by the beam application
and monitoring system (BAMS). It is positioned directly in front of the patient and
uses ionization chambers (IC) to measure the beam intensity and multi-wire pro-
portional counters (MWPC) to measure beam position and width. Since 2013, the
measured intensity is used to control the extraction system using the intensity
feedback system.
During therapy, the patient is positioned on a treatment couch which is sup-
ported by a six-axis robotic arm. It can be used to correct minor setup inac-
curacies prior to treatment. For image guided radiotherapy (IGRT), a kilo-voltage
imaging system is available. Additionally, a patient transport system is avail-
able to transport the patient between the treatment room and an offline PET-CT
system while still immobilized.
2.2.2.8 Treatment Control System - Beam Delivery
Patients at HIT are treated using an intensity controlled raster scan method
(Haberer et al. (1993)), which is characterized by a continuous scanning motion
of the ion beam over the target volume. Active scanning techniques offer high
flexibility and a reduced neutron yield compared to passive beam shaping. Dur-
ing patient treatment, the treatment control system (TCS) supervises and controls
all aspects of the irradiation. It processes the treatment plan and generates the
list of required beam energies, raster point locations and particle numbers. It
controls the scanning system to irradiate each raster point and keeps track of the
already irradiated raster points.
To perform the irradiation, the TCS requests the necessary combination of
ion species, beam energy, focus size, and beam intensity from the accelerator
via the accelerator control system (ACS). The accelerator provides this ion beam
automatically and transports it to the treatment room via the HEBT.
During irradiation, the TCS constantly monitors the beam intensity, position
and width based on the BAMS measurements. The beam position is controlled
by the scanner magnets; any deviation from the desired beam position is cor-
rected using a position feedback system. The dose for each raster point is con-
trolled based on the beam intensity measured in the BAMS. When the charge
measured in the ionization chambers reaches a pre-calculated amount, the raster
point has received the planned number of particles and the next raster point is
selected. Without interruption, the particle beam is moved there, resulting in
a sweeping beam motion, slowing down for raster points with higher particle
numbers. Fig. 3 shows an illustration of this method.
If a beam parameter is incorrect, due to an intensity spike or a change in beam
width, the TCS issues an interlock and interrupts the treatment. The beam abort
is handled directly by the TCS, which safely stops the beam from reaching the
treatment room within 200 µs.
2.2.2.9 Heavy Ion Gantry
The heavy ion gantry offers the same intensity controlled raster scanning tech-
nique as the fixed beam line. Additionally, the beam line can be rotated freely
around the patient, offering new treatment planning options (Fuchs et al. (2004)).
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Figure 3: Intensity Controlled Raster Scan: A mono-energetic ion beam (green) is de-
flected by horizontal and vertical scanning magnets (left), while its position,
width, and intensity is monitored by ionization chambers (center). The beam
stops after a certain path length inside the target volume, releasing most of its
energy in one iso-energy slice (right).
To irradiate a volume, the beam is scanned continuously over each raster point
of an iso-energy slice of the target volume, after which the beam energy is
changed. Then, the next slice is scanned, until all slices of the target volume
are irradiated.
Image: Courtesy of Universitätsklinikum Heidelberg.
Commisioning of the gantry was finished in June 2007 (Fuchs et al. (2008)),
the first patients were irradiated in October 2012 (Galonska et al. (2013)). It has a
mass of 670 tons, of which 600 tons can be rotated, a diameter of thirteen meters
and a length of 25 meters. It can be used for proton and carbon beams over the
full energy range and offers a scanning field of 20x20 cm2. The heavy ion gantry
was designed by GSI and built by MT Mechatronics.
The treatment room is equipped with the same six-axis treatment couch as the
fixed beam lines and offers kilo-voltage IGRT.
2.2.2.10 Accelerator Control System
The HICAT accelerator control system (ACS) is a software and hardware system
which controls all aspects of accelerator operation (Bär et al. (2001); Mosthaf et al.
(2008); Bär et al. (2012)). It is designed as a real-time accelerator control system.
In order to fulfill the strict timing requirements, a real-time ethernet system (real
time bus, RTB) has been implemented to synchronize device control units (DCUs).
Each DCU controls an accelerator device like the linear accelerator, synchrotron
magnets or accelerator RF cavities with microsecond precision.
During operation, the ACS synchronizes all accelerator components, which is
crucial in several phases of the accelerator cycle (during injection, acceleration
and extraction). The exact sequence is pre-programmed into the flash memory
of the DCUs for each available combination of ion type, energy, focus size and
intensity. This process and the accelerator cycle is described in more detail in
chapter 4. During patient treatment, the ACS processes requests from the treat-
ment control system (TCS).
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2.3 treatment planning
For each patient, the treatment is prepared beforehand. Usually, specialized im-
mobilization equipment is adapted to the patient to ensure high reproducibility
of the patient position during treatment. Planning CTs and further diagnostic
images are acquired of the patient in this position and used to create individ-
ual treatment plans. The treatment plans provide the therapy machine with the
necessary instructions to create the desired dose distribution.
Treatment planning for tumors in the thorax and abdomen needs to account
for organ motion. In this section, the influence of organ motion and the possible
mitigation techniques are presented. Further, the treatment planning systems
necessary for dose optimization and calculation are discussed.
2.3.1 Treatment of Moving Tumors
During treatment, patients are immobilized using masks, stereotactic frames or
vacuum cushions. In the head and neck region as well as the extremities, this
is sufficient to reliably position the patient and to irradiate the target volume
correctly. However, in the thorax and abdomen, this is not sufficient to eliminate
the organ motion due to breathing, heart pulsation and intestinal motion due to
the filling of gut and bladder. Here, further mitigation strategies are necessary
to achieve a reliable treatment.
2.3.1.1 Characteristics and Impact of Organ Motion
Patient motion can be subdivided into two categories, inter-fractional and intra-
fractional motion. Inter-fractional motion is characterized as an irregular change
of the patient anatomy due to intestinal motion or change in tumor size. This
change is seen in between therapy fractions and can be countered by robust
planning or adaptive planning strategies. Intra-fractional motion is characterized
by a regular change in patient anatomy on a smaller time scale, due to breathing
or heart beat. It can be anticipated, for example by using 4D imaging (Rietzel
et al. (2005); Bert and Rietzel (2007); Schardt and Elsässer (2010)).
Of these sources of motion, respiratory motion and heart palpitation are the
main contributors (Henkelman and Mah (1982); Langen and Jones (2001); Liang
et al. (2018)). In this thesis, the main focus is on mitigation of respiratory motion
effects.
Respiratory organ motion is mainly translational motion. When the target
volume is close to a fixed structure, like the chest wall, the organ can also be
subject to rotational motion. The consequence of this motion is usually a change
in radiological path length or water-equivalent path length (WEPL), changing the
range of the particle beam. This effect is more important for ion beams due to
the re-positioning of the Bragg peak than for photon beam therapy.
In addition, scanning beam systems are susceptible to the interplay effect. Due
to the superposition of the scanning motion and target motion, some parts of
the target volume are irradiated more than intended, while others are irradiated
less or not at all. This interference effect leads to severe under- and overdosage
(cold/hot spots) and reduces the efficacy of the treatment (Phillips et al. (1992);
Grözinger et al. (2006, 2008); Bert et al. (2008)).
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2.3.1.2 Motion Mitigation Techniques
IMRT and particle therapy with scanned ion beams share similar characteristics
and face similar challenges due to organ motion. Therefore, mitigation strategies
used in particle therapy have been inspired by the experience made in photon
therapy (Langen and Jones (2001); Keall et al. (2006); Rietzel and Bert (2010); Bert
and Durante (2011); Korreman (2012)).
motion reduction One passive approach is the reduction of the motion
amplitude. For example, the breathing motion can be reduced via breath-hold
commands or jet ventilation during the irradiation. For irradiation of the upper
abdomen, belly compression plates can be used to reduce the organ motion.
Finally, relaxation drugs can be administered to the patient to reduce motion
amplitude.
margin concepts The ICRU reports 50 and 62 describe a margin concept, in
which the target volume is expanded to encompass setup errors and changes in
target position (Landberg et al. (1993, 1999)). For the management of moving
organs, the addition of an internal margin (IM) to the clinical target volume (CTV)
is proposed to compensate for movement and size variation of the CTV. The
sum of the CTV and the internal margin is the internal target volume (ITV). This
ITV encompasses the CTV during the whole motion.
Using the internal margin is feasible in static field irradiations, although the
dose to normal tissue and organs at risk is usually increased by this strategy.
In ion beam therapy, the use of margins alone is not sufficient for the mitiga-
tion of interplay effects. It can however be used in combination with gating or
rescanning techniques.
rescanning/repainting In rescanning, a treatment plan is divided into
multiple scans and irradiated repeatedly for a statistical dose-averaging effect.
Assuming no correlation between the irradiation and the organ motion, the vari-
ance of the dose can be decreased a factor of 1/
√
N by irradiating N repetitions.
For this technique, the particle fluence has to be reduced for a precise dose
application which leads to longer irradiation times. Further, with increasing
motion amplitude, the steepness of the dose gradient is reduced.
beam gating For beam gating, the respiration is monitored during treatment
and the irradiation is only activated when the respiratory cycle is in between pre-
defined limits. This way, the residual motion during the irradiation is reduced.
Some of the residual interplay effects can be mitigated by an increased overlap
of beams, for example by increasing the beam focus size and decreasing the
raster spacing (Bert et al. (2009)).
Due to the pauses introduced by the gating technique, treatment times are
increased compared to irradiations with continuous beams.
beam tracking Beam tracking or online motion compensation performs a 3D
compensation of the target motion in real time. The motion of the target volume
is monitored during the irradiation and the position of the treatment beam is
adjusted to match the current position. Ideally, this results in the same dose
distribution in the target volume as in the static case, independent of motion
amplitude, and treatment times are relatively unaffected.
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Beam scanning techniques are a good starting point for beam tracking, as
the treatment beam is already actively scanned by the scanner magnets and can
be used to follow a moving target volume. Still, the approach is technically
challenging, especially the energy change needed for range adaptation (Amaldi
et al. (2004); Amaldi and Kraft (2007)).
In practice, combinations of different motion mitigation techniques are em-
ployed for the treatment of patients with moving target volumes. Further, on-
going improvements in image guided radiotherapy will likely improve the treat-
ment quality (Mori et al. (2013)).
2.3.2 Treatment Planning Systems
Treatment plans are a set of instructions for a specific treatment machine, used
to create a desired dose distribution. For example, a raster scanning treatment
plan contains the gantry angle, ion species and energies, raster point positions
and particle numbers for each irradiation field.
A treatment plan is created using a treatment planning system (TPS), which
uses a volumetric image (usually a treatment planning CT image) and a physical
beam model to calculate the resulting dose distribution. Most TPS may display
additional images such as Magnetic Resonance Images (MRI), Positron Emission
Tomography (PET) or time-resolved 4D-CT images for the delineation of target
volumes and organs at risk.
For advanced treatment methods using fluence modulation (IMRT and IMPT),
the treatment plan is created using inverse planning. An optimization algorithm
uses a cost function which takes into account the dose to the target volume, the
organs at risk and the normal tissue to determine the treatment plan quality. The
particle fluence pattern is then adjusted to create the desired dose distribution.
All treatment plans used in this thesis have been created using this technique.
Three different TPS have been used in this thesis: TRiP and TRiP-4D, devel-
oped at GSI Helmholtz Centre for Heavy Ion Research, and syngo® RT Planning,
developed by SIEMENS AG. TRiP was originally created for the treatment of
patients during the pilot project at GSI, it is now used for research purposes.
TRiP-4D is a development version of TRiP and capable of 4D dose optimization
and calculation. syngo® RT Planning is the commercial TPS used for patient
treatment at HIT.
2.3.2.1 GSI TRiP
Treatment Planning for Particles, 1998 edition (TRiP), is a TPS for ion beams devel-
oped at GSI (Krämer et al. (2000)). It was used for treatment planning during
the GSI pilot project (Jäkel et al. (2001b)), in which more than 400 patients were
treated.
TRiP has been designed for the pencil beam active scanning system in use at
GSI and HIT (Haberer et al. (1993)). It offers a double gaussian pencil beam
model and a dose optimization algorithm, including biological dose calculation
via the local effect model (LEM, Scholz and Kraft (1996); Krämer and Scholz
(2000)). The conversion from the electron density represented in the Hounsfield
units (HU) of the treatment planning CT to water-equivalent path length (WEPL)
2.3 treatment planning 17
necessary for dose calculation is performed using a Hounsfield Look-Up Table
(HLUT, Jäkel et al. (2001a)).
Beam data and most other physical and biological properties are provided by
external text files, which gives TRiP the flexibility to work with different particle
types, accelerators and treatment rooms, such as the SIS at GSI, HICAT at HIT,
the horizontal treatment rooms and the heavy ion Gantry at HIT. As a command
line tool, dose calculations can be scripted and processed in a computation clus-
ter.
In this thesis, TRiP was used to carry out the esophagus treatment planning
study as well as calculating static dose distributions for the experiments.
2.3.2.2 GSI TRiP-4D
TRiP-4D is a 4D treatment planning system based on TRiP and has been devel-
oped further to offer 4D dose calculation and optimization. 4D dose calculation
is necessary to quantify effects of motion and interplay.
4D treatment planning capabilities have initially been incorporated by Bert
and Rietzel (Bert and Rietzel (2007)), including support for gating, rescanning,
tracking and calculation of internal target volumes (ITV). Later developments by
Gemmel (Gemmel et al. (2011)) allow the calculation of biological dose. TRiP-4D
was further integrated for clinical use by Richter, who implemented interfaces
for data input and contour models (Richter (2012); Richter et al. (2013b)).
4D treatment planning systems use time-resolved computed tomography (4D-
CT) for dose calculation (Rietzel et al. (2005)). 4D-CT uses helical imaging span-
ning the whole motion cycle and allows the reconstruction of multiple motion
phases, equivalent to a time series of conventional CTs. Deformable (non-rigid)
image registration is used to calculate deformation vectors from one motion
phase to another, usually using one phase as a reference. These vector fields
are used for contour propagation and 4D dose calculation. Contours of target
volumes and organs at risk are usually not available on each motion phase and
manual delineation is time-consuming and impractical. Using vector fields, con-
tours existing on one CT can be automatically transferred to another. Based on
the 4D-CT and propagated contours, an internal target volume can be calculated.
In the case of particle therapy, variations of the radiological path length need to
be taken into account.
TRiP-4D calculates the time-resolved dose distribution by distributing the par-
ticle fluence of the treatment plan to several motion phases, based on the patient
motion and irradiation time. For each motion phase, an independent dose calcu-
lation is performed. The final dose distribution is then calculated by deforming
the dose grid using the deformation vector information and calculating the dose
sum in one reference motion phase (Gemmel et al. (2011)).
Similar to TRiP, TRiP-4D is modular and uses a variety of data sources as in-
put. Motion phases of 4D-CTs are converted from DICOM CTs. Deformation
vector fields are calculated using Plastimatch (Sharp and Plastimatch Develop-
ment Team (2011)) and converted to TRiP-4D format. Motion surrogate data
can be imported from a wide range of sources. In this thesis, patient motion was
recorded using the ANZAI AZ-733V system, which records the breathing motion
of a patient using a piezo-electric load cell. Irradiation timing information can
be imported from the therapy control system (TCS), which records each patient
treatment, or simulated using an accelerator model.
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In this thesis, TRiP-4D was used for the dose calculations performed for the
stereotactic body radiotherapy of the hepatocellular carcinoma patients and to
test the accelerator simulation.
2.3.2.3 SIEMENS syngo® RT Planning
syngo® RT Planning is the commercial treatment planning system used for treat-
ment planning at HIT. It has been developed by SIEMENS AG. In contrast to
TRiP and TRiP-4D, syngo® RT Planning is licensed as a medical product and
can therefore be used as a TPS for the treatment of patients. It is part of the
Record and Verify treatment system syngo® PT Treatment, which is responsible
for DICOM communication with the picture archive (PACS) and the treatment
control system, as well as integration of contouring and treatment verification.
Similar to TRiP, it is capable of dose optimization and calculation for proton
and carbon ion beams. However, in contrast to TRiP-4D, it is not a 4D TPS and
incapable of 4D dose calculation.
In this thesis, syngo® RT Planning was used for the treatment planning of the
hepatocellular carcinoma patients. In addition, the static dose calculations were
used as a reference for the experimental verification.
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I N T R O D U C T I O N O F A N E W W O R K F L O W F O R L I V E R
I R R A D I AT I O N S
In the time between May 2011 to July 2013, the first thirteen patients suffering
from hepatocellular carcinoma were treated using stereotactic body radiotherapy
(SBRT) at the Heidelberg Ion-Beam Therapy Center (HIT). These irradiations
included the first patient treated using beam gating at HIT. To facilitate dose cal-
culation accounting for intra-fractional organ motion, the 4D treatment planning
system TRiP-4D was introduced. The necessary data acquisition and processing
is presented in this section.
3.1 introduction
Worldwide, tumors of the liver are the third most common cause of cancer-
related death and the fifth most common type of tumor (Parkin et al. (2001)).
In some parts of Asia, Hepatocellular Carcinoma (HCC) is the most common
cause of cancer-related death. It is less common in Europe and the USA, albeit
with an increase in incidence and mortality (Deuffic et al. (1998); El-Serag and
Mason (1999); Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiolo-
gischen Krebsregister in Deutschland e.V. (Hrsg.) (2017)), which is attributed to
an increase in Hepatitis C infections, liver cirrhosis and alcohol consumption.
When diagnosed in an early stage, HCC may be treated curatively using sur-
gical resection, liver transplantation, or local therapies (radio-frequency ablation,
chemo-embolisation) (Llovet et al. (2003)). Unfortunately, only 30 to 40% of pa-
tients in the developed countries are diagnosed in the initial stages. In advanced
stages, therapy options are limited to palliative treatment with poor prognosis,
although liver transplantation may be a viable treatment even for unresectable
hepatocellular carcinoma patients exceeding the Milan criteria (Mazzaferro et al.
(1996, 2009)). Naturally, increasing patient numbers and limited availability of
donor organs increase the waiting times.
External beam radiotherapy of HCC is limited by the low dose tolerance of the
surrounding normal liver tissue. Doses of 30 to 35 Gy, delivered to the whole
liver, are causing radiation induced liver disease (RILD) (Lawrence et al. (1992)),
which can be avoided by reducing the high-dose volume in highly conformal
radiotherapy (Robertson et al. (1993, 1997)). Tumor control can be further in-
creased by the application of higher doses (Park et al. (2002)). Stereotactic body
radiotherapy (SBRT) with photons has been successfully used for the treatment
of HCC and liver metastases with high local control and low toxicities (Blomgren
et al. (1995); Herfarth et al. (2000); Wulf et al. (2000); Timmerman et al. (2003);
Combs et al. (2010); Petrelli et al. (2018)).
Offering high dose conformity and radiobiological benefits, therapy of HCC
with carbon ion beams is a promising approach to increase local control and
reduce toxicities. To evaluate the efficacy of carbon ion radiotherapy, a Phase-I
study for the treatment of patients suffering from HCC was proposed for imple-
mentation at HIT (Combs et al. (2011)). This chapter will present the technical
details of the treatment of these patients.
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Focus of this Study
Most patients at HIT are treated for intracranial lesions and tumors of the head-
and-neck region. For those patients, inter- and intra-fractional motion can usu-
ally be neglected or is already compensated by the usual image guided radiotherapy
(IGRT). Depending on the tumor position, inter- and intra-fractional motion in
the liver is 1 to 2 cm (Langen and Jones (2001); Liang et al. (2018)), which nega-
tively impacts the dose distribution and treatment quality (Phillips et al. (1992);
Bert and Durante (2011)). This study presents the additions to the work flow
currently in use for patient treatment at HIT, introducing organ motion mitiga-
tion techniques as well as the steps necessary for calculating reconstructed dose
distributions.
This includes further development and introduction of a 4D treatment plan-
ning system (4D TPS), initiated at the GSI Helmholtz Centre for Heavy Ion Re-
search. This 4D TPS software, called TRiP-4D, is capable of dose calculation
based on motion phases of 4D-CTs and calculation of dose distributions subject
to organ motion (4D dose distributions). Additionally, it is able to calculate auto-
matically propagated organ contours and internal target volume (ITV) margins
based on non-rigid registration information.
In this study, the TRiP-4D software is utilized for the first time in a realistic
clinical work flow with the goal of showing the feasibility of using the 4D TPS
in this context. Based on this, more information should become available to the
clinical staff for treatment planning and therapy decisions. In preparation for
this work flow implementation, the compatibility of TRiP-4D with the different
data sources at HIT was integrated by Daniel Richter (Richter et al. (2013b)). Re-
viewing this integration with all data sources and discovering useful alternative
data sources is also researched in this study.
Finally, this study covers the necessary data acquisition to calculate the impact
of organ motion on the dose distribution. Prior to the treatment, simulated dose
distributions are of interest for the treatment planning and to ensure safe treat-
ment of the patient. After treatment, reconstruction of the actual in-vivo dose
distribution is of interest to assess the treatment outcome. To calculate this, 4D
images, breathing motion curves and irradiation records must be acquired. From
this information, deformation maps can be derived to calculate 4D dose distri-
butions using TRiP-4D (von Siebenthal et al. (2007a,b); Richter et al. (2013a,b)).
This complements the TPS in use at HIT, syngo® RT Planning, which is currently
not capable of 4D dose calculation.
For the first time at HIT, beam gating is used during patient treatment. This
includes more detailed data acquisition ahead of the treatment for the recording
of breathing information as well as additional imaging and the acquisition of
4D-CTs to measure the extend of the target volume motion and to define an ITV.
In addition to the introduction of TRiP-4D and the necessary data acquisition,
other additions are made to the patient work flow, introducing new immobiliza-
tion equipment and pre-treatment imaging. Immobilization using thermoplastic
mask systems is sufficient for high-precision radiotherapy in the head-and-neck
region. For the extra-cranial SBRT, additional immobilization equipment is in-
troduced to reduce the residual motion and intra-fractional variability, such as
vacuum cushion and belly compression systems (Herfarth et al. (2000)). Position
verification of the patient during the treatment is usually performed using con-
ventional X-ray imaging, which is sufficient for high precision treatment of the
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head-and-neck region but has low soft-tissue contrast. In this study, an offline
PET/CT scanner is used for improved IGRT. For transportation of the patient
between the CT scanner and the treatment room, a new patient transport system
is introduced.
3.2 research background
3.2.1 4D Treatment Planning Development at GSI
All advanced motion mitigation techniques introduced in this study are based on
developments and research performed at the GSI Helmholtz Centre for Heavy
Ion Research. This encompasses the use of the 4D treatment planning system
TRiP-4D, which was developed by the GSI biophysics research group.
TRiP was initially conceived by Michael Krämer as a TPS for patient treatment
planning during the GSI pilot project (Krämer et al. (2000); Krämer and Scholz
(2000)). It was later expanded by Christoph Bert and Eike Rietzel to allow the
calculation of motion effects (Bert and Rietzel (2007)). This 4D TPS was lim-
ited to the calculation of physical dose, which was later corrected by Alexander
Gemmel (Gemmel et al. (2011)), who added the capability of biological 4D dose
calculation.
As a part of the clinical research group KFO-214, Daniel Richter extended
the functionality of TRiP-4D to allow the usage of different clinical sources of
information (Richter (2012); Richter et al. (2013b)). This integration into a com-
mon framework facilitated the use of TRiP-4D and allowed the start of clinical
integration.
Out of the features offered by TRiP-4D, several are of high interest in clinical
routine and have been selected for integration into the current work flow:
• Integration of breathing-motion resolved 4D-CTs for 4D dose calculation
and calculation of deformation vector fields
• Integration of an advanced contour model which allows the automatic
propagation of patient contour information to all 4D-CT motion phases
based on deformation vector fields and the automated calculation of ITVs
• Processing of breathing motion information for simulation and reconstruc-
tion of 4D dose distributions
• Reconstruction of 4D dose distributions of patient treatments, including
gated irradiations
Integration of each feature requires data acquisition during a specific step of
the patient treatment work flow. In this study, the necessary data acquisition
and processing are described, as well as the new information available from the
TRiP-4D calculations.
3.2.2 The Clinical Work Flow at HIT
For most patients treated at HIT, one common work flow is used. This work
flow, designed with mainly head-and-neck patients in mind, is the basis for the
liver irradiation work flow and is described here.
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Figure 4: Overview of the clinical work flow common to all patient treatments per-
formed at HIT.
At HIT, approximately 700 patients are treated per year (PTCOG and Jermann
(2016, 2017)), equivalent to 14 new patients each week. For this reason, physi-
cians, radiographers, technicians and physicists have to work coordinated to
provide the best possible treatment decision, patient immobilization, treatment
plan and irradiation. This is done in a work flow pattern shown in Fig. 4. It con-
sists of six steps: Patient presentation, immobilization and imaging, contouring,
treatment planning, treatment plan verification and patient treatment.
3.2.2.1 Patient Presentation (1)
At first, the patient and a physician discuss the treatment options, possible side
effects and patient specific topics, like previous therapies and chronic conditions
which could interfere with the treatment. The physician then decides if the
radiotherapy is justified or not (“Rechtfertigende Indikation”), sets the aim of
the treatment (curative or palliative) and prescribes the treatment dose.
3.2.2.2 Immobilization and Imaging (2)
In a next step, the patient is prepared for CT imaging using immobilization
devices, for example thermoplastic masks, casts, vacuum cushions or leg rests.
They are individually adjusted for each patient and ensure the same positioning
for each treatment fraction, as well as increased comfort during the treatment.
When the immobilization equipment is adjusted, the patient is transferred to
CT scanner, immobilized again and a treatment planning CT image is created.
This CT image is used as the basis for contouring and treatment planning. In
addition, more diagnostic imaging can be added, for example using contrast
agents. If necessary, permanent markings are tattooed on the patient’s body to
reproduce the body position during therapy.
3.2.2.3 Contouring (3)
Using the treatment planning CT as well as overlayed diagnostic images (for
example, PET, diagnostic CT or MRI images with or without contrast agents),
physicians or technicians delineate target volumes and organs at risk. This yields
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three-dimensional representations of the tumor volume, the patient’s organs and
other structures, for example markers or implants, which are the basis for treat-
ment planning.
3.2.2.4 Treatment Planning (4)
In treatment planning, the treatment plan is created, which defines the patient
positioning, couch and treatment beam angles, particle energies and fluence pat-
terns which will be used during treatment to create the desired dose distribution.
This complex task is performed using a treatment planning system (TPS), syngo®
RT Planning, which takes into account the treatment planning CT and the con-
tours created in step 3.
syngo® RT Planning is an inverse planning TPS, which optimizes the fluence
based on a cost function using weighted dose constraints defined on the target
volumes and the organs at risk. The TPS then calculates the biological dose
resulting from this fluence. Once the resulting dose distribution is satisfactory,
the resulting treatment plan and its corresponding dose distribution is checked
and approved by medical physicists and physicians and ready for treatment.
Initially, syngo® RT Planning was not capable of calculating the resulting dose
on a CT other than the treatment planning CT. Due to this limitation, a re-
calculation of the resulting dose on a multiphase CT or an optimization taking
into account the motion of the target volume was not possible.
3.2.2.5 Treatment Plan Verification (5)
Before any treatment plan is used in patient treatment, it is first irradiated into
a water phantom. Using a set of ionization chambers, the resulting dose is mea-
sured and compared to the dose distribution calculated in the TPS. This way, the
calibration of the machine and the accuracy of the TPS can be monitored and the
physicists can decide if the treatment plan is safe for the patient. Treatment plan
verification is a standard approach for all advanced treatment techniques like
IMRT (Intensity-Modulated RadioTherapy) or IMPT (Intensity-Modulated Parti-
cleTherapy). In addition, if the treatment plan is yielding too many interlocks
during irradiation, which can be the case for some combinations of energy, inten-
sity or focus size settings, the treatment plan is re-planned to ensure a reliable
treatment plan.
3.2.2.6 Patient Treatment (6)
Finally, the patient returns to the hospital for treatment. Inside the treatment
room, he or she is positioned with the help of the immobilization equipment
already used in step 2 to reproduce the same position in which the treatment
planning CT was created. Based on the tattooed markings and X-ray radiogra-
phy, the patient is positioned with sub-millimeter precision in front of the beam
port and the irradiation is started.
The patient treatment is usually fractionated, hence the patient returns on
weekdays for the course of up to two months. On each therapy day, this step
is repeated, until all fractions of the series have been irradiated and the full
dose has been applied. In hypofractionated or certain stereotactic treatments,
the patient may only receive one to eight treatment fractions.
In addition to the treatment, the patient is examined regularly by a physician
to ensure that the treatment is tolerated well. Sometimes, changes to the patient’s
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Figure 5: Patient Presentation: Physicians decide if the patient should receive particle
therapy, gather relevant information and relay them to the physics staff.
anatomy require a re-planning on a new CT. In this case, the work flow is
repeated from step 2. After the final treatment, follow-up appointments are
scheduled, in which the well-being of the patient and the progress of the tumor
growth is closely monitored.
3.3 results
This previously introduced usual work flow (Fig. 4) is well suited for most pa-
tients which are treated in the head or head-and-neck region, where organ mo-
tion can largely be neglected. For patients suffering from hepatocellular carci-
noma, with larger inter- and intra-fractional motion of the target volume due to
breathing and bowel motion, this work flow must be adjusted to ensure a high
quality of treatment. In the following section, the measures taken to account
for intra- and inter-fractional motion are presented as well as the resulting new
information which is available due to this new work flow.
In the scope of this thesis, thirteen patients with hepatocellular carcinoma were
treated in the time from May 2011 to July 2013. For each patient, the author and
a small team of medical physicists accompanied the work flow steps to introduce
new treatment techniques and to acquire patient data. The details of each step
in this work flow as well as the differences to the common work flow and the
additional information gained is presented in the following sections.
3.3.1 Integration of TRiP-4D into the HIT Work Flow
In collaboration with the physicists at GSI and HIT, as well as the physicians
and technicians of the University Hospital of Heidelberg, several additions to
the usual work flow were made. For each step of the work flow, a graph is
used to illustrate the traditional tasks of the medical and physics staff (light blue
boxes) and the new tasks performed by the research group (green boxes). In
addition, the flow of information (white boxes) and newly gained information
(yellow boxes) are shown, see Figs. 5, 6, 12, 14, 16 and 17.
3.3.1.1 Step 1: Presentation of the Patient
While the first step of the work flow is very similar to the usual work flow,
physicians now also decide if the patient should receive a treatment with carbon
ions or even a treatment using gated irradiation. If so, information relevant to
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Figure 6: Immobilization and Image Acquisition: The acquisition of a breathing curve
and the reconstruction of more motion phases with subsequent calculation of
non-rigid image registration are introduced. Both are used for the calculation
of dose distributions subject to organ motion.
the treatment, like general health problems, difficulty breathing or lying down
as well as anxieties is gathered and used for treatment decisions.
If the physicians decide to use particle therapy, the medical physics staff is
informed of this decision and can start the preparations for data acquisition.
Fig. 5 shows a graphical representation of this step.
3.3.1.2 Step 2: Immobilization and Image Acquisition
In this step, several additions are made to the work flow: The patient is immo-
bilized using vacuum cushions and a belly compression plate, a breathing curve
is acquired using the ANZAI AZ-733V system and 4D-CT images are acquired.
Furthermore, the breathing motion data and 4D-CTs are processed for use with
TRiP-4D. This part of the work flow is represented in Fig. 6.
patient immobilization : Most patients at HIT are treated using thermo-
plastic mask systems for immobilization. The patients suffering from hepatocel-
lular carcinoma are immobilized in a supine position using various immobiliza-
tion equipment from IT V (Innovative Technologie Völp, Austria). A vacuum cush-
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(a) (b)
Figure 7: Patient Immobilization: (a) The vacuum cushion and arm rest which are used
to stabilize the patient and reproduce the patient’s position during treatment.
(b) The belly compression which is used to reduce the breathing motion ampli-
tude.
(a) (b)
Figure 8: Acquisition of breathing curves: (a) The ANZAI AZ-733V belt and pressure
sensor used to record the breathing motion. (b) Recording the breathing mo-
tion using the ANZAI AZ-733V system.
ion (BodyFIX BlueBAG TOTAL BODY), ranging approximately from the shoul-
ders to the knees, and an arm rest (WingSTEP) are used to ensure a reproducible
body position and to keep the patient’s arms outside of the irradiation field. Ad-
ditionally, a belly compression (BodyFIX Diaphragm Control) is used. This plate,
kept in place using a carbon frame and a screw, compresses the abdomen. Due
to this compression, the patient cannot breathe in as deep as before and has to
resort to a shallower breathing motion, hence reducing the motion in the upper
abdomen. The vacuum cushion and belly compression equipment is presented
in Fig. 7.
Some patients did not tolerate the belly compression. As a result, the motion
of the target volume was considered and discussed by medical physicists and
physician. If the motion was small enough, the patient was treated without
compression. This immobilization strategy had already been introduced earlier
for photon SBRT at Heidelberg University Clinic and was adapted for use at HIT
(Herfarth et al. (2000)).
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acquisition of breathing curves : When the patient is immobilized, a
breathing motion curve is acquired for 10 to 20 minutes. This motion curve is the
basis for later dose simulation calculations. In addition, the patient’s tolerance to
the immobilized state and the regularity of the breathing motion can be tested.
Based on this information, physicians and physicists can decide if the patient
can be subject to gated irradiation.
Acquisition of the breathing motion is performed using the ANZAI AZ-733V
system, provided by ANZAI MEDICAL CO., LTD, Japan. It measures the motion
of the chest wall using a pressure sensor (called a “Load Cell”) inside a flexible
belt around the thorax. When the patient breathes in, the pressure on the sensor
increases, which is registered by the sensor port and wave deck electronics and
relayed to a laptop computer which stores the motion data. Fig. 8 shows an
overview of the setup. The same system is used for the acquisition of the 4D-CT
and in the treatment room.
For the actual acquisition, the patient was told to breathe in a normal way,
without speaking, for 10 to 20 minutes, simulating a regular irradiation time.
When the patient became accustomed to the immobilization and had a regular
breathing pattern, the motion amplitude was normalized and the acquisition
started. In some cases, if the breathing was very regular and the patient coop-
erative, the belly compression was removed and another breathing curve was
acquired, using the same amount of time.
Two examples of breathing motion curves are shown in Fig. 9, acquired over
the time of ten minutes for two different patients. Breathing curve (a) was ac-
quired from a patient who tolerated the belly compression. The patient exhibits
a regular breathing pattern and almost no shift of the baseline and amplitude. If
the patient breathes like this in a gated irradiation, one would expect an quick
treatment without the need to adjust regularly.
Example (b) is from another, less compliant patient. The patient did not tol-
erate the belly compression, exhibited other motion (due to moving, coughing
or talking) and a shift of the baseline. As the ANZAI AZ-733V system uses
amplitude-based gating windows, such a patient could only be treated if the
breathing curve was re-normalized during treatment, which would prolong the
total treatment time.
Based on the acquired breathing motion curves, physicians and physicists can
now decide more reliably if a patient should be treated using gating techniques
or not. In addition, the breathing motion information is used in all dose calcula-
tions involving organ motion and can now be used in the simulations before the
actual treatment.
acquisition of planning and 4d ct images : When the breathing mo-
tion has been recorded, patient and immobilization equipment are transferred to
a SIEMENS SOMATOM Sensation Open CT scanner. The patient is immobilized
again and three series of CT images are acquired: A treatment planning CT with-
out contrast agent, a 4D-CT triggered by the breathing motion, and a diagnostic
CT using contrast agent. While the acquisition of the planning CT and contrast
agent CT are standard procedure, the acquisition of 4D-CTs was not done for
patients treated at HIT before.
To acquire the 4D-CT, the patient’s breathing motion is once again detected
using the ANZAI AZ-733V system. Fig. 10 (b) shows the patient inside the CT,
with the ANZAI AZ-733V system to the left. During a continuous CT scan, the
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Figure 9: Breathing Curves of two different patients: (a) Compliant patient with belly
compression, the patient exhibits a regular breathing pattern with constant
amplitude, higher frequency and without baseline drift. (b) Non-compliant
patient who did not tolerate the belly compression and exhibits a very irregular
breathing pattern, in part due to moving, talking or coughing.
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(a) (b)
Figure 10: CT Aquisition: (a) All immobilization equipment is transferred to the CT
scanner. (b) The patient is immobilized again for treatment planning imaging.
To the left, the ANZAI AZ-733V system is visible which is used for triggered
acquisition of 4D-CT images.
patient’s breathing motion is also recorded. The acquisition settings are chosen
so that each patient region is scanned at least once in each motion phase (from
full inhale to full exhale and to full inhale again). After acquisition, the CT
sinograms are sorted according to the motion phase in which they were created
and reconstructed. When reconstruction is finished, a set of CTs is available,
each CT corresponding to one motion phase.
post-processing of the acquired ct images : When all CT images
have been acquired, some post-processing of the image data has to be performed:
Some 4D-CT motion phases have to be reconstructed manually and sent to the
central image storage system (DICOM PACS). Then, all images have to be ex-
ported for processing in external software.
By default, only eight 4D-CT phases are reconstructed by the CT software:
Four phases of the inhale period (20%, 25%, 50% and 75% lung volume) and
four of the exhale period (100%, 70%, 40%, 0% lung volume). For a more accu-
rate dose calculation, missing phases are reconstructed in 10% increments (In0%,
In10%, . . . , In100% (inhalation), Ex100%, Ex90%, . . . , Ex0% (exhalation)). This is
done manually in the CT software following the image acquisition. The CT im-
ages are then transferred to the DICOM PACS of HIT for treatment planning.
Most of the data processing and dose calculation software for research pur-
poses must not be installed on a computer which is also used for the treatment
of a patient (a medical product). Likewise, some calculations were performed in
a computing cluster without connection to the HIT DICOM network. To allow
for this, the patient data was exported, anonymized and further processed on
research computers using a set of DICOM tools specifically written for this task.
For all further calculations, the images are sorted, cropped to a similar length
and co-registered.
non-rigid image registration : With the planning CT and the 4D-CT
available, it is now possible to calculate a non-rigid registration between them
and among individual motion phases. The displacement of organs due to breath-
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Figure 11: Image Registration: Two motion phases of a 4D-CT are shown in green and
purple. The corresponding vector field, calculated using Plastimatch, is repre-
sented using green arrows.
ing motion is represented as a vector field and is the basis for 4D dose calcula-
tion.
Using the free open source software Plastimatch (Sharp and Plastimatch De-
velopment Team (2011)), the transformation vector fields of the patient’s motion
are calculated. The non-rigid registration is carried out using the built-in B-spline
method of the Plastimatch register command. Plastimatch provides a vector field
of the displacement, ~ur,i, between motion phases r and i. It is connecting the
position of point ~xr in reference motion phase r to its position ~x 0i in motion phase
i:
~x 0i = ~xr + ~ur,i(~xr). (13)
Fig. 11 shows a result of this calculation. Two phases of a 4D-CT are over-
laid in green and purple, the different positions of the diaphragm and liver are
clearly visible. In addition, the green arrows show the projection of the calcu-
lated motion vectors in this plane.
Registration between the planning CT and the 4D-CTs is performed in two
steps: First, the registration between the treatment planning CT and one ref-
erence phase of the 4D-CT is calculated, usually 0%Ex. Then, the registration
between the reference phase of the 4D-CT and all other motion phases is cal-
culated. This reduces the necessary number of registrations between motion
phases.
The transformation vector field can now be used in TRiP-4D for further calcu-
lations. It is necessary for the calculation of 4D dose distributions (the dose is
calculated in separate motion phases and must be summed up in the reference
phase). It can also be used to automatically propagate contours created only on
the treatment planning CT to the 4D-CT.
3.3.1.3 Step 3: Contouring
Based on the treatment planning CT and diagnostic imaging, contours of organs
at risk and the target volume are created. TRiP-4D features a new contour model
and offers the automated propagation of contours based on the deformation vec-
tor field. This encompasses an automated calculation of an ITV from propagated
CTVs, taking into account the extend of the organ motion. In this section, the
compatibility with the acquired data is tested. Fig. 12 gives an overview over
this step.
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Figure 12: Contouring: Based on the planning CT, either a physician or technician cre-
ates a set of contours. These contours can be automatically propagated to the
registered 4D-CT using vector fields.
creation of contours on the planning ct : Most of the contouring is
done in the same way all patient contours are created at HIT. Using commer-
cial contouring software provided by SIEMENS, specially trained technicians or
physicians look at each slice of the planning CT image and draw the outlines of
each organ at risk and of the visible tumor mass. If needed, other diagnostic im-
ages can be overlayed, such as contrast agent CTs, MRI and PET images. In this
way, contours of the organs and the Gross Tumor Volume (GTV) are created. Based
on clinical experience, physicians also delineate the areas in which microscopic
tumor growth is expected, yielding the Clinical Target Volume (CTV).
To account for organ motion, a physician now estimates the motion of the tar-
get volume from the 4D-CTs. This is done by measuring the motion of the liver
or visible lesions in or near the CTV. The maximum excursion in all three di-
mensions is added as an additional margin around the CTV to form the Internal
Target Volume (ITV). An additional margin is added for known uncertainties due
to patient setup, particle range and imaging uncertainties. This Planning Target
Volume (PTV) is later used for treatment planning.
calculation of automatically propagated contours : Contours are
not only used for therapy planning, but also for evaluation of the treatment plan.
To evaluate the quality of a treatment plan after dose calculation on the 4D-CT,
the contours must be available on this CT as well. However, creation of contours
by hand is a time-consuming and error-prone task, depending on the complex-
ity of the treatment. Therefore, automated propagation of contours from the
planning CT to the registered 4D-CT using the vector fields can help the process.
Fortunately, TRiP-4D contains a newly added feature for automated contour
transfer.
To propagate the contours, they are first exported from the HIT PACS as
DICOM files and converted into TRiP format. Using the vector fields calculated
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(a) Planning CT (b) 4D-CT, Motion Phase Ex0%
Figure 13: Automated Contour Propagation: Patient volumes are transferred from the
planning CT to the reference phase of the 4D-CT. While the PTV (green),
CTV (outer purple), liver and lung (both yellow) have been transferred well,
the GTV and RF-ablated volume (innermost purple) show artifacts from a
malformed vector field. In orange, an ITV has been created from all 4D-CTs.
in step 2, TRiP-4D is then used to propagate the contours to the reference phase
of the 4D-CTs and further to all other motion phases.
Based on the transformed CTVs in all motion phases, TRiP-4D can then be
used to calculate an ITV based on the transformation vector fields. This calcu-
lation can be an alternative to the usually used estimation of the motion of the
target volume and adding this as a margin.
The resulting volumes are shown in Fig. 13. The contours, taken from the
planning CT, have been transferred to the Ex0% reference phase of the 4D-CT. In
this case, the contours of the organs (liver and lung in yellow), PTV (in green)
and CTV (outermost purple) have been transferred well and without artifacts.
For the contours of the GTV and RF-ablated volume (medium and innermost
purple), some artifacts are visible. Hence, when working with automated con-
tour propagation, the user should at least check the quality of the transferred
contours. In orange, the ITV created from all combined CTVs is shown. This vol-
ume is created automatically by TRiP-4D and can be used as a basis for robust
4D treatment planning.
3.3.1.4 Step 4: Treatment Planning
With the treatment planning CT and the patient contours available, medical
physicists now create the treatment plan. As for all patients treated at HIT,
treatment planning is done with the commercial treatment planning software
SIEMENS syngo® RT Planning. This treatment plan is exported from the HIT
PACS and converted to a TRiP-compatible format. Using the treatment plan and
the information acquired in the previous steps, a simulated 4D dose can now be
calculated using TRiP-4D, as shown in Fig. 14.
treatment planning : Patient treatment is based on the PROMETHEUS-
1 study design (Combs et al. (2011)), which proposes a hypo-fractionated dose
escalation study starting at 4× 10.0 Gy (RBE) and incrementing the fraction dose
by 1.0 Gy (RBE) up to 4× 14.0 Gy (RBE), depending on the toxicity. In this study,
only carbon ions are used.
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Figure 14: Treatment Planning: A treatment plan is created using the commercial TPS
SIEMENS syngo® RT Planning. Based on the treatment plan and the informa-
tion acquired in earlier steps, a 4D dose can now be simulated. This dose
distribution can be helpful in decision making or defining a gating window.
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(a) Original Treatment Plan (b) Reconstructed on Ex0% of the 4D-CT
Figure 15: Re-Calculation on a 4D-CT: Original treatment plan calculated on the treat-
ment planning CT in the SyngoPT treatment planning system, re-calculated
dose on the Ex0% phase of the 4D-CT using TRiP. This calculation can deter-
mine if the dose coverage is sufficient in all motion phases or if there is an
increased dose to organs at risk, in this example the spinal cord.
All treatment plans used a single treatment field with a gantry angle of 90◦
(horizontal), the treatment couch was positioned perpendicular to the beam
(270◦) so that the particles entered the patient from the right. If the belly com-
pression bracket was in the way, the couch angle was altered. For target volumes
on the cranial end of the liver, breathing in could result in an overshoot of dose
into the spinal cord. In this case, the couch angle was also adjusted.
Treatment plans were created using the commercial SIEMENS syngo® RT Plan-
ning treatment planning system. At the time of this study, this TPS could not
be used for dose calculation on motion phases of the 4D-CT. Hence, treatment
planning with this TPS could not take the effects of organ motion into account.
4d dose simulation using trip-4d : As with the CT images and the con-
tour data, the treatment plan is exported from the HIT PACS as a DICOM file
and converted into a TRiP compatible treatment plan file. In combination with
the 4D-CT, registration information and the patient’s breathing curve, TRiP-4D
is now used to calculate a 4D dose distribution.
In the simplest approach, instead of using the original treatment planning CT,
TRiP is used to calculate a static dose using a single motion phase of the 4D-
CT, ignoring all further motion and interplay effects. This simple reconstruction
of dose can already reveal areas of over- or underdosage and can be used to
determine the size of a gating window, for example if the PTV is not covered at
full inhalation. Fig. 15 shows the result of such a calculation, and the esophagus
treatment planning study in Chapter 5 uses the same approach.
In the example of Fig. 15, the liver moves downwards and partially out of
the therapy beam when the patient inhales. In certain cases, this can lead to an
increased dose in the spinal cord. Using this information, the decision to adjust
the treatment plan or to use a gated treatment can be made.
Alternatively, it is also possible to do a more sophisticated 4D dose simulation
using TRiP-4D. Using the known breathing motion curve from the immobiliza-
tion step, 4D-CT images, non-rigid registration vector fields and the treatment
plan, a 4D dose distribution is calculated which takes into account the effects of
organ motion.
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In the 4D calculation, TRiP-4D determines which part of the treatment plan
is irradiated during each motion phase of the patient. In order to do this, the
breathing motion curve is used to determine in which motion phase the patient
is at a certain point in time of the irradiation. Additionally, an accelerator sim-
ulation is used to determine when each part of the treatment plan is irradiated.
The treatment plan is then split up into several treatment plans with correspond-
ing motion phases. TRiP-4D then calculates the dose irradiated in each of the
4D-CT motion phases. Using the vector fields, the dose is then transformed and
summed up on the reference motion phase, usually Ex0%.
In comparison to the static dose calculation, this approach can be more accu-
rate, taking into account interplay effects. On the other hand, the quality of the
dose calculation depends on the quality of the input data and the reliability of
the accelerator simulation.
Calculation of simulated dose distributions from data acquired based on the
work in this thesis is discussed in more detail in Richter et al. (2011).
3.3.1.5 Step 5: Treatment Plan Verification
Like in the usual treatment work flow, verification measurements are carried
out to guarantee that the treatment plan is irradiated correctly by the treatment
machine and yields the correct dose distribution. Furthermore, the accelerator
records from the irradiation are exported and used for improved dose calcula-
tions. Further, an advanced verification setup is introduced to assess the impact
of motion on the dose distribution and can also be used to verify a gated irradi-
ation.
improved dose simulation : During verification, the treatment plan is ir-
radiated into a water phantom with 24 pin-point ionization chambers. This mea-
surement detects deviations from the computed dose distribution, errors in the
dose prescription and determines if the accelerator provides the treatment in the
necessary quality and without interlocks. In addition, the accelerator records
of this irradiation give the most accurate information on the timing structure
during treatment.
The accelerator records are now exported from the therapy control system
(TCS) and converted into a TRiP-compatible format, a Beam Delivery Sequence, in
the form of an LMDOUT file. Using TRiP-4D, this information is used to cal-
culate a more accurate and reliable dose distribution. Fig. 16 gives an overview
over this step.
This improved dose distribution, as well as the results of the verification, can
be used to decide if a treatment plan can be administered to the patient or if it
should be re-planned.
advanced verification techniques : In addition to the water phantom
normally used in treatment plan verification, a small water phantom, mounted
on a QUASAR(TM) Respiratory Motion Platform, was introduced. This water phan-
tom can be shifted horizontally based on a supplied motion trajectory. The setup
is also used in Chapter 4 and shown in Fig. 46 on page 85.
When the recorded breathing motion of the patient is supplied to the motion
platform, the water phantom moves in a similar pattern as the organs of the
patient. By repeating the irradiation using this moving platform, more informa-
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Figure 16: Treatment Plan Verification: Accelerator Records, created during the treat-
ment plan verification, are used to calculate more reliable 4D dose distribu-
tions.
tion can be obtained from the verification which is important for the 4D dose
calculation.
By irradiating the treatment plan into the moving water phantom, the result-
ing dose measurements can be compared to 4D dose calculations using TRiP-4D.
This is an important check of the dose calculation software and can reveal prob-
lems in the data acquisition or dose calculation settings.
Further, the ANZAI AZ-733V respiratory gating system can be attached to
the QUASAR(TM) Respiratory Motion Platform and the whole verification can be
repeated in gated mode. In this mode, the gating system enables and disables
the beam based on the motion amplitude. Based on this, the performance of
the gating system can be checked as well as the approximate duration of the
treatment using gated irradiation.
Also, as the accelerator simulation of TRiP-4D does not include gating as of
this study, this is the only way of calculating simulated dose distributions for
gated treatment.
3.3.1.6 Step 6: Patient Treatment
Several additions were made to the usual work flow for the actual patient treat-
ment, both to improve treatment quality and to acquire data for the reconstruc-
tion of the actual dose distribution. In this step, the most intense changes to the
work flow were introduced.
Prior to each treatment, a CT image is acquired to detect inter-fractional mo-
tion and setup inaccuracies. The patient is then transferred to the treatment
room using a newly introduced patient shuttle system. During treatment, the
breathing motion is recorded for later reconstruction of the applied dose to the
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Figure 17: Patient Treatment: Prior to each treatment, a CT image is acquired in treat-
ment planning quality for position verification. This image can be used for
replanning or dose reconstruction. Additionally, the patient treatment yields
accelerator records and a breathing motion curve, with which the irradiated
4D dose can be reconstructed.
patient using the ANZAI AZ-733V system. Based on this system, the first pa-
tient was treated using gated irradiation. After the treatment, the patient is
transferred back to the HIT PET/CT scanner for acquisition of activity from 11C
decay. Finally, all data sets are exported from various sources, synchronized and
converted to TRiP-compatible formats. Fig. 17 gives an overview of this step.
pre-treatment imaging : Each HIT treatment room is equipped with inte-
grated radiography equipment used for image guided positioning of the patient
prior to treatment. This system provides enough image information to accu-
rately identify the position of the bony anatomy and is therefore sufficient for
intra-cranial irradiation. Unfortunately, the contrast of the organs in the abdom-
inal regions is not high enough and image guidance requires either a cone beam
or in-room CT scanner. At HIT, pre-treatment imaging is provided by an addi-
tional PET/CT scanner next to the treatment rooms.
38 introduction of a new work flow for liver irradiations
Due to the high dose per fraction, the acquisition of a CT image prior to each
treatment is required to decide if the treatment can be administered safely. At
the beginning of each treatment, the patient is immobilized inside HIT’s PET/CT
scanner room and inserted into the scanner. A CT image of treatment planning
quality is aquired and compared to the original planning CT by a physician. If
the image is similar enough for a safe treatment, it is continued, otherwise, the
patient is irradiated on the following day. Reasons for anatomical deviations
could be large abdominal motion a or a large buildup of gas compared to the
original planning CT.
The patient is immobilized with the same vacuum cushion and belly com-
pression already used when the treatment planning CT was acquired. Also, the
ANZAI AZ-733V gating system used to measure the breathing motion is now
attached to the patient and tested. Fig. 18 (a) shows the patient inside the HIT
PET/CT scanner.
patient transport : Without interrupting the immobilization, the patient
is transferred to the treatment room. This is done using the automated shuttle
system ONCOlog PatLog, which picks up the CT couch top including immobi-
lization equipment and patient, transfers it to the treatment room and places the
couch top on top of the treatment couch.
Fig. 18 (b) shows the shuttle transporting the patient to treatment on the HIT
corridor. In automatic mode, it is capable of moving from room to room without
further interaction, following a black line on the floor. Fig. 18 (c) shows the shut-
tle in its final position inside the treatment room. The patient is then transferred
on top of the treatment couch. The whole transport from the PET/CT scanner
to the treatment room couch takes approximately five minutes, all patients toler-
ated the transport well.
treatment : To start the treatment, the patient is positioned first using per-
manent markings on the patient’s skin and the in-room laser system. Then, using
orthogonal radiography, the patient is positioned using the bony anatomy. This
final position is shown in Fig. 18 (d), with the beam nozzle coming in from the
right and the patient positioned in front of it. Before treatment starts, the AN-
ZAI AZ-733V gating system is connected to the therapy control system and to the
pressure sensor already on the patient. The system is visible in the background,
with the cable connected to the pressure sensor running along the patient’s left
side.
For improved control during treatment, the ANZAI AZ-733V control interface
and breathing motion curve is relayed to the control room, shown in Fig. 18 (e)
and (f). Here, the amplitude of the breathing motion curve is monitored during
treatment and can be recorded. If the patient is treated using gating, it is enabled
and disabled via this interface.
The resulting breathing motion curve is recorded by the ANZAI AZ-733V sys-
tem, the irradiation information is logged by the therapy control system (TCS).
The treatment information was extracted, converted to TRiP-readable formats
and synchronized. It is later used for reconstruction of the resulting 4D dose
distribution. As a backup measure, both informations were also recorded by the
Beckhoff EtherCAT real time data logging system, which is part of the accelerator
control system (ACS) and can store the data if the ANZAI AZ-733V system fails.
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Figure 18: Treatment: (a) Position Verification using the HIT PET/CT. (b), (c) Transfer
to the treatment room using the patient shuttle. (d) Patient setup prior to
treatment start. (e), (f) Data acquisition in the control room during treatment.
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(a) Fraction 1 (b) Fraction 2
(c) Fraction 3 (d) Fraction 4
Figure 19: Reconstructed dose distributions of all four fractions of a patient treatment.
Depending on the breathing motion and the accelerator timing pattern, the
dose distribution changes.
Gating was introduced as a viable motion mitigation technique in one of the
thirteen patients who were treated until July 2013. The data acquisition and
preparation is the same as in the non-gated treatments, with the exception that
the ANZAI AZ-733V system is used to enable the irradiation based on the breath-
ing pattern.
post-treatment imaging : During the irradiation, 11C and 15O nuclei are
created as fragments of carbon ions and atoms in the patient’s tissue. Both nuclei
are β+ emitters and their activity can be captured using the PET/CT scanner.
Some patients were transported back to the CT room using the ONCOlog PatLog
shuttle system where the PET activity was measured for approximately 25 to 30
minutes.
Based on this data, the PET research group performed the first steps towards
in vivo treatment verification in the clinical routine at HIT (Bauer et al. (2013a,b);
Kurz et al. (2015); Gianoli et al. (2015)). This is done by comparing the measured
activity distribution to model calculations and might at one point be able to
detect range or setup errors.
dose reconstruction : Using the data collected during treatment, it is now
possible to reconstruct the actual 4D dose distribution applied in this fraction.
The breathing motion curve and the accelerator records are exported and con-
verted into TRiP-4D compatible formats. Using this information and the existing
4D-CT information, the dose is reconstructed using TRiP-4D.
Fig. 19 shows the dose distributions calculated for all four fractions of a patient
treatment. All images use the same color-scale and all dose distributions are cuts
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in the same height of the patient. The different dose distributions are a conse-
quence of different breathing motion and accelerator timing patterns. Details
of this dose reconstruction have been published as part of the clinical research
group by Richter (2012) and by the author and Richter et al. (2013a, 2014).
In addition, the calculations can be improved by using the treatment planning
CT which is acquired daily. For some patients, a new 4D-CT was also acquired,
which could potentially also be used for improved reconstruction of the fraction
dose. Based on the reconstructed dose distributions, a physician can now decide
if the treatment should continue or if the patient treatment should be re-planned,
for example if the target volumes do not receive enough dose or there is too much
dose in an organ at risk.
3.4 summary
In the course of this study, thirteen patients suffering from hepatocellular carci-
noma have been successfully treated using a new work flow, including the first
patient irradiated using motion gating. The newly introduced data acquisition
and data processing has been shown to be compatible with dose calculation us-
ing the TRiP-4D therapy planning system and was used for the reconstruction
of individual therapy fraction dose distributions.
In the new work flow, time-resolved 4D-CTs are systematically acquired and
additional motion phases are reconstructed. The 4D images were shown to be
usable for 4D dose calculations and the calculation of deformation vector fields
using the Plastimatch software. The deformation vector fields are necessary for
4D dose calculation in TRiP-4D and for automated contour propagation.
The integration of an advanced contour model in TRiP-4D allows automated
contour propagation from the treatment planning CT to the motion phases of
the 4D-CT and automated calculation of an ITV from propagated CTVs. The
contours created at HIT could be imported into TRiP-4D and the contour prop-
agation worked, albeit with some artifacts visible in the created contours. The
automated creation of an ITV was usable, although the practical definition of the
PTV used during treatment planning did not rely on the ITV.
Breathing motion information was acquired using the newly introduced AN-
ZAI AZ-733V system. It was used during immobilization, during 4D-CT imag-
ing and during treatment. During immobilization, a breathing motion curve
was acquired to accustom the patient to regular breathing in the immobilization
equipment. This information was also later used for verification and simulation
purposes. The same equipment was used during 4D imaging to ensure the same
motion surrogate is used as during treatment. During patient treatment, the
ANZAI AZ-733V system was used for gated therapy and to acquire the actual
breathing motion during the irradiation, both in gated and non-gated irradia-
tions. The ANZAI AZ-733V data was found to be compatible with TRiP-4D and
was used for dose calculations.
All data sources were used in combination for the calculation of 4D dose dis-
tributions using TRiP-4D. This encompasses the import of DICOM CT, contour
and treatment plan information, treatment records from the therapy control sys-
tem, deformation vector information and breathing motion information. All data
sources were found to be compatible with the new TRiP-4D software.
Dose distributions can now be calculated in two different ways. Prior to the
treatment, the available information can be used to calculate a simulated 4D
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dose distribution, based on a simulated beam delivery sequence or on treatment
records from the treatment plan verification. This results in a simulated 4D dose
distribution.
During patient treatment, the breathing motion is acquired and can be used
with the treatment records to reconstruct the actual fraction dose distribution.
This results in a reconstructed 4D dose distribution. Examples of reconstructed
4D dose distributions can be found in Richter (2012); Richter et al. (2014).
In addition to the data acquisition necessary for motion-gated therapy and 4D
dose calculation using TRiP-4D, passive motion mitigation measures were intro-
duced as well. Based on the established practice at the Heidelberg University
Clinic (Herfarth et al. (2000)), vacuum cushions and belly compression systems
were successfully introduced for SBRT at HIT. To mitigate the lack of cone-beam
CT image guided radiotherapy at HIT, the PET/CT was integrated into the work
flow for pre-treatment imaging. To transfer the patient from the CT to the treat-
ment room, a patient shuttle (ONCOlog PatLog) was introduced.
3.5 discussion
While the introduction of TRiP-4D and 4D dose calculations into the work flow
for the treatment of hepatocellular carcinoma was a success, it is merely a start-
ing point for further development. With the new work flow, more information
is available for treatment decisions, but the data acquisition and processing re-
quired is both time-consuming and error-prone.
In its current implementation, the export of treatment data, synchronization
of time-critical log files and conversion to TRiP-readable format is performed
manually, taking approximately two weeks of intensive data processing and dose
calculation to arrive at a usable 4D dose distribution. All of the data processing
has to be done by researchers with intimate knowledge of the TRiP framework,
which reduces usability for non-research clinical staff.
To facilitate the use of TRiP-4D, two strategies were pursued: Automation
of the data processing and dose calculation, and integration of TRiP-4D into a
visualization solution. This way, physicians and medical physicists would be
able to get information fast and without the need to consult a research team.
Automation of the data processing has been achieved with the use of Python
scripts for automatic processing of the DICOM files used in the calculations,
including cropping of the CT images to a common length and conversion to
a TRiP-compatible file format. The creation of command-files for the automatic
calculation of registration vector fields using Plastimatch and for basic dose calcu-
lations using TRiP were also created. Unfortunately, the TRiP-4D version used in
this thesis was only available at the AIX cluster at GSI; further steps for automa-
tion were postponed until a Linux version of TRiP-4D would become available
on the HIT computing cluster.
Visualization options have been researched, with the MeVisLab framework as
a promising basis. MeVisLab is already used by other research groups at HIT, al-
lows the use of Python scripts for data processing and offers built-in visualization
options for medical images. When combined with the automated data process-
ing, this could offer the possibility to check plan quality and see the effects of a
treatment decision almost instantaneously.
In addition to improved usability by means of automation and visualization,
data acquisition could be further improved by using additional data sources.
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Currently, data from different sources must be compiled and synchronized, for
example the ANZAI AZ-733V breathing motion information and the therapy
control system irradiation records. Both data set operate on different clocks
and need manual synchronization. One solution could be the EtherCat system,
which is part of the accelerator control system. This system already has real-
time information on the irradiation and can accept external data input from the
ANZAI AZ-733V system. By using log files created in the EtherCat system, the
data acquisition could be further simplified and sources of error reduced.
When the automation is implemented, further research could be carried out
to decide which information is most interesting for treatment decisions, for ex-
ample, simulated dose distributions for during planning, reconstructed dose dis-
tribution after the verification measurements or reconstructed dose distributions
after the patient treatment.
3.6 outlook
During the work on the treatment work flow, two interesting research topics
were identified: For one, the simulation of the time structure of the therapy ac-
celerator is not very detailed and ignores many properties of the actual acceler-
ator. This leads to unreliable and imprecise dose calculations prior to treatment.
Additionally, the complex data preparation necessary for a 4D dose calculation
takes a lot of time and patient cooperation. Using a simplified approach for dose
calculation might be sufficient in some cases and speed up the dose calculation
process.
Therefore, in Chapter 4, the mode of operation of the HICAT accelerator in-
stalled at HIT is analyzed. Based on the the results of this analysis, an optimized
simulation of the accelerator timing has been conceived, taking into account the
energy-dependent and random properties of this accelerator. In an experimental
verification, the efficacy of this approach for the calculation of simulated dose
distributions is confirmed.
In Chapter 5, the complex 4D dose calculation approach is replaced by a sim-
plified quasi static approach for the calculation of doses in a treatment planning
study concerning esophageal carcinoma. While complex effects, like over- and
underdosage due to interplay, are not taken into account, it can be used to gain
initial insight into a treatment planning case and to decide between several plan
variations or gating window definitions.

4
A N A LY S I S A N D M O D E L I N G O F T H E H I T A C C E L E R AT O R
C Y C L E
In this chapter, the properties of the HIT accelerator are analyzed to create a
realistic energy-dependent model of the cycle timing. Based on the results, a
simulation software is developed, which allows the prediction of realistic timing
sequences for treatment plans, a key to the simulation of 4D dose distributions.
To verify the accuracy of the predicted sequences, they are compared to treat-
ment records and to experimental dose measurements using a moving phantom.
4.1 introduction
When calculating a 4D dose distribution, two important pieces of information
are necessary: The patient’s motion sequence (usually supplied in the form of
a breathing motion curve) and the accelerator’s beam delivery sequence, which
states the time in which each raster spot has been irradiated. Only when both
are precisely known, the particle fluence of a treatment plan can be assigned to
the right motion phase and the calculation of motion effects is reliable.
In the reconstruction of an already irradiated treatment plan, breathing motion
curves and accelerator information is available and can be used for calculations.
In simulations, either for analyzing a treatment plan for a single patient or as
part of a treatment planning study, the beam delivery sequence is not known
and must therefore be simulated using a sufficient accelerator model.
For the accelerator installed at HIT, the Heidelberg Ion-Beam Cancer Therapy
(HICAT) accelerator, simulation software is available which translates a treat-
ment plan into a beam delivery sequence. Unfortunately, this simulation only
models the accelerator using a simplified approach. For example, the simulation
assumes a fixed pause of 5 seconds between two acceleration cycles, when in
reality this pause has both an energy-dependent and a random aspect. Also, the
simulation assumes that the nominal beam intensity is available for treatment,
when effectively an intensity of 50 to 95% of this value is realistically used. In
this chapter, the existing simulation software is replaced by a more refined ver-
sion, taking into account various effects which influence the timing of the beam
delivery.
In the following sections, the timing properties of the HICAT accelerator are
presented. Based on this information, the model base data to be used for the
simulation is extracted from various sources. Furthermore, the fundamentals
and implementation of the beam delivery sequence simulation software are de-
scribed.
Finally, to check the validity of the simulation, the simulation results are com-
pared to machine records of a treatment plan which is regularly used for quality
assurance purposes. Additionally, verification measurements are carried out us-
ing dose measurements in a moving water phantom.
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Figure 20: The accelerator cycle: Consisting of three Macrophases (initialization, accel-
eration and reset), it is repeated until the treatment plan has been fully ir-
radiated. Phases with fixed duration are shown in cyan, energy dependent
phases in red, the non-deterministic extraction phase in green.
4.2 creation of the accelerator simulation
4.2.1 Timing Characteristics of the HICAT Accelerator
Patient treatments at HIT are performed using active raster scanning with fixed
particle energy. To cover the full treatment volume, the energy of the particle
beam is changed between each pass of the raster scan. Currently, the beam
energy can not be changed during the extraction of a continuous beam; instead,
the HICAT accelerator switches the energy between two extractions. With this
pulsed mode, approximately five seconds of beam extraction time are available,
with approximately five seconds between two extractions.
Irradiations are controlled by the therapy control system (TCS), which controls
the beam position and dose monitoring during treatment. The TCS requests the
required beam energy and intensity from the accelerator control system (ACS)
which directs the accelerator, consisting of the sources, linear accelerator, syn-
chrotron and other components, to provide the correct beam to the treatment
room.
For each beam request from the TCS, the ACS follows a programmed sequence
of events, called a synchrotron cycle, which is presented in Fig. 20. In each
cycle, the synchrotron is prepared for ion beam injection, the particle beam is
accelerated to the requested energy and extracted out of the synchrotron. Finally,
any remaining particles are removed and the accelerator is reset to perform the
next cycle. In a typical patient case, 50 to 100 cycles are necessary to irradiate
the full volume.
Regardless of the requested particle type, energy or intensity, the accelerator
cycle always consists of three distinct phases (called macrophases), which are fol-
lowed by an inter-cycle pause. To understand the behavior and timing of the
4.2 creation of the accelerator simulation 47
HICAT accelerator, it is necessary to understand the timing properties of each of
these phases and the pause.
Each macrophase is initiated by an event signal from the ACS to all devices of
the accelerator. This signal both synchronizes all devices and selects the correct
programmed sequence to accelerate the beam to the requested energy. Each
macrophase is further divided into one or more miniphases, during which certain
functional steps are performed. Miniphases are not initiated by event signals,
their starting time is calculated via an offset from the event signal and they are
mainly used for analysis and clarification.
macrophase i (initialization): This phase is initiated by the broadcast
event signal (evt_broadcast) and prepares the synchrotron for injection of the
particle beam, mainly by increasing the magnetic field of the synchrotron dipole
magnets to the necessary field strength.
This macrophase consists only of one miniphase, Initialisation (INIT). Because
the injection energy is the same for all requested particle energies and intensities,
the duration of this macrophase is always the same. In Fig. 20, miniphases with
a fixed duration are represented in cyan.
macrophase ii (beam acceleration and extraction): This phase is
initiated via the synchrotron start event signal (evt_RTBS_Start). In this phase,
the beam is injected into the synchrotron, bunched and prepared for acceleration,
accelerated to the desired energy, prepared for extraction and finally extracted
for treatment.
In terms of timing, the first two miniphases, Injection (INJ) and Capture (CAPT),
are similar to the Initialisation miniphase. Because they are performed at the
same injection energy regardless of the requested particle energy, these two
miniphases are also of fixed duration. In Fig. 20, they are represented in cyan.
The Acceleration (ACC) miniphase is different in its timing behavior. During
acceleration, the particle energy is increased gradually using a resonant radio-
frequency cavity. Synchronously, the field strength of the dipole magnets in the
synchrotron is increased to keep the particle beam from moving outwards. In
order to reach higher energies, the radio-frequency cavities are accelerating the
particle beam for a longer time.
At higher energies, the particle beam has a higher magnetic rigidity R = Bρ,
that is, a higher magnetic field strength B is necessary to achieve the same bend-
ing radius ρ. This rigidity also affects the Preparation miniphase (PREP) in which
the beam is prepared for extraction using sextupole magnets. A particle beam at
higher particle energies takes longer to be prepared for extraction.
Hence, both the durations of the Acceleration and Preparation miniphase are
energy-dependent. In Fig. 20, miniphases with an energy-dependent duration
are represented in red.
Finally, during the Extraction miniphase (EXTR), the ion beam is slowly ex-
tracted out of the synchrotron. During extraction, accelerator control is handed
over to the TCS, which determines the duration of this phase. Depending on the
requirements of the treatment plan, the beam is extracted until either all raster
points for the requested energy have been irradiated or until all particles have
been extracted out of the synchrotron. The exact duration of this phase is de-
pendent on the treatment plan, the raster points already irradiated in previous
synchrotron cycles and the actual beam intensity, as well as possible interlocks,
48 analysis and modeling of the hit accelerator cycle
gating commands or user interactions. Because of the special nature of this
miniphase, it is covered in detail later, when the accelerator model is described.
In Fig. 20, the Extraction miniphase is represented in green.
macrophase iii (accelerator reset): This phase is initiated via the syn-
chrotron stop event signal (evt_RTBS_Stop). During this phase, the remaining
particles are removed from the synchrotron and the synchrotron is prepared for
the next cycle.
When the TCS has finished irradiating all raster points of the current beam
energy or once all particles have been extracted from the synchrotron, control
of the synchrotron is returned to the ACS. Then, during the Dump microphase
(DUMP), the remaining beam inside the synchrotron is deflected upwards until
it hits a scraper target inside the synchrotron. As in the Preparation miniphase,
a beam at higher energies is more rigid, therefore the Dump microphase takes
longer for higher beam energies.
When the beam has been removed, the dipole and quadrupole magnets in
the synchrotron are conditioned. During this, the magnetic field is increased
up to a defined field strength, higher than the field strength necessary for the
highest particle energies. This creates a defined magnetic remanence in the mag-
netic yokes, necessary for precise beam steering. Finally, the current through the
dipole and quadropole magnets is reduced to zero and all accelerator parts are
returned to their idle state.
Conditioning is performed during two miniphases, Wash (WASH) and Reset
(RESET). During Wash, the magnetic field strength is increased to the maximum
level. Depending on the field strength already reached during acceleration, this
miniphase will have different durations and is therefore energy-dependent. Dur-
ing Reset, magnetic field strength is returned from the maximum level to zero,
regardless of the beam energy. Therefore, the Reset phase has the same duration
in every accelerator cycle.
Finally, the End-of-Cycle event signal evt_EOC is sent to all devices, which
prompts them to return to the idle state. Most devices return status information
to the ACS as a response.
inter-cycle pause : After each synchrotron cycle, consisting of the three
macrophases, the TCS determines if there are parts of the treatment plan left to
be irradiated. If so, the TCS sends a new beam request to the ACS, stating the
type of particle, energy, focus size and intensity level required by the treatment
plan, after which a new cycle is started by sending a broadcast event signal.
During the inter-cycle pause, both the ACS and TCS will report status infor-
mation to a database, after which the next synchrotron cycle is started. There
are no strict timing requirements for this operation and while the whole pause
usually only takes 200 to 300 milliseconds, it can take take up to 3 seconds.
While the inter-cycle pause is not energy dependent, the actual duration of
this phase is too uncertain to be considered in the fixed time category. Similar to
the Extraction miniphase, the inter-cycle pause will be covered in detail later.
summary : The HICAT accelerator is operated in a sequence of synchrotron
cycles. During the cycle, some phases are always taking the same time to com-
plete (cyan in Fig. 20), some phases exhibit a deterministic energy dependence
(red). The duration of particle extraction, controlled by the TCS, depends on
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several factors such as the treatment plan and beam intensity. Finally, the dura-
tion of the inter-cycle pause depends on database operations and has therefore
a random component.
In the following section, all necessary data to define the duration of each phase
is presented. This model base data is later used in the simulation software.
4.2.2 Determining the Model Base Data
In order to compile the model base data for the simulation, several sources have
been considered. The timing of the accelerator during operation is controlled
by the ACS, and detailed information on the duration of each miniphase can be
extracted from the control system. Additionally, to get information on the inter-
cycle pause duration, the records of an internal ACS database were evaluated.
Furthermore, the two broadcast event signals in the beginning and the end of
the synchrotron cycle, evt_Broadcast and evt_EOC, add a finite pause to each
cycle. Not being part of the macrophases or the inter-cycle pause, the duration
of this pause was measured using an oscilloscope during patient treatment.
To determine a realistic duration for the Extraction miniphase, the duration of
each raster point irradiation will later be calculated using the required particle
number and the real beam intensity. In this analysis, beam intensities were cal-
culated from irradiation records created during patient therapy, extracted from
the TCS database.
4.2.2.1 Duration of the Synchrotron Cycle Macrophases
Each device in the HICAT accelerator is controlled by a Device Control Unit
(DCU) which, for example, controls the current profile of a dipole magnet or
the amplitude and frequency of an accelerating radio-frequency cavity. In each
DCU, the sequence of set-point values required for operation is stored in flash
memory and is simply recalled when the Broadcast signal is received.
All this information can be obtained from the ACS in the form of a large XML
file. At ≈ 500 MB, this Flash Dump contains the operation information for all
DCUs of the HICAT accelerator, including the durations of the miniphases, from
which the duration of the macrophases can be calculated.
For this analysis, only the data describing the operation of the synchrotron
bending magnet power supply (S0MU1) was used. This magnet is relevant in all
three macrophases, therefore the data derived from its DCU is reliable through-
out the whole cycle.
For each of the 255 available carbon ion energies, there is a separate entry
containing the polynomial functions for voltage, current and the duration of each
miniphase in the flash dump. Using the self-written program flashdump2csv.py,
the duration of all miniphases as well as the duration of the macrophases were
extracted for each energy step.
Fig. 21a shows the duration of each Macrophase as a function of nominal en-
ergy. The solid black line is macrophase I (initialization), the dashed red line
shows the energy-dependent duration of the macrophase II (acceleration), the
dash-dotted blue line shows the duration of the macrophase III (reset). In this
graph, the duration of the extraction miniphase (EXTR) is not yet taken into ac-
count.
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Figure 21: Energy-Dependent Duration of the Accelerator Macrophases: Left, from bot-
tom to top: Initialization (black), acceleration without extraction (red) and
reset (blue). On the right, the sum of all macrophases is shown.
To test the validity of this analysis, a set of macro phase durations was looked
up using the official graphical user interface of the accelerator, Modi(DVM),
which matched the results of the analysis. Additionally, the analysis was re-
peated using old Flash Dump datasets. These were routinely created in the
course of prior changes to the accelerator configuration. Based on this informa-
tion, no deviation of the accelerator timing over the course of this analysis could
be found.
In Fig. 21b, the sum of all macrophases is plotted, exhibiting an almost linear
relation. Using linear regression, the following approximation was found:
TCycle - EXTR = 3.137+ 0.001828
[E]
MeV/u
s. (14)
Over the whole energy range, the uncertainty of this approximation is below
0.01 seconds. Therefore, this will be used later in the simulation software instead
of a look-up table.
4.2.2.2 Duration of the Inter-Cycle Pause
Between two synchrotron cycles, the ACS and TCS performs post-processing
and preparation tasks. Amongst other things, status information is saved into a
control system database. Only when all tasks are finished, the next synchrotron
cycle is initiated. Therefore, depending on the duration of these tasks, the dura-
tion of the inter-cycle pause varies.
In order to measure the duration of the pause, the status information saved
into the ACS database was used. For each synchrotron cycle, the time stamps
of the Broadcast Start (evt_Broadcast) and Broadcast Stop (evt_EOC) event signal
are available. By calculating the time difference between Broadcast Stop and the
subsequent Broadcast Start, the duration of the inter-cycle pause is easily deter-
mined.
From the database, the time stamps of all therapy mode irradiations of 39
weeks in 2012 were extracted from the accelerator. Based on this data, the du-
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Figure 22: Duration of Inter-Cycle Pauses: The majority (95%) of all inter-cycle pauses
last 200 to 300 milliseconds. In logarithmic scale, a second peak at 2.7 to 2.8
seconds becomes apparent.
rations of the inter-cycle pause were calculated, using an upper cut-off of five
seconds. From this dataset, a total of 350977 inter-cycle pause intervals were
evaluated. A histogram of the resulting distribution is shown in Fig. 22.
Out of all inter-cycle pauses, 343911 (98%) lasted for less than 0.5 seconds,
with 333434 (95%) attributed into the 0.2 and 0.3 second histogram bins. 2217
(0.6%) of all intervals were longer than two seconds, with an accumulation at 2.6
to 2.8 seconds.
The appearance of the second peak at 2.7 seconds can be explained when
looking into the operation principles of the ACS. When the Broadcast event signal
is sent to all DCUs of the accelerator to start a new synchrotron cycle, each DCU
reports back with a status signal and if they need extra time for initialization. If
any one of the DCUs does not respond to the Broadcast signal, the cycle does not
start and a second Broadcast signal is sent after 2.5 seconds, precisely the interval
seen in the data.
For approximately half of the weeks in the data set, an increased fraction of
inter-cycle pause times between 0.5 and 1.0 seconds was found, while for the
others, it was completely missing. From the available data, it was not possible
to determine the reason for this behavior; the use of special treatment plans or
accelerator settings during treatment was ruled out. Because of the minor impact
of this effect, it was decided to treat the data of all weeks equally.
In the simulation, the duration of this inter-cycle pause could simply be im-
plemented as a fixed pause of 250 milliseconds. While this is a viable approach,
the duration of the simulated pauses is instead determined by calculating a ran-
dom number which has the same probability density function as the histogram.
This way, the random nature of this pause is preserved and included into the
simulation, ensuring that all simulated irradiations are different.
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4.2.2.3 Duration of the Broadcast Delay
During the first tests of the simulation software, the pause between two con-
secutive synchrotron cycles was found to be 400 milliseconds longer than ex-
pected. When no error could be found in the analysis of the synchrotron cycle
and inter-cycle pause times, other sources of delay were investigated and found:
The broadcast delay and the finite rise time of the beam intensity.
The main reason for the delay is the finite duration of the broadcast signals.
When the ACS issues the Broadcast Start event signal, the first macrophase of the
synchrotron cycle is not immediately started. Instead, it initiates communication
between the DCUs and the ACS’s Timing Master computer, after which the syn-
chrotron cycle is started. Similarly, the Broadcast Stop event signal is also a result
of communication after the third macrophase. Therefore, the inter-cycle pause
also starts with a delay.
measuring the broadcast delay time : To quantify the duration of the
broadcast delay, direct measurements of the cycle times were carried out during
patient treatment and compared to the model base data.
Each DCU has two output jacks which can be programmed to output a 5
Volt signal for 100 ms when it receives an event signal from the ACS. Using
two DCUs and a digital oscilloscope for recording the wave forms, four different
event signals were recorded for this analysis, in detail: Broadcast (evt_Broadcast),
Synchrotron Start (evt_RTBS_Start), Extraction (evt_phase_EXTR) and Synchrotron
Stop (evt_RTBS_Stop).
To determine the broadcast delay at the start of the synchrotron cycle (TDelay 1),
the time difference between the Broadcast and Synchrotron Start event signals is
measured and compared to the expected duration of macrophase-I. The differ-
ence between the two is the broadcast delay:
TMP-I + TDelay 1 = tevt_RTBS_Start − tevt_Broadcast (15)
To determine the broadcast delay at the end of the synchrotron cycle (TDelay 2),
the time difference between the Synchrotron Stop and Broadcast event signals is
measured. This interval is as long as macrophase-III and the inter-cycle pause
plus the broadcast delay:
TMP-III + IC-Pause + TDelay 2 = tevt_Broadcast − tevt_RTBS_Stop (16)
To double-check the validity of the measurements, the duration of the second
macrophase should not differ from the model calculations:
TMP-II - Extr = tevt_EXTR − tevt_RTBS_Start (17)
And finally, the duration of the complete cycle and inter-cycle pause without
the extraction phase should reflect both delays:
TCycle - Extr + TDelay 1 + TDelay 2 = tevt_EXTR − tevt_RTBS_Stop (18)
To acquire the data for this analysis, six data sets of approximately 30 seconds
were recorded during regular patient therapy. In Fig. 23, one data set is por-
trayed, with the Broadcast signal in blue, Synchrotron Start in purple, start of the
Extraction in green and Synchrotron Stop in yellow. In total, 24 full cycles were
recorded at various carbon ion energies.
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Figure 23: Broadcast Delay Investigation: Measurement of the accelerator timing during
treatment, beginning with Synchrotron Stop (Yellow), then Broadcast (Blue),
Synchrotron Start (Purple) and start of Extraction (Green). The measured times
are compared to the model base data.
For each measured cycle, the energy-dependent duration of the macrophases
was calculated using the data from the previous analysis, the inter-cycle pause
was assumed to be 250 milliseconds long. It was then subtracted from the inter-
vals measured with the oscilloscope. Table 2 shows the results of this analysis.
Interval Difference/s
TMP-I +0.19± 0.03
TMP-III + IC-Pause +0.17± 0.06
TMP-II - Extr −0.01± 0.01
TCycle - Extr +0.35± 0.07
Table 2: Difference between simulated and measured synchrotron cycle times.
Based on this data, the duration of the broadcast delay in the beginning of
the synchrotron cycle is TDelay 1 = 190 ± 30 milliseconds, the duration of the
broadcast delay at the end of the cycle is TDelay 2 = 170± 60 milliseconds. This
is compatible with the total cycle time (TCycle - Extr) being 350± 70 milliseconds
longer than expected. In addition, macrophase-II is, within the measured un-
certainty, as long as expected. In the simulation software, the broadcast delay
duration of 350 ms is added to the pause time.
finite intensity rise time : Another delay has been identified when look-
ing at the exact shape of the beam intensity profile. When the beam is extracted
from the synchrotron using knock-out extraction, it does not immediately reach
the full intensity (Hoffmann et al. (2008); Ondreka and Weinrich (2008)). Instead,
it takes a certain amount of time for the first raster point to be irradiated. In this
analysis, the remaining 50 ms are attributed to this effect.
The sum of both effects, the omission of the broadcast delay times and the
finite rise time of the beam intensity, fully explain the 400 ms additional pause
time. This extra pause time was implemented as a fixed pause time into the sim-
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ulation. The effect of this correction is presented in the appendix, section A.2.1,
page 132.
4.2.2.4 Determination of the Beam Intensity using Irradiation Records
The duration of the Extraction phase will be calculated based on the treatment
plan using a procedure which will be described in detail later. In principle, the
simulation calculates the time ∆ti which is needed to irradiate each raster point
i by dividing the required number of particles Ni by the beam intensity I:
∆ti =
Ni
I
. (19)
For this calculation, the actual intensity of the therapy beam must be known.
Unfortunatly, the nominal intensity and the actual intensity differ by as much as
50%, which must be accounted for in the simulation. In this analysis, the ratio
between the actual beam intensity I and the nominal beam intensity INominal is
described by the Extraction Efficiency η:
η =
I
INominal
. (20)
During each patient treatment, the TCS stores the irradiation records. The
records contain the number of irradiated particles Ni and the time at which each
raster point was irradiated, ti, as well as the nominal beam intensity INominal.
From this information, the actual beam intensity Ii for each raster point can be
calculated:
Ii =
Ni
∆ti
=
Ni
ti+1 − ti
, (21)
with
ηi =
Ni
∆ti · INominal
. (22)
For each patient treatment plan, approximately 50, 000 to 100, 000 raster points
are irradiated with various intensity and energy settings. Each month, over 1000
treatments are performed. This is sufficient data to derive reliable information
on the actual intensity and the stability of the beam intensity over time.
data sets used for generating the simulation model base data :
To create the model base data set to be used in the simulation, two sets of irradi-
ation records were used:
• All patient irradiations using carbon ions from 2012-07-02 to 2012-07-31
and
• All patient irradiations using carbon ions from 2013-06-01 to 2012-07-14.
The two time periods were deliberately chosen because of a change in the
particle extraction system. In early 2013, the HICAT accelerator’s knock-out
extraction system was improved by introducing a feed-back intensity control
system as described by Schömers (2013); Schömers et al. (2013). This system
provides a more stable extraction and higher beam intensities.
In the irradiation records from 2012, the old extraction system is still in use;
in the record from 2013, all irradiations are already performed with the new
extraction system. Using both data sets, the simulation capability in both the old
and the new accelerator setup is explored.
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Figure 24: Deviation of Efficiencies in July 2012.
median daily intensity in 2012: Using the data set from 2012, the extrac-
tion efficiency η was calculated for each irradiated raster point in patient therapy
mode. In Fig. 24, the whole data set is shown, grouped by the irradiation date.
As a quick reference: The center line of the box plot marks the median value of
the distribution. The edges of the box mark the first and third quantile, therefore,
the box covers 50% of the data points. The whiskers are added at a distance of
1.5 inter-quartile ranges (IQR) from the box edges; in a gaussian distribution, this
is equal to 2, 7σ or approximately 99, 3% of all data. In addition, a transparent
scatterplot in the background of the plot gives a graphical representation of the
outlying points.
From the plot, the overall reduced intensity can be derived: During the pe-
riod, the median extraction efficiency η is between 55% to 75%. In addition, the
median extraction efficiency η can be seen to change from day to day.
The reduction of beam intensity is done mainly as a safety measure. During
extraction, the beam intensity is not completely constant and sudden increases
are expected. When the beam intensity increases during therapy, this is detected
by the TCS, and if it exceeds a safety threshold, the treatment is aborted. To keep
the rate of interlocks low, the total beam intensity was reduced accordingly.
The change in extraction efficiency can also be explained; in 2012, the HICAT
accelerator still worked without active feedback knock-out extraction, where the
beam intensity is directly proportional to the number of particles in the syn-
chrotron and therefore directly dependent on the particle number extracted from
the ion sources and injected into the synchrotron. The beam intensity from the
ion sources fluctuates slowly and their extraction current was adjusted daily.
intensity level dependency in 2012 data : To accurately describe the
accelerator in the simulation, it is crucial to know if the variation in extraction
efficiency η is uniform across all beam intensities and particle energies or not. If
it is independent, a single value is sufficient to describe the actual beam intensity,
else, a factor based on the nominal beam intensity or beam energy must be
introduced.
In Fig. 25, the extraction efficiency is presented as a function of the nominal
intensity step (η(INominal)) for three different therapy days. Already in the first
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Figure 25: Extraction Efficiency η(INominal) as a function of nominal beam intensity: For
three days in July 2012, η is plotted as a function of nominal beam intensity,
showing different and independent extraction efficiencies for each nominal
beam intensity.
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(a) Intensity I5 (1 · 107 particles/s) (b) Intensity I7 (2 · 107 particles/s)
(c) Intensity I8 (3 · 107 particles/s) (d) Intensity I9 (5 · 107 particles/s)
Figure 26: Extraction Efficiency η(E) as a function of particle energy for individual inten-
sity levels: The extracted beam intensity is mostly independent from particle
energy.
plot, Fig. 25 (a), a significant difference between the η values between each inten-
sity step can be found. Furthermore, the values change independently for each
intensity step on different days.
particle energy dependency in 2012 data : Having established a de-
pendence on the nominal beam intensity, it is necessary to investigate a depen-
dence on particle energy. In Fig. 26, extraction efficiency values of a single day
have been separated by the nominal beam intensity and shown as a function of
particle energy (η(E)). The trending line was added to the scatter plot to visual-
ize the mean value. While there are fluctuations of η as a function of energy, no
energy-dependent trend can be derived from the data.
In the accelerator model, the actual beam intensity will be accounted for by
calculating an “intensity of the day” for each of the nominal intensity levels, but
independent of the beam energy. This reflects the procedure of fine-tuning the
58 analysis and modeling of the hit accelerator cycle
Figure 27: Deviation of Efficiencies in June and July 2013. Note the higher Efficiency η
and smaller fluctuations due to the feed-back extraction. The gap end of June
was due to a scheduled accelerator shutdown. On June 9 and 10, there were
no regular patient treatments, only test-irradiations in patient mode.
beam intensity, which is performed daily by the accelerator staff. As the source
output is slowly changing, it is necessary to adjust the injection intensity to keep
the intensity at the right level, usually between 50 and 80%. As seen in the data
set, this is done independently for each beam intensity, usually before patient
treatment.
median daily intensity in 2013 : As for the 2012 data set, the extraction
efficiency η was calculated for each raster point in the 2013 data set. In Fig. 27,
the results are presented for the overall extraction efficiency.
In comparison to Fig. 24, it is apparent that the median beam intensity has
increased, with η between 85% and 100%. The median daily value of η is still
fluctuating, albeit with a reduced day-to-day variation.
This result is expected and a direct result of the introduction of the active
intensity feedback system. This system controls the rate at which the particles
are extracted, which reduces the fluctuation of the beam intensity. With less
fluctuation, the intensity can be increased without the risk of causing interlocks
during therapy.
intensity level dependency in 2013 data : In Fig. 28, the extraction
efficiency η is shown for two different dates as a function of the nominal beam
intensity. On both dates, the values for η are almost the same for the same
nominal intensity step. On both dates, the median extraction efficiency of the
intensity steps I5, I7 and I8 (1.0, 2.0 and 3.0 · 107 particles/s nominal intensity)
is close to 95%. For intensity step I9 (5.0 · 107 particles/s), the median extraction
efficiency is close to 75%
Note that there was a complete shutdown of the accelerator between the two
dates, in which parts of the accelerator were revised and the sources completely
cooled down and re-calibrated.
Reducing the beam intensity for the highest intensity level is deliberately done
due to a limited number of particles in the accelerator. The synchrotron, when
fully filled with particles, does not contain enough particles to sustain a beam
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Figure 28: Extraction Efficiencies (η(INominal)) as a Function of Nominal Intensity: After
the installation of the intensity feedback system, the beam intensity is both
higher and more stable. The highest intensity level is deliberately throttled to
80% of its nominal intensity.
extraction for five seconds at this intensity level. When the synchrotron runs
out of particles this triggers an interlock in the TCS, delaying patient treatment.
Hence, the intensity is reduced to approximately 80%.
particle energy dependency in 2013 data : In Fig. 29, the extraction
efficiency is shown as a function of particle energy, η(E). Because all data sets
for the lower intensity levels I5 to I8 (1.0 to 3.0 · 107 particles/s) are similar in
this plot, they are shown in the same window (Fig. 29 (a)). The data for intensity
level I9 (5.0 · 107 particles/s) is shown seperately (Fig. 29 (b)). Again, a blue
regression line indicates the mean η.
Apart from the low energy portion, the mean efficiency η(E) is constant over
the whole energy range in every beam intensity setting. In the lower energy
range, a reduction of intensity is observed. This is due to overflow effects in the
ionization chambers at very low energies. To prevent interlocks due to this, the
intensity is lowered to 50% of the nominal value at energy step E1 (88.83MeV/u)
and linearly increased to 100% at E25 (136.92MeV/u), at which the peak is in
approximately 4 centimeters depth. Hence, this reduction is only noticeable in
very shallow targets.
properties of the extraction efficiency In both the 2012 and 2013
data sets, the extraction efficiency η is subject to fluctuation. Mainly random, the
intensity varies from one raster point to the next. In addition, the median value
of η varies with time and as a function of the nominal intensity. In addition, in
the 2013 data, a reduction of η at lower particle energies is introduced.
In this analysis, a median “intensity of the day” is assumed. In this assump-
tion, the random fluctuations in intensity between raster points cancel each other
out, instead, all raster points are treated as if they are irradiated with the same
median intensity. The median intensity is assumed to be independent for each
intensity level, stable during one simulation run and changing for the next.
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(a) Low Intensity < 5 · 107 particles/s (b) High Intensity 5 · 107 particles/s
Figure 29: Accelerator Efficiencies η(E) as a function of energy for both low and high
intensity levels. The fluctuations of the mean intensity are reduced. For low
energies, the extraction efficiency is reduced to prevent an overflow in the
ionization chamber.
The dependence on energy is not taken into account for this simulation. In
the 2012 data set, the energy dependence is mostly random and is assumed to
cancel out. In the 2013 data set, almost no energy-dependence is seen, apart
from a deliberate throttling in the lowest energies. This is only relevant for a
small fraction of patient plans and none of the test plans used in this thesis use
relevant low energies.
4.2.2.5 Subsampling of the Intensity Base Data
The extracted beam intensity not only fluctuates from day to day; as can be
seen from the scattered values in Fig. 29, the intensity even fluctuates when
using the intensity feedback system to stabilize the beam. This fluctuation of the
beam intensity on a much smaller time scale, most prominently due to a 150 Hz
oscillation, alters the beam intensity from one raster point to the next.
To take this into account in the simulation, there are two possible approaches:
Either, an individual extraction efficiency ηi is assigned to each irradiated raster
point i. Or, the fluctuations are assumed to cancel each other out and a single
median extraction efficiency η is assigned to all raster points. In this analysis,
the latter option was chosen, with a single value for η for each intensity level.
For a typical patient treatment plan, the number of irradiated raster points is
of the order of O 104 . To calculate the median extraction efficiency, a similar
number of raster points was sampled from the data set.
For the use in the simulation, all data was split up based on the irradiation
day and nominal intensity. For each data set, the individual extraction efficiency
values ηi were calculated for each raster point. Using this, 10, 000 η values were
randomly selected from the ensemble and the median value hηiINominal,Day of this
sample was calculated. For each day and intensity step, 100 different samples
were created.
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Figure 30: Averaged Extraction Efficiencies: By randomly sampling 10, 000 raster points,
a median extraction efficiency was calculated. This was repeated 100 times for
each day and nominal intensity level. The histograms are used to determine
a median “intensity of the day” for the simulation.
In Fig. 30, the result of this averaging process is shown for intensity step I7
(2.0 · 107 particles/s). Based on these histograms, the median intensity of the day
is calculated for the simulations.
4.2.3 Simulation Principles
In order to calculate the irradiation time for each raster point of a treatment
plan, the simulation software uses a simplified model of the accelerator which is
described in this section.
Instead of simulating the whole accelerator, a simplified phenomenological
model is used, which is summarized in Fig. 31. During operation, the accelerator
can either emit a particle beam (Beam Status “On”) or not (Beam Status “Off”).
While the beam status is “On”, the raster points of a treatment plan are irradiated
sequentially (the Rasterpoint Index i increases), at the same time, the number of
particles remaining inside the synchrotron ring decreases (Ring Fill Status).
When the Ring Fill Status drops to 0%, no more particles can be extracted and
the irradiation of raster points is halted (Beam Status “Off”). This also happens
when the last raster point of a certain energy is irradiated and a different energy
is requested. In both cases, a pause results, in which the synchrotron ring is
“refilled” to 100% and the irradiation is resumed.
Using this model, the simulation software calculates a duration for each task
of the accelerator. The time in between two extractions of the particle beam is
designated TPause and depends on the particle energy and a random pause. The
time needed to irradiate an individual raster point is designated TRasterpoint; it is
dependent on the beam intensity and the number of particles prescribed to this
raster point. By adding up the time needed to irradiate each individual raster
point and the pauses in between irradiations, the irradiation time for each raster
point is determined.
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Figure 31: Simplified Accelerator Model: In the phenomenological model of the HICAT
accelerator, the beam is in the “on” or “off” state. During “Beam on”, raster
points are irradiated while the number of particles in the synchrotron “Ring”
decreases. Once all particles are extracted, the beam status switches to “off”
until the synchrotron is refilled and the next irradiation can start.
4.2.3.1 Calculation of the Inter-Cycle Pause
Based on the duration of the synchrotron cycle, the inter-cycle pause and the
broadcast delay, the pause time between two extractions can be calculated. In the
previous section, the synchrotron cycle time was found to be energy dependent,
the inter-cycle pause has a random component and the broadcast delay can be
treated as fixed:
TPause (Energy) = TCycle (Energy) + TInter-Cycle (Random) + TBroadcast, (23)
with TBroadcast = 400 ms.
Calculating the deterministic synchrotron cycle time TCycle (E) is achieved us-
ing equation 14 (page 50). The energy required in this formula is the nominal
particle energy from the treatment plan.
The random duration of the inter-cycle pause TInter-Cycle (Random) is calculated
using the CERN ROOT software package. Using ROOT’s TH1 histogram class,
random numbers can be created which follow the probability density function
of the distribution entered into the histogram (Brun and Rademakers (1997)). To
calculate the random duration of the inter-cycle pause, the contents of Fig. 22
were entered into a ROOT histogram. Using the GetRandom() function, a new
random duration of the inter-cycle pause is calculated for each simulated pause.
4.2.3.2 Calculation of the Raster Point Irradiation Time
Calculating the irradiation time for each raster point is done by dividing the
assigned number of particles Ni by the beam intensity Ii:
TRasterpoint,i =
Ni
Ii
. (24)
While the number of particles is provided by the treatment plan, the beam inten-
sity must be computed.
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The HICAT accelerator provides several intensity levels which can be used for
treatment. Selecting the appropriate beam intensity is part of the process data
generation routine (Prozessdatengenerierung), which converts the treatment plan
into a format which can be used by the TCS for irradiation.
During irradiation, the position of each raster point is measured by the TCS. If
the position can not determined, an interlock stops the irradiation. To avoid the
failure of a position measurement, the beam intensity is reduced until all raster
points can be reliably measured. Due to the design of the accelerator, all raster
points with the same particle energy have to be irradiated using the same beam
intensity. Hence, the beam intensity for all raster points of a certain energy is
determined by the raster point with the smallest number of particles, and the
beam intensity is selected by the process data generation to ensure a certain
irradiation time for each raster point.
SIEMENS provides the program code to calculate the process data generation
via the software suite XML-PT. Using this software, the nominal beam intensities
Ii,Nominal are calculated for the simulation.
To determine the actual beam intensity, the nominal intensities are then mul-
tiplied with the extraction efficiencies η. In the simulation, one value of η is
calculated for each intensity level in the beginning of the calculation and used
for the whole treatment plan.
Similar to the calculation of the random inter-cycle pause, the values for η
are calculated using CERN ROOT’s TH1 histograms, which are populated using
the averaged extraction efficiency values (see Fig. 30). By choosing the 2012 or
2013 model base data, the same simulation software can be used to simulate to
simulate the accelerator with or without the intensity feedback system.
By adding the irradiation times TRasterpoint,i for each raster point, the time at
which each raster point is irradiated can be calculated. In this model, all raster
points of a certain energy are irradiated sequentially, after which the accelerator
proceeds to the next energy with a delay of TPause.
4.2.3.3 Limited Extraction Time
Because of the limited number of particles in the accelerator, the extraction of
particles is stopped after TExtraction, which is 5 seconds. After this time, a new
beam has to be accelerated before the irradiation can be continued.
If the irradiation of all raster points of a certain particle energy takes less time
than TExtraction, all raster points are irradiated with one fill of the accelerator.
The accelerator then proceeds with the irradiation of the next energy, which
starts after a delay of TPause. If the irradiation takes more time, raster points
are irradiated until TExtraction is reached. Then, the irradiation is halted, a new
particle beam is accelerated to the same energy and the irradiation continues
from the last irradiated raster point. This behavior is also shown in Fig. 31.
In the simulation, this is implemented by adding a pause of length TPause when
the cumulative irradiation time exceeds TExtraction.
4.2.3.4 Implementation of the Beam Delivery Sequence Generator
Instead of creating the simulation software from scratch, the precursor software
makeLmdout, created by Peter Steidl and Daniel Richter at GSI (Steidl (2011)), was
taken as a basis. In its original form, makeLmdout was already able to import treat-
ment plans and calculate a beam delivery sequence, although TPause was fixed
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Figure 32: Simulation Flowchart
to 5 seconds and the beam intensity was fixed at 100% of the nominal intensity.
For the final version of makeLmdout, realistic accelerator timing is factored into
the calculations at several points of the simulation.
In Fig. 32, the implementation of the accelerator model into simulation soft-
ware is presented as a flow chart. Beginning at “Start”, the simulation is pre-
pared, which includes retrieving a list of all raster points from the treatment
plan and the calculation of energies and beam intensities. After this, a loop is
started which calculates the irradiation times for each raster point. When the
irradiation times have been calculated for each raster point, the loop ends and
all information is written to the hard disk.
pre-loop calculations : These steps are only carried out once before the
loop calculations start:
• At the start of the simulation, the treatment plan is imported from a DICOM
file. From the file, a list of all raster points, the number of particles (Ni)
and the beam energies (Ei) are extracted.
• Using the SIEMENS software suite XML-PT, the process data generation is
emulated for the treatment plan. The result is a list of nominal intensities
INominal,i for each raster point.
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• Next, the actual beam intensities are calculated. This is done once for each
intensity level to generate an “Intensity of the Day” and uses the random
number generation of the averaged extraction efficiency histograms which
was previously discussed. For each nominal intensity level, one extraction
efficiency η (INominal) is calculated.
For each raster point of the treatment plan, the actual beam intensity is
then calculated by multiplying with the nominal beam intensity:
Ii = INominal,i · η INominal,i . (25)
This way, intensities are varied each time the simulation is started, but fixed
during one fraction of the treatment.
• Before the calculation loop is started, the variables describing the state of
the accelerator are initialized. The clock is set to zero (t = 0.0) and the
first raster point is selected (i = 0). Further, the synchrotron is assumed
to be empty in the beginning, which is taken into account by setting the
remaining extraction time to zero (TExtraction = 0.0).
loop calculations : During the loop, the duration of each raster point is
calculated in sequential order, starting with the first one. It is then repeated until
all raster points have been calculated. When no more raster points are left, the
loop ends and the results are written to disk.
During the loop, several yes/no decisions are made, indicated by red dia-
monds in Fig. 32. Depending on the answer, different routes are taken through
the flow chart.
• First, the loop checks if there are raster points left for irradiation. If yes, the
loop is continued. If no, the loop is terminated.
• Next, the loop checks if there are particles left in the accelerator by checking
if TExtraction > 0. If yes (there are particles left), the loop is continued. If no,
the synchrotron must be refilled.
• To fill the synchrotron, in the simulation, the time needed to refill the syn-
chrotron is added to the total irradiation time t. This is done by calculating
the pause time TPause (Ei) corresponding to the current particle energy Ei.
The time is then added to the clock:
t→ t+ TPause (Ei) . (26)
After that, the extraction time is set to five seconds (TExtraction = 5 s) and
the loop is continued.
• To simulate the irradiation, the time needed for irradiation of the current
raster point TRasterpoint is calculated using the number of particles Ni and
the beam intensity Ii for this raster point:
TRasterpoint =
Ni
Ii
. (27)
This time is added to the clock t:
t→ t+ TRasterpoint (28)
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and also subtracted from the remaining extraction time TExtraction:
TExtraction → TExtraction − TRasterpoint (29)
The clock time t and raster point index is saved and later saved to disk.
After that, the next raster point is selected (i→ i+ 1).
• Finally, the loop checks if the beam energy for the next raster point is
the same as for the current, Ei == Ei−1. If yes, the loop is restarted to
calculate the next raster point. If no, the energy must be changed before
the next raster point can be irradiated.
In the simulation, this is done by setting the remaining extraction time to
zero (TExtraction = 0). In the next pass of the loop, this is recognized and the
synchrotron is refilled. After that, the loop is restarted.
after-loop calculations When the duration of all raster points has been
calculated, the simulation is finished by writing all necessary data to disk. The
results are exported as a LMDOUT file, which can be used by TRiP-4D and
contains the irradiation time for each raster point of the treatment plan. An
example of the file format is presented in the appendix, section A.1 on page 131.
Concluding, the simulation now includes the calculation of an “intensity of
the day” for each intensity level and calculates a realistic pause time. In the
following sections, the performance of the simulation is compared to data and
measurements created at the HICAT accelerator.
4.2.4 Summary: System Analysis and Simulation Implementation
In this first section, the timing of the HICAT accelerator cycle and beam intensity
was analyzed. Each accelerator cycle consists of three energy-dependent macro
phases and an inter-cycle pause of random duration. The beam intensity was
found to vary from day to day, which has to be considered in a simulation.
Based on this knowledge, model data was determined for use in the simula-
tion. Several phases of the accelerator cycle are deterministic and either have a
fixed or energy-dependent duration. The duration of these phases were deter-
mined from the control data set used by the accelerator called the Flash Dump.
Data on the random inter-cycle pause time was extracted from the accelerator
control system (ACS) data base, which automatically logs the beginning and
end of each accelerator cycle. The duration of an additional broadcast delay
time was measured using a direct measurement on an accelerator device control
unit (DCU).
Information on the effective beam intensity was determined from irradiation
records created by the therapy control system (TCS). For each irradiated raster
point, nominal particle numbers and duration of the irradiation were used to
calculate the effective beam intensity. Two data sets were used; the data set
from 2012 indicates large variation of effective beam intensity due to intensity
variations of the ECR ion-beam sources. In 2013, the introduction of the dynamic
intensity control (DIC) system both increased and stabilized the effective beam
intensity, reflected in the 2013 data set.
Based on this analysis, a simulation software to calculate realistic beam deliv-
ery sequences (BDS) from a treatment plan was implemented. The implemen-
tation uses realistic times between consecutive beam extractions based on the
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model base data. The beam intensity is determined by sub-sampling the effec-
tive beam intensity from the model base data and selecting an Intensity of the
Day, a set of fixed beam intensities used for the calculation of the entire treat-
ment plan.
With the simulation software implemented, it is now necessary to analyzed
the predictive power of the simulation. This is done in the following section.
4.3 verification of the simulation software
To assess the quality of the simulation software, simulated beam delivery se-
quences are compared to recorded sequences of a treatment plan. This test plan
was irradiated regularly during 2012 and 2013 and the resulting data set is there-
fore used to evaluate simulations using both the 2012 and 2013 model base data.
Additionally, the predictive power of the simulation is verified experimentally
by measuring a dose distribution in a moving water phantom. Using a test plan
and a genuine patient treatment plan, the agreement between simulated and
measured dose distributions is shown.
4.3.1 Analysis of Beam Delivery Sequences
To evaluate the predictive power of the simulation, the results of the simulation
are compared retrospectively to irradiation records created in 2012 and 2013.
During this time, the same treatment plan was irradiated regularly for quality
assurance. By comparing the recorded beam delivery sequences with the simu-
lated sequences, the simulation software and the model base data from the same
time period is tested.
In this section, several approaches have been used to compare simulated and
recorded data. Two analyses are based on comparing the irradiation times of
simulated and recorded treatments. Furthermore, two analyses are based on
dose calculations and directly reflect the impact of the sequences on dose distri-
butions.
4.3.1.1 VX-Vorbestrahlung as Test Treatment Plan
Instead of creating a dedicated treatment plan for testing the simulation software
and irradiating it repeatedly, a treatment plan was found which was already in
use for regular quality assurance. The VX-Vorbestrahlung treatment plan was
introduced to pre-irradiate the pin-point ionization chambers prior to verifica-
tion measurements. It contains six energy levels and delivers a homogeneous
physical dose of 1 Gy using a carbon ion beam. The treatment plan and the
positions of the ionization chambers are shown in Fig. 33.
This treatment plan was irradiated repeatedly, typically on three days per
week, and at similar times of the day, directly after the patient treatment. Each
irradiation was performed by a medical physicist, usually two times in a row
before the verification measurements were started. Because it is irradiated in
verification mode, this data set is very close to patient treatment conditions, but
not part of the training data set used in the creation of the model base data set.
For this analysis, only irradiation records from the same period as the training
data set were used: During the 2012 period (July 2nd to July 31st 2012), the
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Figure 33: VX-Vorbestrahlung treatment plan as displayed in the HIT TPS syngo® RT
Planning. The dose calculations are performed in a water phantom geometry,
the positions of the ionization chambers are indicated by white circled dots.
In the lower right, the dose values and gradients are reported. This treatment
plan was used for ion chamber warm-up prior to verification measurements.
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treatment plan was irradiated 31 times. During the 2013 period (June 1st to July
14th 2013), 26 irradiations were recorded.
In Fig. 34, four examples of recorded and simulated beam delivery sequences
are presented for 2012 (top) and 2013 (bottom). On the y-axis, the raster point
index indicates the progress of the treatment plan, the x-axis shows the total
treatment time.
From these examples, the general ability of the simulation software to model
the accelerator can be seen. The overall structure and duration of the irradiation
is reflected in the simulated irradiation sequences. Further, the reduction of
irradiation time due to the intensity feedback extraction (DIC) installed in 2013
is reflected, with fewer extractions needed to finish the irradiation, leading to a
reduction of the total irradiation time of approximately 30 seconds.
4.3.1.2 Finding a Similarity Measure
One basic challenge in comparing beam delivery sequences is their random na-
ture. Two irradiations of the same treatment plan under the same conditions
will yield different sequences. And the simulation, by design, calculates varying
sequences in much the same way. How can two sets of beam delivery sequences
be compared to each other when they are intrinsically different?
While there are several standard methods of comparing dose distributions
or treatment plan quality (like Γ -index, DVH parameters, dose conformity and
dose homogeneity indices, see Chapter 5), there is no established method of
comparing beam delivery sequences. Hence, the first step in comparing the
sequences is to find a reasonable similarity measure.
One approach is to take the beam delivery sequences and perform a statistical
analysis based on the individual raster point irradiation times. This approach
has the benefit of not needing too many assumptions and being very universal;
on the other hand, differences may be hard to interpret.
Another approach is to calculate a 4D dose distribution from the beam delivery
sequences using a defined phantom setup and phantom motion. This approach
requires a large set of assumptions, like phantom geometry, motion amplitude
and speed, but it allows the evaluation of a dose distribution, and therefore the
impact of the differences between simulation and recorded BDS.
Both approaches were evaluated in this analysis. The first two analyses are
only taking the timing of raster points into account. Recorded and simulated
beam delivery sequences are directly compared using statistical methods. In
the latter two analyses, dose distributions are calculated from the recorded and
simulated beam delivery sequences. Using two different statistical methods, the
dose distributions are compared to each other.
analysis i : timing spectra : In this analysis, the duration of each raster
point irradiation, TRasterpoint, and inter-cycle pause, TPause, is calculated for a set of
simulated and recorded beam delivery sequences. Histograms of the durations
are evaluated and the spectra of real and simulated irradiations are compared to
each other.
This method is sensitive enough to test the overall performance of the sim-
ulation and detect implementation errors. For example, the missing broadcast
delay in the simulation of the inter-cycle pause was detected in this first analysis.
Other analyses were performed to spot more subtle differences.
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(a) Recorded Data, 2012 (b) Simulation, 2012
(c) Recorded Data, 2013 (d) Simulation, 2013
Figure 34: First Simulation Results: Recorded and simulated beam delivery sequences
(BDS) for the VX-Vorbestrahlung treatment plan. The irradiations were per-
formed in 2012 (a, b) and 2013 (c, d) and compared to simulations using
model base data sets from the same time periods. Irradiated raster points are
shown as circles, pauses between two raster points are indicated as horizontal
lines.
Despite the random nature of the irradiation, similar irradiation sequences
are found in the records and the simulation. Due to the intensity feedback
extraction (DIC), the irradiation in 2013 is faster and exhibits less variation.
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analysis ii : root-mean-square deviation : In this analysis, the root-
mean-square deviation of all raster points irradiation times ti is calculated for a
simulated and a recorded beam delivery sequence. Based on this property, the
difference between the simulation and the irradiation is estimated which allows
a first interpretation of the simulation quality.
analysis iii : χ2 calculation : In this analysis, the simulated and recorded
beam delivery sequences are used to calculate 4D dose distributions. For the cal-
culations, a phantom geometry, motion amplitude and breathing curve must be
assumed, ideally, they are close to the realistic motions of a patient.
Based on the calculated dose distributions, mean doses (µD (~x)) and standard
deviations (σD (~x)) are calculated for each voxel. From this, χ2 values can be
calculated for each 4D dose distribution. The χ2 values are used to evaluate the
similarity of the dose distribution and therefore the simulation quality.
analysis iv : volumes of interest : In this analysis, the same 4D dose
distributions are used as in the previous analysis, but instead of calculating the
χ2 values, dose values are evaluated in 24 volumes of interest, based on the de-
tector positions used for treatment plan verification. The dose values calculated
from the simulated and the recorded sequences are compared to each other us-
ing the Kolmogorov-Smirnov test.
As with the previous analysis, dose values calculated from a good simulation
should be similar to the values of recorded beam delivery sequences. Further,
this analysis is the basis for further experimental verification.
4.3.1.3 Analysis I: Timing Spectra
For this analysis, beam delivery sequences were simulated for the VX-Vorbe-
strahlung treatment plan. As for all following analyses, 200 simulation cycles
were calculated using the 2012 model base data set, and 200 simulation cycles
were calculated using the 2013 model base data set. All 31 (2012) and 26 (2013)
recorded irradiations were evaluated.
From the simulated and the recorded beam delivery sequences, the time dif-
ference between two irradiated raster points was calculated:
∆ti = ti+1 − ti. (30)
The calculated time differences ∆t are shown in the histograms in Fig. 35 and
Fig. 36. In the first histograms, the time scale is in milliseconds, which is the
typical time for the irradiation of a single raster point and can be interpreted as
the spectrum of TRasterpoint. In the second set of histograms, the time scale is from
2 to 8 s, which is typical for the the pause between two extractions and can be
interpreted as TPause.
interpretation of TRasterpoint : In Fig. 35, the spectrum of TRasterpoint is
shown for the 2012 (top) and 2013 (bottom) data for the millisecond time scale.
In general, there is a good agreement between the measured (left) and simulated
(right) spectra. With the peak positions in the same position, this is the first
hint that the beam intensity is correctly simulated. This is true for the 2012 data
with the lower intensity (and longer irradiation time) and for the 2013 data with
higher intensity (and shorter irradiation time).
72 analysis and modeling of the hit accelerator cycle
0
5000
10000
0.00 0.01 0.02 0.03 0.04 0.05
Time Difference [s]
Fr
eq
ue
nc
y
(a) Measurement, 2012
0
25000
50000
75000
0.00 0.01 0.02 0.03 0.04 0.05
Time Difference [s]
Fr
eq
ue
nc
y
(b) Simulation, 2012
0
5000
10000
15000
0.00 0.01 0.02 0.03 0.04 0.05
Time Difference [s]
Fr
eq
ue
nc
y
(c) Measurement, 2013
0
50000
100000
150000
200000
0.00 0.01 0.02 0.03 0.04 0.05
Time Difference [s]
Fr
eq
ue
nc
y
(d) Simulation, 2013
Figure 35: Spectrum of TRasterpoint for measured and simulated beam delivery sequences:
In both 2012 (top) and 2013 (bottom), the spectra of raster point irradiation
times is similar to the simulation. In the simulated data, the distribution
is less smooth due to one single intensity chosen for each simulation cycle,
while the intensity is fluctuating more in the real irradiation.
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Figure 36: Spectrum of TPause for measured and simulated beam delivery sequences: The
calculated pause times between two extractions are similar to the recorded
differences, with similar median pause times and peak shapes in all data sets.
One difference is found in the width of the peaks, which are narrower in
the simulation than in the recorded data. This is explained by examining the
nature of the simulation: While the simulation assumes one constant extraction
efficiency η for each simulation cycle, the beam intensity is fluctuating more in
reality, leading to an extra broadening of the irradiation times. The impact of
this difference on the simulation quality is further analyzed in the upcoming
sections.
interpretation of TPause : In Fig. 36, the timing spectrum for the pause
time TPause is shown. Because the newly introduced intensity feedback system
only affects the extraction and no changes have been made to the acceleration
system, the base data for the pause time is the same for 2012 and 2013 and all
four distributions should be essentially the same.
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This is reflected in the data, the median duration of all pauses larger than
2 seconds in the 2012 irradiation records is 4.48 s, while the simulation has a
median value of 4.41 s. Likewise, in the 2013 irradiation records, the median
pause duration is 4.43 s, while the simulation yields a median value of 4.42 s.
Also, the peak shape is the same in all data sets.
When this analysis was performed with the first version of the simulation, a
discrepancy was found between the simulated and measured pause time. The
difference of approximately 400 ms was mainly attributed to the omission of the
broadcast delay time and corrected when the duration of the broadcast pause
was confirmed. The data of this first analysis is found in the appendix in Sec-
tion A.2.1 on page 132.
4.3.1.4 Analysis II: Root Mean Square Deviation
While the first analysis is sensitive enough to detect large deviations between the
simulation and the real beam delivery sequences, undetected smaller deviations
can add up over the course of a treatment plan, causing large deviations. In
this analysis, the root mean square deviation (RMSD) of the absolute irradiation
time of each raster point is calculated for simulated and recorded beam delivery
sequences. As before, the analysis was performed using all irradiation records
of the VX-Vorbestrahlung treatment plan and 200 simulation calculations using
the 2012 and 2013 model base data.
Not all beam delivery sequences start at t = 0, in some recorded BDS, the
first raster point is irradiated with an offset. For the first analysis, this offset did
not matter, but to calculate a comparable RMSD for the whole data set, the offset
between the simulated and recorded data is removed. This is done by calculating
the mean offset h∆ti of all raster points:
∆ti = tsim,i − texp,i h∆ti = 1
N
X
i
∆ti (31)
The offset is subtracted from the irradiation times of each simulated raster point
tsim,i:
tsim,i → t 0sim,i = tsim,i − h∆ti (32)
This time-shifted simulation data is used to calculate the root mean square devi-
ation σ:
σ =
s
1
N
X
i
t 0sim,i − texp,i
2
(33)
The RMSD can be interpreted as the standard deviation of the predicted irradia-
tion time.
In this analysis, the RMSD was calculated for each pair of simulated and
recorded beam delivery sequences of the 2012 and 2013 data set. The result-
ing histograms are shown in Fig. 37. Additionally, to give an estimation of the
simulation quality, the RMSD was calculated between pairs of recorded beam de-
livery sequences, comparable to an auto-correlation. Assuming that a recorded
irradiation sequence is the optimal simulation result, the calculated RMSD val-
ues can be used as a reference for the analysis. The results are shown in Fig. 38.
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Figure 37: Root Mean Square Deviation σ between simulated and recorded beam deliv-
ery sequences. The RMSD was calculated for the 2012 (left) and 2013 data set
(right) separately.
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Figure 38: Root Mean Square Deviation σAuto calculated from the recorded irradiation
sequences only. Based on this “autocorrelation” data, reference values for the
optimal simulation can be estimated. With the introduction of the intensity
feedback system in 2013, the beam intensities are more stable which leads to
a higher reproducibility of the irradiation.
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interpretation of 2012 data : Using the 2012 data set, the median RMSD
σ was calculated to be 3.40 seconds, with the distribution reaching up to 30
seconds (Fig. 37 (a)). Using the recorded data only, the median value of the auto-
correlated RMSD σAuto, was calculated to be 4.49 seconds. This is very close to
the values obtained with the simulated data, and the distribution is similar to
the simulated distribution (Fig. 38 (a)).
The similar values of σ and σAuto are an indication that the simulation is ac-
curate in modeling the accelerator and the calculated beam delivery sequences
are valid. On the other hand, the resulting beam delivery sequences have a large
variance. To put the values into perspective, a typical breathing cycle has a dura-
tion of approximately four seconds. With a σ of 3.40 seconds, the motion phase
in which a raster point is irradiated can not be accurately predicted.
Hence, for the 2012 data set, created prior to the introduction of the inten-
sity feedback system, the simulation is accurate, but the resulting beam delivery
sequences will have a large variance. This effect is dominated by large devia-
tions of the beam intensity. The extreme RMSD values are most likely due to
interruptions of the irradiation due to interlocks.
interpretation of 2013 data : When using the 2013 data set, the median
RMSD σ is reduced to 0.72 seconds, with a maximum deviation of 2.8 seconds
(Fig. 37 (b)). The median auto-correlated RMSD σAuto is further reduced to 0.13
seconds with no values higher than 0.25 seconds (Fig. 38 (b)).
Assuming the same breathing cycle of four seconds, 0.72 seconds is equal to
18% of the cycle duration. Therefore, a prediction of the correct motion phase
should be possible using the simulation. This will be further investigated in the
dosimetric analyses.
While the predictive power of the simulation is improved using the 2013 data
set, there is a significant difference between the recorded and the simulated beam
delivery sequences. With a mean σAuto of 0.13 seconds, the differences between
two recorded beam delivery sequences is smaller than the difference between a
simulation and an irradiation.
summary : The first two analyses show a good agreement between the simu-
lated and recorded beam delivery sequences. For the 2012 data set, the variance
between individual beam delivery sequences is large, mainly due to the fluctu-
ating beam intensity. This is reflected well by the simulation software but the
quality of a dose prediction is likely reduced.
With the introduction of intensity feedback control (DIC), the beam intensities
are more stable, which is reflected in the 2013 data set. Now, the variation
between two beam delivery sequences is reduced and the irradiation becomes
more reproducible. This increases the potential to predict dose distributions and
reveals subtle differences between the simulation and the recorded data.
4.3.1.5 Dosimetric Analyses
Analyzing the beam delivery sequences by themselves showed an overall good
performance of the simulation software, albeit with small deviations from the
recorded data sets. The impact of those deviations on the dose distribution is
hard to determine, as it depends on the patient, including the anatomy and
breathing motion. To be able to interpret the differences between the simulated
and recorded beam delivery sequences and to determine the simulation quality,
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dose distributions were calculated from all beam delivery sequences using a
standard phantom geometry and motion.
All dose distributions were calculated using TRiP-4D on the AIX computa-
tion cluster at GSI. The calculations assumed a homogeneous water phantom
positioned in the isocenter, moving in a sinusoidal lateral motion of ±7 mm at
a motion period of T = 4.0 s. This resembles a typical abdominal motion, for
example in the liver.
For the dose calculation, the motion was split into 21 motion phases, with
phase φ = 0◦ defined as the water phantom centered (x = 0.0 mm), φ = 90◦
corresponds to maximum deflection in one direction (x = 7.0 mm). Dose distri-
butions calculated from recorded BDS (“Reconstructed Dose Distributions”) were
calculated using a starting phase φ = 0◦, that is, the first raster point is irra-
diated with the phantom at x = 0.0 mm. Dose distributions calculated from
simulated BDS (“Simulated Dose Distributions”) were calculated using 5◦ phase
shifts (φ = 0◦, 5◦, 10◦, . . . ).
All dose distributions were calculated using TRiP-4D’s all-points divergent-
beam (apdb) algorithm based on HIT beam data. This algorithm includes spe-
cific properties of the HIT facility and makes the dose distribution comparable
to calculations of the HIT TPS and dose measurements.
Based on these calculations, several hundred different dose distributions have
been created, which can not be compared manually. In the following sections,
they are analyzed using statistical methods.
4.3.1.6 Analysis III: χ2 Analysis
This analysis uses a modified χ2 test to determine if a given dose distribution
is similar to an ensemble of dose distributions. In this case, the simulated dose
distributions are compared to the ensemble of reconstructed dose distributions.
The χ2 values are calculated independently for each voxel ~x of the dose distri-
bution. Before the χ2 values can be calculated, the reconstructed dose distribu-
tions of the VX-Vorbestrahlung treatment plan (31 for the 2012 data, 26 for the
2013 data) are used to calculate two statistical properties: The mean dose of the
ensemble in each voxel (µD (~x)) and the standard dose deviation of the ensemble
in each voxel (σD (~x)):
µD (~x) =
1
n
nX
Ensemble,i
Di (~x) (34)
σD (~x) =
vuut 1
n
nX
Ensemble,i
(Di (~x) − µD (~x))
2 (35)
Using this, the χ2 value is calculated in each voxel ~x:
χ2 (~x) =
(D (~x) − µD (~x))
2
σ2D (~x)
, (36)
where D (~x) is the dose distribution to be tested.
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Figure 39: Example visualization of the mean dose µD (~x) (gray scale) and standard de-
viation σD (~x) (color) for one slice of a patient treatment plan.
For the analysis, the mean χ2 value is calculated for all voxels inside the high
dose region volume of interest (VOI) by adding the individual χ2 values and
dividing by the number of voxels N:
χ2 =
1
N
χ2total =
1
N
X
VOI
χ2 (~x) . (37)
Using the mean χ2 has another benefit: For large numbers of degrees of free-
dom (ndof), the mean χ2 value of a normal distribution approaches ndof. In this
analysis, the dose values in the voxels are assumed to be independent, there-
fore the degrees of freedom are approximately equal to the number of voxels,
ndof ≈ N. The VOI contains N = 43920 voxels, which is assumed to be suffi-
ciently large. Hence, if all assumptions are correct and the dose values are in
fact gaussian distributed, the mean χ2 should be in the order of 1.
To analyze the performance of the simulation, χ2 values of all simulated and
reconstructed dose distributions are calculated. The dose distributions which are
calculated from the recorded BDS are assumed to be the reference and are used
to calculate µD (~x) and σD (~x). The resulting mean χ2 values of the reconstructed
and simulated dose distributions are then compared to each other.
interpretation of the 2012 data set : For the analysis of the 2012 data
set, µD (~x) and σD (~x) were calculated using 31 reconstructed dose distributions
with a starting phase of φ = 0◦. Further, 10 simulated beam delivery sequences
were used to calculate the simulated dose distributions. Out of the simulated
dose distributions, 12 starting phases (φ = 0◦ to 330◦ in 30◦ increments) were
evaluated.
Inside the VOI, the mean dose µD is (0.939± 0.110) Gy (with a planned dose
of 1.00 Gy), the standard deviation σD is (0.243± 0.047) Gy.
In Fig. 40, the calculated mean χ2 values are presented for the reconstructed
dose distributions (left) and for the simulated dose distributions (right), sepa-
rated into the different starting phases. For the reconstructed dose distributions,
the median χ2 value is 0.92, close to the expected value of 1 for a gaussian dis-
tribution. For the simulated dose distributions, the median χ2 value depends
weakly on the starting phase, between χ2 = 1.46 for φ = 30◦ and χ2 = 1.16 for
φ = 270◦.
As in the previous analyses, the simulated dose distributions show no signifi-
cant difference from the reconstructed dose distributions, hence, the simulation
software calculates valid beam delivery sequences. Additionally, the starting
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Figure 40: Resulting χ2 values for the 2012 data set: The χ2 values of the reconstructed
dose distributions (left) are the reference for the simulated dose distributions
(right). The graph shows a high agreement between reconstructed and simu-
lated data and low dependence on the starting phase.
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Figure 41: Resulting χ2 values for the 2013 data set: In comparison to the 2012 data,
the χ2 values of the simulated dose distributions are elevated and highly
dependent on the starting phase φ.
phase used in the calculation of the simulated dose distributions has no signifi-
cant impact on the χ2 values. This confirms the result of the previous analysis.
interpretation of the 2013 data set : For the analysis of the 2013 data
set, µD (~x) and σD (~x) were calculated using 26 reconstructed dose distributions
and a starting phase of φ = 0◦. As before, 10 simulated beam delivery sequences
were used to calculate simulated dose distributions.
Within the VOI, the mean dose µD is (0.962± 0.286) Gy, the standard devia-
tion σD is (0.095± 0.043) Gy. In comparison with the 2012 data set, µD exhibits
a higher variation, while σD is reduced. This can be interpreted as a more pro-
nounced interplay pattern which is repeated reliably in each repeated irradiation
instead of canceling out.
In Fig. 41, the calculated χ2 values are shown for the reconstructed and sim-
ulated dose distributions, note the logarithmic scale on the y axis. For the re-
constructed dose distributions, the median χ2 value is 0.40, which is below the
expected value for a gaussian distribution. For the simulated dose distributions,
the χ2 values vary significantly with the starting phase, with values up to 40 for
a starting phase φ = 210◦ and as low as 1 for a starting phase of φ = 30◦.
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Figure 42: Detailed result of the χ2 values for the 2013 data set: This plot shows the
results for starting phases between φ = 0◦ and φ = 60◦. For φ = 35◦, the
median χ2 reaches a minimum.
To find the optimal starting phase, the resulting χ2 values are shown in detail
for starting phases φ = 0◦ to φ = 60◦ in Fig. 42. The best agreement is found in
the simulated dose distribution with φ = 35◦, at a median χ2 value of 1.82.
This confirms the results of the second analysis: The calculation of a BDS is
more accurate than the duration of a breathing cycle, therefore, the dose distri-
bution is sensitive to the starting phase of the dose calculation.
estimation of the dose deviation : Using χ2 in this analysis is a pow-
erful tool to compare dose distributions, unfortunately, the values are hard to
interpret by themselves. By rearranging equation 36, the uncertainty of the dose
calculation can be estimated from the χ2 values:
(D (~x) − µD (~x))
2 = χ2 (~x) · σ2D (~x) (38)
|D (~x) − µD (~x)| =
q
χ2 (~x) · σD (~x) (39)
Hence, by multiplying the square root of the χ2 value and the standard devi-
ation, an estimate of the mean dose uncertainty can be calculated. For the 2012
data, the median χ2 value is around 1.3 across all starting phases, the mean stan-
dard deviation is 0.243 Gy. Hence, the mean uncertainty is about 0.28 Gy. For
the 2013 data, the median χ2 value of the 35◦ starting phase is 1.82, the mean
standard deviation is 0.095 Gy, therefore the mean uncertainty is about 0.13 Gy.
4.3.1.7 Analysis IV: Volumes of Interest
The final analysis is inspired by the dose verification system currently used at
HIT. Each treatment plan is verified by irradiating the treatment plan into a
water phantom. Inside the water phantom, the dose is measured in 24 positions
using pinpoint ionization chambers. By comparing the measured doses with
the calculated dose distribution, the validity of the treatment plan can be as-
sessed. In Fig. 33 (p. 68) the measurement positions and calculated dose values
are shown as calculated in the HIT TPS syngo® RT Planning.
For the analysis, dose values are calculated in the same positions for simulated
and reconstructed dose distributions. The similarity of the data sets is evaluated
by comparing the doses in a representative part of the dose distribution. In this
analysis, the distal part of the dose distribution was selected.
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The 24 ionization chambers are positioned in a fixed geometry relative to each
other in a chamber fixture referred to as the detector block. Using the extract+
software, created by Christian Karger (at DKFZ) and further improved by Daniel
Richter (at GSI), the doses of all detector positions are evaluated based on a
calculated dose distribution. The extract+ software uses trilinear interpolation of
the dose values around each ionization chamber to calculate the dose value at
each chamber position. Additionally, a standard deviation of the dose values is
calculated from the surrounding dose values.
This analysis uses the same calculated dose distributions as before. The cal-
culated dose values are presented using box plots. In addition, the dose values
are analyzed using the Kolmogorov-Smirnov test (KS test). The KS test calcu-
lates the probability with which two sets of random variables are samples of the
same distribution. It is designed to be valid independently of the actual proba-
bility density function and can be used for data samples which are not gaussian
distributed (Kolmogorov (1933); Smirnov (1948)).
For set of simulated and reconstructed dose samples, the Kolmogorov-Smirnov
test calculates the probability p with which the two samples are from the same
probability density function. For values p 6 0.05 (5%), two samples can be con-
sidered significantly different. Note that for 24 independent measurement posi-
tions, at least one position is likely to be significantly different due to statistical
deviation.
In addition, the difference between the reconstructed and simulated median
dose values is calculated to quantify their difference. This value is calculated as
∆D = median (DReconstructed) −median (DSimulated) (40)
for each detector position.
interpretation of the 2012 data set : Using the same dose calculations
as in the previous analysis, dose values were calculated from the 2012 data set.
As before, the starting phase φ was chosen to be φ = 0◦ for the reconstructed
dose distribution and φ = 0◦, 30◦, . . . , 330◦ for the simulated dose distributions.
In Fig. 43, the results are shown.
In the top graph, the reconstructed and simulated dose values are shown as
box plots for each pinpoint chamber position. The edges of the box plots mark
the first and third quartiles, the black center line marks the median dose value.
As shown in Fig. 33, lower position numbers are in the plateau region, higher
position numbers are in the spread-out bragg peak region. Visually, the two
samples match well, with both samples having a large spread and similar median
doses.
The lower graph shows the p-values of the two-sample Kolmogorov-Smirnov
test, which confirms the visual assessment: Out of 24 pinpoint chamber posi-
tions, only one (number 17) exhibits a p value below 5%. Based on this data,
there is no reason to assume that the two dose distributions are significantly
different.
Additionally, the difference of the median dose, calculated for each ionization
chamber, is ∆D = (0.069± 0.124) Gy, at a planned dose of 1.0 Gy.
interpretation of the 2013 data set : The results for the 2013 data set
are presented in Fig. 44. As before, the calculations used a starting phase of
φ = 0◦ for the reconstructed dose distribution and φ = 0◦, 30◦, . . . , 330◦ for the
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Figure 43: Dose values for the VX-Verification treatment plan, calculated in 24 mea-
surement positions for the 2012 data set. Starting phase is φ = 0◦ for
the reconstructed doses and φ = 0◦, 30◦, . . . , 330◦ for the simulated doses.
The simulated dose values (blue) match the reconstructed dose values (red)
visually. In addition, the p values calculated for each measurement posi-
tion are above 5% except in position 17. Deviation of the median doses
∆D = (0.069± 0.124) Gy.
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Figure 44: Dose values for the 2013 data set, using a sum of start phases φ =
0◦, 30◦, . . . , 330◦ for the simulated dose distributions. Due to the different
starting phases, the simulated dose distribution exhibit larger variation than
the reconstructed dose distributions. This is also reflected in the low p values.
Deviation of the median doses ∆D = (0.065± 0.147) Gy.
84 analysis and modeling of the hit accelerator cycle
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0.6
0.9
1.2
1.5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Pinpoint
Ab
so
lu
te
 D
os
e 
[G
y]
Reconstructed Simulated
●
●
●
●
●
●
●
● ●
● ●
● ● ●
●
● ●
●
●
●
●
●
●
●0.00
0.25
0.50
0.75
1.00
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Pinpoint
p−
Va
lu
e
Figure 45: Dose values for the 2013 data set, using start phase φ = 30◦ for the simulated
dose distributions. The difference between the simulated and reconstructed
dose distributions is decreased, which is also reflected in the increased p
values. Deviation of the median doses ∆D = (0.013± 0.058) Gy.
simulated dose distributions. The differences can already be seen in the box
plots, where the reconstructed dose values exhibit much smaller variance and
substantially different median values in comparison to the simulated dose values.
This is also reflected in the KS test, which yields a significant p value for each
pinpoint position, and in the median dose deviation ∆D = (0.065± 0.147) Gy.
This result reflects the results of the χ2 analysis, which showed a strong depen-
dence on the starting phase, with a minimum deviation for a simulation starting
phase of φ = 35◦. Hence, the analysis was repeated using only single starting
phases for the calculation of the simulated dose distributions.
Fig. 45 shows the result for starting phase φ = 30◦. The variance of the sim-
ulated dose values is reduced visibly and the median dose values of the simu-
lation and reconstruction are now closer to each other. The p values are higher,
although five measurement positions are significantly different (1, 8, 9, 16, 17).
The calculated median dose deviation is ∆D = (0.013± 0.058) Gy. Considering
the planned dose of 1.0 Gy, this translates to a combined uncertainty of 5.9%.
The analysis was repeated using starting phases of φ = 0◦ and φ = 60◦, see
Fig. 72 and 74 on pp. 135f in the appendix. With ∆D = (0.020± 0.165) Gy (for
φ = 0◦) and ∆D = (0.005± 0.140) Gy (for φ = 60◦), a starting phase of φ = 30◦
was confirmed as optimal starting phase, similar to the χ2 analysis.
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(a) (b)
Figure 46: Experimental setup: (a) The small water phantom, with the entrance window
facing forwards, is attached to the QUASAR(TM) Respiratory Motion Platform.
The whole water phantom is moved laterally by the stepper motor in the
center. A LASER distance tracker (lower left) is used for position read out. (b)
24 PTW PinPoint ionization chambers are are used for dose measurement.
4.3.1.8 Summary of Analyses
In the previous four analyses of simulated beam delivery sequences, the efficacy
of the simulation software could be established. While small deviations between
the simulated and recorded irradiation records have been identified, the predic-
tive power of the simulation has been shown for both the 2012 and 2013 data
set.
For the 2012 data set, the agreement between simulated and recorded records
was found to be very high, which can be partly attributed to the large variation
between individual irradiation. Due to the large deviations, subtle differences
between simulation and recorded data are less significant.
For the 2013 data set, the variation between the irradiation records is reduced,
which reveals small differences between simulation and recorded data. Fortu-
nately, the difference in absolute dose calculation was shown to be small, with
uncertainties of 5.9% for the test plan used in the analysis.
In the following section, the analysis is continued using an experimental setup.
The measurements were carried out in August of 2013, after the installation of
the DIC extraction control system.
4.3.2 Experimental Verification
To complete the analysis of the simulation software and to investigate the ap-
plicability of the simulation method for experimental setups and in vivo dose
calculation, an experimental verification was performed. In this experiment, the
dose distributions of the VX-Verification treatment plan and a patient treatment
plan were measured in treatment conditions in a moving water phantom using
ionization chambers. The measured dose distributions were compared to simu-
lated dose distributions calculated using the simulation software and TRiP-4D.
The experiment was performed in one of HIT’s patient treatment rooms (H2)
in regular patient treatment conditions. Fig. 46 (a) shows the experimental setup:
86 analysis and modeling of the hit accelerator cycle
Figure 47: Patient treatment plan as displayed in the HIT TPS syngo® RT Planning. The
dose calculations are performed in a water phantom geometry, the positions
of the ionization chambers are indicated by white circled dots. In the lower
right, the dose values and gradients are reported. This treatment plan was
used in a stereotactic liver irradiation.
On top of a ModusQA QUASAR(TM) Respiratory Motion Platform, a small water
phantom is attached. The motion platform can be moved laterally using a step-
per motor and is controlled by a laptop computer. For all measurements, the mo-
tion of the phantom was chosen to match the previous calculations: Sinusoidal
motion in the x direction with an amplitude of 14 mm peak-to-peak (±7 mm)
and a motion period of 4 seconds.
The water phantom was developed and built at HIT (Chaudhri et al. (2012))
and contains the same detector block which is used in the regular verifications,
Fig. 46 (b). The detector block contains 24 PTW TM31009 and TM31015 0.030 cm3
pinpoint ionization chambers and can be moved freely inside the water phantom
to match a planned position for which the doses were calculated in the TPS.
The dose was measured using a PTW MULTIDOS multi-channel dosemeter
setup, which reads the dose from all 24 ionization chambers simultaneously. To
calculate the dose, the chamber-specific calibration factor (ND,w) and the correc-
tion factors for air density (kρ) and beam quality (kQ) were applied.
Two treatment plans were used in the experiment: The previously analyzed
VX-Vorbestrahlung treatment plan (with a maximum dose of 1.01 Gy in water
and an irradiation time of one minute) was used for pre-irradiation of the ion-
ization chambers and also for the experimental verification. Additionally, the
experiments were carried out using a patient treatment plan for a liver irradia-
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tion (with a maximum dose of 4.56 Gy in water and an irradiation time of nine
minutes). The patient treatment plan is presented in Fig. 47.
The motion of the water phantom was recorded using a LASER distance
tracker connected to the ANZAI AZ-733V gating system. This signal was not
used for gating, but the ANZAI AZ-733V system was used for recording the
actual motion and determination of the starting phase φ.
Before irradiation, the water phantom and the detector block was positioned
using the treatment table (for positioning the water phantom in front of the
beam nozzle) and the stepper motor of the detector block (to control the depth
in water). The entrance window of the water phantom was positioned in the
isocenter; the detector block was positioned to match the dose calculations in
syngo® RT Planning and TRiP.
Prior to the measurements, the ionization chambers were pre-irradiated using
the VX-Vorbestrahlung treatment plan. Irradiating with a total of 3 Gy is used
to “warm up” the dosimetry equipment and increases the reliability of the mea-
surements. After that, a zero balance was performed to mitigate any drift of the
measurement values.
The measurements were performed in four sessions: First, the VX-Vorbestrah-
lung treatment plan was irradiated into the stationary water phantom once.
Then, the sinusoidal motion of the water phantom was started and the VX-Vor-
bestrahlung treatment plan was irradiated into the moving water phantom for
five times. Then, the position of the water phantom and detector block was re-
adjusted for the patient treatment plan. This treatment plan was also irradiated
into the stationary phantom once and into the moving phantom for an addi-
tional seven times. During all measurements, the doses in the pinpoint ICs, the
motion trajectory measured using the ANZAI AZ-733V system and the accelera-
tor records were recorded.
Results of the dose measurements are compared to 4D dose distributions cal-
culated using TRiP-4D and extract+, similar to Analysis IV. To rule out setup
errors and systematic errors in the dose calculation, measurements using the
static phantom are compared to static dose calculations in syngo® RT Planning
and TRiP.
4.3.2.1 Results of the Static Measurements
For both treatment plans, static dose distributions were calculated using the
commercial TPS syngo® RT Planning and TRiP. For syngo® RT Planning, the
dose values and gradients were taken directly from the verification preparation
workspace, visible in the lower right of Fig. 33 and 47. For the doses calculated
using TRiP, the dose values and uncertainties were calculated using the extract+
program already used earlier.
In order to validate the dose calculation and the positioning of the water phan-
tom during the experiment, the measured dose values are compared to the cal-
culated doses at the positions of each PinPoint ionization chamber. Fig. 48 and
Fig. 49 show the result of this comparison for the VX-Vorbestrahlung and the pa-
tient treatment plan, respectively. In the graph, the measured dose is presented
in red, the calculation in the HIT TPS is presented in green and the dose calcu-
lation using TRiP in blue. The uncertainties for the syngo® RT Planning calcula-
tions were calculated from the provided dose gradient and a general uncertainty
of 2 mm in setup.
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Figure 48: Static dose measurement results for the VX-Vorbestrahlung treatment plan:
The measured doses are (−1.6 ± 0.8)% lower than the syngo® RT Planning
dose calculations, within the±3% tolerance. The difference between the doses
calculated with TRiP and syngo® RT Planning are acceptable, the TRiP results
are even closer to the measurement.
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Figure 49: Static dose measurement results for the patient treatment plan: The measured
doses are (−0.2± 2.2)% lower than the syngo® RT Planning dose calculations,
within the ±3% tolerance. The difference between the doses calculated with
TRiP and syngo® RT Planning are acceptable.
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For both treatment plans, the measured and calculated doses are close to each
other, in the case of the VX-Vorbestrahlung treatment plan, the measured doses
deviate by (−1.6± 0.8)% (relative to Dmax) from the HIT TPS calculations. For
the patient plan, the measured doses deviate by (−0.2 ± 2.2)%. At HIT, the
measured doses are required to deviate less than 3% from the calculation to be
accepted in dose verification, which is the case for this measurement.
The small difference between the dose calculated by TRiP and syngo® RT Plan-
ning was found to be acceptable. Especially in the VX-Vorbestrahlung treatment
plan, the TRiP dose calculation seems to match the measurements even better
than the syngo® RT Planning dose calculation. Based on the results, the experi-
mental setup and the dose calculations can now be assumed to be accurate.
4.3.2.2 Results of the Motion Measurements
The 4D dose distributions were calculated using the same calculation parameters
as for the dosimetric analyses. For each treatment plan, 10 simulated beam
delivery sequences were calculated using the simulation software and the 2013
model base data set. The dose distributions were again calculated using TRiP-
4D.
Each calculation assumed a uniform water phantom moving laterally by x =
±7 mm in a sinusoidal motion, with a cycle length of 4 seconds. A starting phase
of φ = 0◦ corresponds to the water phantom being centered (x = 0 mm) when
the first raster point is irradiated. Simulated dose distributions were calculated
with starting phases of φ = 0◦, 30◦, . . . , 330◦. For each combination of starting
phase and beam delivery sequence, the resulting dose distribution was sampled
using the extract+ software.
Similar to the previous analysis, the result of the dose calculation is shown as
a box plot; the measured dose values are superimposed as red circles. As before,
the calculated and measured dose values are analyzed using the Kolmogorov-
Smirnov (KS) test. For p values below 5%, two samples can be assumed to be
significantly different.
Finally, the difference between the measured and the simulated dose distribu-
tion is calculated. Due to the low number of samples in the experiment, instead
of using the median (as in Analysis IV), the mean value of all measured doses
DMeasured is used instead:
∆MeanD = mean (DMeasured) −median (DSimulated) . (41)
Both treatment plans were irradiated multiple times into the moving water
phantom and the doses measured. The VX-Vorbestrahlung treatment plan was
irradiated five times, each time without an interlock. The patient treatment plan
was irradiated seven times, four times encountering an interlock resulting in a
treatment pause lasting several seconds, three times without interlock. Due to
technical limitations, all irradiations were started with a random starting phase
φ, which was recorded using the ANZAI AZ-733V system.
The measured dose values are now analyzed in two different ways: First, all
measurements are grouped together and compared to dose calculations using
all starting angles φ. Then, only the irradiations which were irradiated without
interlocks and which had a common starting phase φ are considered. These are
compared to the dose calculation with the same starting phase.
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Figure 50: Experimental verification of the VX-Vorbestrahlung, using all starting phases
φ. Top: The simulated doses are shown as box plots, the measured doses by
the red circles. Bottom: The calculated p values of the Kolmogorov-Smirnov
test. Both show high conformity of the two dose distributions. The deviation
between measured and simulated doses is ∆meanD = (0.057± 0.138) Gy or
(5.6± 13.7)%
analysis of all irradiations : In the first analysis, all measured dose
distributions are considered, including the irradiations encountering interlocks.
In this data set, the starting phase can be considered to be random, and the
resulting doses are compared to dose calculations using all starting phases φ =
0◦, 30◦, . . . , 330◦.
Fig. 50 shows the results for the VX-Vorbestrahlung treatment plan, with the
simulated and measured doses indicated using the box plots and the red cir-
cles. Below, the p values calculated using the Kolmogorov-Smirnov (KS) test are
presented.
From visual inspection, the simulated dose values fit the measured doses well.
This is also reflected by the p values which are below 5% for chambers 7 and
15 only. Again, with 24 measuring positions, at least one can be expected to
be significantly different due to statistical fluctuation. The dose deviation was
calculated to be ∆MeanD = (0.057± 0.138) Gy or (5.6± 13.7)%.
Fig. 51 shows the results for the patient treatment plan. The simulated dose
values fit the measurement results excellently in both the high-dose region (po-
sitions 1 to 16) and still very good in the distal region (17 to 24). This is also
reflected by the p values, which are only significantly different reduced for the
distal measurements with lower point doses. Note that the difference between
measurement and calculation is already present in the static case, hence the low
p values can most likely be attributed to the positioning in the steep dose gra-
dient. The dose deviation was calculated to be ∆meanD = (0.066± 0.264) Gy or
(1.4± 5.8)%).
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Figure 51: Experimental verification of the patient treatment plan, using all starting
phases φ. Top: The simulated doses are shown as box plots, the measured
doses by the red circles. Bottom: The calculated p values of the Kolmogorov-
Smirnov test. Both show high conformity of the two dose distributions, espe-
ciall in the high dose region (1 to 16). The deviation between measured and
simulated doses is ∆meanD = (0.066± 0.264) Gy or (1.4± 5.8)%)
analysis of specific starting phases : For the previous analysis, all
measured doses were included regardless of interlocks and with arbitrary start-
ing phases φ. To reduce the influence of these factors on the analysis, all irra-
diations which were disturbed by an interlock are now excluded. Further, all
irradiations with a similar starting phase were found and grouped together. In
the measured data set, three matching irradiations were found for each treatment
plan: For the VX-Vorbestrahlung treatment plan, a starting phase of φ ≈ 60◦ was
recorded for measurements 2, 3 and 4; for the patient treatment plan, φ ≈ 180◦
for measurements 2, 3 and 4. In this analysis, the measured doses are com-
pared to the dose calculations with the respective starting phases (φ = 60◦ and
φ = 180◦).
Fig. 52 and Fig. 53 show the result of this analysis for the VX-Vorbestrahlung
and patient treatment plan. In comparison with the previous calculations, the
calculated and measured dose values of both treatment plans show a smaller
variance. This is especially visible in the shorter VX-Vorbestrahlung treatment
plan, but also in the longer patient treatment plan1.
For the VX-Vorbestrahlung treatment plan, the agreement between the mea-
sured and calculated dose is improved. This is confirmed by the increased p
values calculated by the KS test and by the reduced dose difference ∆MeanD =
(0.000± 0.076) Gy or (0.0± 7.5)%. Hence, the simulation has a high predictive
power with the right starting phase, while being very sensitive to a shift in the
starting phase or disturbances due to interlocks.
1 See section A.2.2.2 on page 137 in the appendix.
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Figure 52: Resulting doses for the VX-Vorbestrahlung treatment plan for all measure-
ments with a starting phase of φ ≈ 60◦ and no interlocks (red dots). The
simulated doses (box plot) were calculated with a starting phase of φ = 60◦.
Below are the p values calculated using the Kolmogorov-Smirnov test.
∆MeanD = (0.000± 0.076) Gy or (0.0± 7.5)%
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Figure 53: Resulting doses for the patient treatment plan for all measurements with a
starting phase of φ ≈ 180◦ and no interlocks (red dots). The simulated doses
(box plot) were calculated with a starting phase of φ = 180◦.
∆MeanD = (0.045± 0.331) Gy or (1.0± 7.3)%
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For the patient treatment plan, the difference to the previous analysis is smaller.
As before, three measurement positions have p values less than 5%, and the dose
difference ∆MeanD = (0.045± 0.331) Gy or (1.0± 7.3)% is comparable to the pre-
vious outcome2.
One explanation is the longer irradiation time of the patient treatment plan
of approximately nine minutes. During the longer irradiation time, small de-
viations will accumulate, this reduces the phase coherence due to the random
nature of the beam pauses and irradiation times. This reduces the accuracy with
which the correct phase for the distal raster points is estimated. These raster
points usually are irradiated with the highest particle numbers and have the
highest contributions to the overall dose.
4.3.3 Summary: Simulation Analysis and Experimental Verification
The quality of the simulated beam delivery sequences (BDS) were analyzed both
using irradiation records extracted from the treatment control system (TCS) and
using an experimental setup with a defined motion pattern. Both resulted in a
satisfactory agreement between simulation and measurement.
For the retrospective analysis using irradiation records, a test treatment plan
(VX-Vorbestrahlung) was used. This treatment plan was irradiated regularly be-
fore each treatment plan verification to pre-irradiate the ionization chambers, an
ideal candidate for a retrospective study.
To create the data sets, irradiation records of the VX-Vorbestrahlung treatment
plan from two time periods in 2012 and 2013 were extracted from the TCS, yield-
ing 31 records in the 2012 and 26 records in the 2013 data set. Simulated beam
delivery sequences were calculated with base data from the same periods, ex-
cluding the beam records used for analysis.
Four different analysis methods were used to compare the records to simu-
lated BDS: Analysis I and II used spectra of irradiation times and root-mean-
square calculation of the deviation of each raster point irradiation time to com-
pare the BDS based on timing of each irradiated raster point alone. For Analysis
III and IV, 4D dose calculations were performed based on the BDS and statistical
analysis was performed on the dose distribution to find deviations.
Analysis I, which investigated the spectrum of raster point irradiation timing,
found a good agreement between the simulated and recorded beam delivery
sequences for both the 2012 and 2013 data set. Being more sensitive to sub-
tle differences, the other analyses found qualitative and quantitative differences
between both data sets.
2012 data set Prior to the introduction of the dynamic intensity control
(DIC), fluctuations of the ECR ion-beam sources caused beam intensity fluctu-
ations leading to high variability between irradiations of the same plan. This
variability was found in the irradiation records and is correctly reflected by the
simulation but was found to reduce the predictive power of the simulation.
All analyses found a good agreement between the simulated beam delivery
sequences and the irradiation records. At the same time, the uncertainty of the
irradiation time of each raster point was so large that even for this relatively short
2 See section A.2.2.3 on page 140 in the appendix.
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treatment plan (70 to 100 seconds), dose contributions to each motion phase can
not be reliably predicted.
Analysis II found a median root-mean-square σ of 3.40 seconds. This is similar
to the result obtained when irradiation records are compared to each other: σ =
4.49 seconds. With breathing cycle times of approximately four seconds, the
uncertainty is in the same order of magnitude, limiting the predictive power in
the 2012 data set.
Analysis III confirms the results, with χ2 values of 0.92 for reconstructed dose
distributions and 1.16 to 1.46 for simulated dose distributions. A good agree-
ment is found between simulated and reconstructed dose distributions, but the
agreement is independent on the motion starting phase. This indifference to the
starting phase is indicative of high irradiation variability.
Analysis IV also confirms the previous results, with a high agreement between
the simulated and reconstructed dose distribution (median dose difference ∆D =
(6.9± 12.4)% for a comparison with mixed motion starting phases). Also here,
the result is not dependent on the motion starting phase.
2013 data set Early in 2013, the dynamic intensity control (DIC) system was
introduced, which reduces beam intensity fluctuations and decreases variability
between irradiations. This is reflected in the 2013 data set, leading to more
reproducible irradiation sequences and more accurate predictions.
Analysis II found a median root-mean-square σ of 0.72 seconds, almost a factor
five lower than with the 2012 data set. Due to the reduced irradiation variability,
the quality of the simulation is improved with less than a second uncertainty,
and offers an increased predictive power. When comparing the recorded BDS
to each other, the median σ is even lower, at 0.13 seconds, which hints that the
simulation could be further improved.
Analysis III confirms the results, with χ2 values of 1.82 at a motion starting
phase of φ = 35◦. In this analysis, a high dependency on the motion starting
phase was found, confirming the reduced variability of the irradiation. Similar
to Analysis II, the comparison of the irradiation records with each other show
even lower χ2 values of 0.40, confirming that the simulation could potentially be
improved further.
Analysis IV also confirms the previous results, showing a high agreement
between the simulated and reconstructed dose distributions. For motion starting
phase φ = 30◦, the median dose difference ∆D = (1.3± 5.8)%. Also here, a phase
dependence is seen, a comparison with mixed motion starting phases (φ = 0◦,
30◦, . . . , 330◦) does not reproduce the dose values with ∆D = (6.5± 14.7)%.
In the 2013 data set, both recorded and simulated irradiation sequences show
less variability leading to more accurate predictions. The increased reproducibil-
ity is reflected by a dependency on the motion starting phase. The increased
reproducibility also uncovers subtle differences between the simulated and re-
corded beam delivery sequences. Even with the already high predictive power,
improvement of the simulation could be possible. Between the simulated and
recorded BDS, an unexplained offset of φ = 35◦ was found. This vanished in
the experimental verification, hence it is most likely an offset to be found in the
TCS.
experimental verification Finally, the results of the simulated dose cal-
culations were verified by a dose measurement using 24 ionization chambers
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in a moving water phantom. Motions were chosen to mimic typical breath-
ing amplitudes and frequencies encountered in treatments of abdominal tumors.
Two treatment plans were selected, the VX-Vorbestrahlung treatment plan already
used in the previous analyses, and one SBRT treatment plan used for the treat-
ment of hepatocellular carcinoma. All measurements were performed in 2013
after the introduction of the dynamic intensity control (DIC), hence phase sensi-
tivity was expected.
The resulting dose measurements were found to be in good agreement with
the simulated dose calculations. In addition, a set of measurements with simi-
lar motion starting phases φ and no interlocks were selected for each treatment
plan and compared to dose calculations with multiple simulated motion start-
ing phases. This analysis found an optimal agreement for simulations with the
same starting phase and less optimal agreement for differing starting phases,
confirming the phase dependency. For the VX-Vorbestrahlung treatment plan,
the mean dose difference ∆MeanD was found to be (0.000± 0.076) Gy, equivalent
to (0.0 ± 7.5)%. For the patient treatment plan, ∆MeanD = (0.045 ± 0.331) Gy,
equivalent to (1.0± 7.3)%.
While the motion starting phase dependency could be found in both treat-
ment plans, it was higher in the shorter (70 to 100 seconds) VX-Vorbestrahlung
treatment plan and reduced in the longer (nine minutes) patient treatment plan.
4.4 summary
In this chapter, a new simulation software was presented which predicts the tim-
ing of an irradiation based on the treatment plan. The software uses model base
data sets which were created in an extended analysis of the HICAT accelerator
parameters.
The simulation uses a stochastic approach to model the observed variation in
beam intensity and pause timing. For the beam intensity, an “intensity of the
day” approach was used, which selects a fixed beam intensity in each repetition
of the simulation. To calculate the pause timing, a combination of deterministic
energy-dependent and stochastic parameters were used.
Due to modifications in the beam extraction system, the characteristic of the
HICAT accelerator changed significantly in early 2013. To incorporate this change,
two model base data sets were created for the simulation to reliably model the
accelerator for 2012 and 2013 (see DIC, Schömers (2013); Schömers et al. (2013)).
In an extensive retrospective analysis of irradiation records, simulated accel-
erator response was compared to actual irradiation records of a test plan. This
test plan was repeatedly irradiated during 2012 and 2013 and provided a good
reference data set outside of the training data set. The result of these analyses
suggest a good agreement between the simulation and the irradiation records.
The analysis of the 2012 data set found a large day-to-day beam intensity vari-
ation. This translates to large variations in the beam delivery sequence and large
day-to-day differences in the resulting dose distributions. This is reproduced
well by the simulation software. It also leads to a reduced dependence on the
starting phase of the organ motion.
In the analysis of the 2013 data set, the variation in beam intensity was found
to be much smaller. The beam delivery sequences have a higher reproducibil-
ity, which improves the predictive power of the simulation. This also translates
into a stronger dependence on the starting phase of the organ motion, especially
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Figure 54: Example of an irradiation with several interlocks: During the irradiation of
the VX-Vorbestrahlung treatment plan, at least five interlocks occured, visible
as long horizontal lines between circles representing the irradiation of a raster
point. This leads to unpredictable changes of the motion phase and compli-
cates the calculation of dose distributions.
when calculating treatment plans with a shorter irradiation time. This is mod-
eled well by the simulation, although subtle differences between simulated and
reconstructed data are apparent.
Finally, dose measurements were performed using a moving phantom. In this
experiment, a test plan and a patient treatment plan were measured in conditions
comparable to typical patient motion. For the patient treatment plan, a dose
deviation of (1.0± 7.3)% was observed between the measurement and the dose
prediction. This demonstrated the predictive power of the simulation as well as
the dependence on the starting phase.
The simulation software has been used for further research in the research
group (Batista (2016); Batista et al. (2018)).
4.5 discussion
While the simulation software already gives a high agreement between simulated
and recorded data, subtle differences are apparent, especially in the analysis of
the 2013 data set. The inclusion of several effects into the simulation could
lead to improved simulation results: Implementation of the correct extraction
behavior, inclusion of a spill pause and mitigation of the effects of interlocks.
In the current simulation, the extracted beam rises to full intensity immedi-
ately, when, in reality, it takes some milliseconds. By implementing a realistic
spill shape, some of the deviation between simulation and measurements could
be removed (Grözinger et al. (2006); Peters et al. (2008)). Further, the accelerator
includes a spill pause, a voluntary beam hold, when the distance between two
irradiated raster points exceeds a threshold. This 300 ms pause is currently not
considered in the simulation.
Finally, the influence of interlocks has not been studied or implemented in
this analysis. Due to their properties, they are hard to consider, as they are very
infrequent and introduce a long pause of ≈ 40 seconds. This adds a random
phase shift. Fig. 54 shows an example of an irradiation with at least five inter-
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locks. Fortunately, the ongoing improvement of the HIT systems also reduces
the number of interlocks.
Currently, calculating beam delivery sequences for gated treatment is not yet
implemented. This could be added by taking the patient’s breathing curve into
account and would enable the simulation of gated irradiations using TRiP-4D.
The ongoing changes to the accelerator operation pose a challenge to the sim-
ulation software: Due to the implementation of new features of the acceleration
process (for example, second-generation DIC, dynamic field control), the soft-
ware can get out of date fast. Additionally, to calculate the model base data, a
lot of manual data processing is necessary.
One solution could be an easy to use implementation of the simulation soft-
ware. The model base data, which is currently calculated from several different
measurements and data processing, could in future be automatically created us-
ing a specialized treatment plan. This treatment plan could be used to probe
wide ranges of possible beam parameter combinations, which are automatically
translated into base data. Further, this could be integrated into the normal QA
process and also used for other automated measurements (intensity, beam posi-
tion and width, homogeneity, ...).
With TRiP being a modular platform for dose calculation in ion beam therapy,
it can be used for other facilities as well. Therefore, it could be beneficial to
expand the simulation to encompass other proton or carbon facilities. Finally, the
χ2 and other statistical analyses could in future be used to characterize interplay
in the clinical context.

5
4D T R E AT M E N T P L A N N I N G S T U D Y F O R E S O P H A G E A L
C A N C E R
In this chapter, a treatment planning study for the treatment of esophageal car-
cinoma is presented. With the introduction of the heavy-ion gantry at HIT, new
treatment options are available for tumors of the thorax and abdominal region.
This study investigates the robustness of different planning geometries using
a simplified 4D dose calculation and recommends optimal treatment planning
options for each study patient.
5.1 introduction
Similar to hepato-cellular carcinoma, esophageal cancer is a relatively rare dis-
ease. Only 1.5% of cancer incidences in Germany is attributed to esophageal
cancer. Unfortunately, five-year survival rates are low at 21%, attributing to 2.4%
of cancer deaths in 2014 (Robert Koch-Institut (Hrsg.) und die Gesellschaft der
epidemiologischen Krebsregister in Deutschland e.V. (Hrsg.) (2017)).
In the treatment of esophageal cancer, radiotherapy is usually combined with
surgery and chemotherapy (Sjoquist et al. (2011); Kranzfelder et al. (2011)). To im-
prove the efficacy of the treatment, dose escalation studies (Minsky et al. (2002))
and new chemotherapy agents (Crosby et al. (2013)) have been introduced, al-
beit with little improvement of the treatment outcome. On the other hand, high
dose conformity and local dose escalation (Carrington et al. (2016); Roeder et al.
(2014)) have been shown to have a positive effect on the treatment outcome. In
addition, the introduction of carbon ion radiotherapy has already been shown
to have beneficial effects in the treatment of other cancers (Kamada et al. (2015);
Jensen et al. (2015)). Hence, treating patients suffering from esophageal cancer
using carbon ion radiotherapy may be beneficial as well.
In October of 2012, the heavy ion gantry at HIT has been introduced into
the clinical routine (Galonska et al. (2013)). Since then, new beam angles are
available in addition to the fixed horizontal beam lines, facilitating the treatment
of esophageal cancer and other tumor sites closer to the center of thorax and
abdomen.
In this chapter, a preliminary treatment planning study for the treatment of
esophageal cancer is presented. Several questions are investigated within the
study: Which are the best gantry angles for the therapy? Which of them are
least affected by organ motion due to breathing? For the calculation of the dose,
a simplified 4D dose calculation algorithm has been used. Hence, the sensitivity
of this dose calculation to organ motion is a further topic of this study.
For the treatment planning study, CT data of four bronchial carcinoma patients
has been used. Each data set contains a treatment planning CT and a 4D-CT
consisting of seven motion phases. For each data set, a boost target volume for
esophageal cancer was created by a physician, as well as contours for the lungs,
heart muscle and spinal cord.
Treatment plans were created based on thirteen different treatment planning
geometries and optimized using the treatment planning CT. The resulting treat-
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ment plan was re-calculated quasi-statically on each of the motion phases and
the resulting dose distributions were evaluated for target volume coverage and
dose to organs at risk.
For each patient, it was possible to find at least one acceptable treatment plan
geometry. In addition, the sensitivity of the calculation method to organ motion
could be tested. For example, it is possible to estimate the size of a required ITV
margin, further, a gating window was calculated which increases PTV coverage
and reduces dose to organs at risk.
5.2 materials and methods
In this section, the patient data sets and the details of the treatment planning
are discussed. Further, the methods of evaluating the dose distributions are
presented.
5.2.1 Patient Datasets
5.2.1.1 CT Images
For the study, treatment planning CTs and co-registered 4D-CTs of four bronchial
carcinoma patients were used as a basis of a treatment planning study. Because
the study was done retrospectively on selected patient data sets, breathing mo-
tion was not recorded during imaging or treatment and was not available for
analysis. For each patient, one free-breathing treatment planning CT as well as a
time-resolved 4D-CT was available. Both CTs were created in the same imaging
session and using the same position and immobilization equipment. The CT
scanner used was a SIEMENS SOMATOM Sensation Open.
In the case of patients 1 and 2, the slice distance of the planning CT was
5 mm, in the case of patients 3 and 4, the slice distance was 3 mm. In all
cases, the slice distance of the co-registered 4D-CT was 3 mm. For each time-
resolved CT, three images were reconstructed for the inhale phase (In25%, In50%,
In75%) and four for the exhale phase (Ex100%, Ex70%, Ex40%, Ex0%). In this
terminology, “In25%” refers to a patient inhaling, who has reached 25% of the
maximum motion amplitude. “Ex70%” refers to the patient exhaling, with 70%
of the maximum motion amplitude still left. Hence, in motion phase “Ex40%”,
the patient has exhaled further than at “Ex70%”.
The validity of the co-registration of the planning CT and the 4D-CT was
checked visually by opening the CTs in a DICOM viewer and verification of the
relative position of the bony anatomy. It was found to be accurate within the
error of a slice distance.
Further, the presence of contrast agent was checked in each CT image. Con-
trast agent has a large impact on range uncertainties and reduces the accuracy
of the dose calculation. It was not found in any CT image.
compatibility of hounsfield units Treatment planning CTs and 4D-
CTs are using different reconstruction algorithms. Most noteworthy, the recon-
struction kernels used are different, which leads to different Hounsfield Unit
values for the same structures. Because the treatment planning system relies
on a fixed relationship between electron density (represented by the Hounsfield
Units in the CT) and the Water-Equivalent Path Length (WEPL) in a piece of
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material, differences in the reconstructed electron density may lead to dose cal-
culation errors.
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Figure 55: Representation of the Hounsfield Look-Up Table (Body-HLUT) used in this
study.
In treatment planning, this issue is addressed by agreeing on a fixed set of
imaging parameters and regularly measuring the electron density using stan-
dardized samples with known WEPL. This relationship is represented in the
Hounsfield Lookup Table (HLUT). Unfortunately, this data is not available for
the CT images used in this study.
Instead, the standard Body HLUT is used, shown in Fig. 55, which introduces
a systematic error in particle range calculations. This systematic error does not
exist if the Hounsfield Units of the planning CT and the 4D-CT are similar to
each other, canceling out. Hence, the difference in Hounsfield units was evalu-
ated for each patient data set.
For each CT, the Hounsfield Units (HU) of all CT voxels were entered into a
histogram, as shown in Fig. 56 for the treatment planning CT and the 4D-CT of
patient 1. In this histogram, several peaks are prominent, each representing a
type of tissue: Air (at −1000 HU), lung tissue (at −900 HU) and soft tissues (at
−150 to +100 HU).
The position of the peak center is similar, although the increased noise level
of the 4D-CTs leads to a broadening of the peak widths. The largest peak center
deviation of all patients is a shift of approximately 10 HU of the peak at −100 HU
(Fatty Tissue). The fatty tissue in the 4D-CT appears to be more dense than in
the treatment planning CT. Similar shifts were also found in the other patient
datasets, the positions of other peaks were unaffected.
To estimate the impact of this shift, the change in Water-Equivalent Path
Length can be calculated: At this position, the Hounsfield Lookup Table has
a slope of 0.08/100 [WEPL/HU], a shift of 10 HU is therefore equivalent to a
shift of 0.008 in WEPL. At −100 HU, the WEPL is 0.95, the relative error is there-
fore 0.008/0.95 = 0.8%. In 5 cm of fatty tissue, this introduces a range error of
less than a millimeter. This uncertainty is considered small relative to the motion
effects and was not corrected for this analysis.
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Figure 56: Comparison of Hounsfield Units (HU) of the Planning and 4D CTs for Pa-
tient 1. Each peak represents a certain type of tissue, with air (at −1000 HU),
lung tissue (at −900 HU), fatty tissue (at −100 HU), and muscle tissue
(at +40 HU). While most tissues are relatively unaffected, fatty tissue (at
−100 HU) is shifted by ≈ 10 HU.
5.2.1.2 Patient Contours
Each patient data set was contoured by a physician, who delineated the pa-
tient’s organs at risk (both lungs, the spinal cord and heart) on the treatment
planning CT. Because none of the patients were originally patients suffering
from esophageal cancer, a treatment volume was assumed for each patient and
the corresponding PTV created by the physician.
The locations of the target volumes are shown in Fig. 57. For patients 1 and
2, the target volume is medium sized and approximately in the center of the
esophagus. For patient 3, a smaller target volume located more in the cranial
direction was chosen. Patient 4 has a large target volume, approximately twice
the size of the one in patients 1 and 2, extending closer to the stomach.
contour propagation To evaluate the quality of the treatment plan, the
contour sets created on the treatment planning CT were transferred to the 4D-
CTs. To reduce the necessary work and to increase the reproducibility of the
contour transfer, the 4D re-contouring module of OnQ rts V2.0 by OSL Oncology
Systems Limited was utilized. This software uses non-rigid registration to propa-
gate patient volumes between non-rigid registered CT images.
The resulting contours were then reviewed by a physician, who removed any
artifacts introduced by the automatic contour propagation and checked the va-
lidity of all contours.
itv margin approximation Later in the study, an additional question was
introduced: Is the calculation method sensitive enough to define an ITV margin?
For this reason, the definition of CTV contours would have been necessary and
the calculation of several dose optimizations for each PTV derived from the CTVs
and ITVs. This was not done in this study, instead, a CTV was derived from
the PTV on the 4D-CT images by subtracting a uniform margin of 2, 4, 6, 8
and 10 mm. These volumes were used to estimate the size of an ITV margin
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(a) Patient 1 (b) Patient 2
(c) Patient 3 (d) Patient 4
Figure 57: Planning CTs and assumed target volume locations (PTV in red) of all four
patients.
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necessary to attenuate the motion effects. Of course, this can only be viewed as
a preliminary study.
5.2.2 Treatment Planning
The treatment planning study was performed based on 13 different planning
templates with different treatment field geometries. Treatment plan optimization
and quasi-static dose calculation was performed using the TRiP software; the
resulting dose distributions were evaluated using dose-volume parameters.
5.2.2.1 Geometries
Taking into account the current and projected capabilities of the Heavy Ion
Gantry used at the Heidelberg Ion Therapy center, four single-beam treatment
plan variations and nine dual-beam treatment plan variations have been selected.
It was assumed that the four principal gantry angles (0◦, 90◦, 180◦, 270◦) would
be available initially. Only later, more gantry angles would be available.
All planning geometries are shown in Table 3 and Fig. 58 and 59, starting with
simple single-beam geometries and following up with more complex two-field
geometries with gantry angles more appropriate for the treatment of esophageal
carcinoma.
Plan Geometry Gantry Angle (Field 1) Gantry Angle (Field 2)
Geometry 1 0◦
Geometry 2 180◦
Geometry 3 90◦
Geometry 4 270◦
Geometry 5 90◦ 270◦
Geometry 6 135◦ 225◦
Geometry 7 0◦ 180◦
Geometry 8 25◦ 335◦
Geometry 9 155◦ 205◦
Geometry 10 175◦ 135◦
Geometry 11 185◦ 225◦
Geometry 12 90◦ 180◦
Geometry 13 270◦ 180◦
Table 3: Planning Template Geometries: Geometries 1 to 4 are using one single treat-
ment field from one of the principal gantry angles. For geometries 5 to 13, two
treatment fields are used from different gantry angles.
5.2.2.2 Treatment Plan Optimization
Dose calculations were performed in two steps. First, a treatment plan was op-
timized based on the treatment planning CT and each of the Template Planning
Geometries. The resulting doses were then calculated, first on the treatment
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(a) Geometry 1 (b) Geometry 2
(c) Geometry 3 (d) Geometry 4
(e) Geometry 5 (f) Geometry 6
Figure 58: One- and two-field configurations used in this study. The angles were chosen
to match the initially available and projected capabilities of the HIT heavy-ion
gantry. At first, only the main angles (0, 90, 180 and 270◦ would be available,
later, the full upper hemisphere would be added. Finally, all angles would
be available for treatment. Thus, some simpler geometries and some more
specific for the irradiation of the esophagus were selected.
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(a) Geometry 7 (b) Geometry 8
(c) Geometry 9 (d) Geometry 10
(e) Geometry 11 (f) Geometry 12
(g) Geometry 13
Figure 59: The remaining two-field configurations used in the study.
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planning CT as a reference, but also on each of the motion phases of the 4D-
CT. In this calculation, the treatment plan was not split up between the 4D-CT
motion phase, but calculated on one motion phase only. This is referred to as
“quasi-static” dose calculation.
All treatment plans use an actively raster scanned carbon ion pencil beam with
parameters similar to the Heidelberg Ion Gantry. In coherence with the clinical
protocol used in most carbon ion irradiations at HIT, the prescribed fraction
dose was selected as 3 Gy (RBE). Hence, treatment is hypo-fractionated, with
15 fractions leading to a total dose of 45 Gy (RBE), 18 fractions to a total of
54 Gy (RBE).
All dose calculations were performed using the non-4D capable version of
TRiP, developed at GSI. Because it uses text files as input for all commands,
it has an inherent scripting support, hence it was possible to optimize thirteen
different treatment plans for each of the four patients and calculate the doses on
each of the seven motion phases.
Treatment planning was performed with TRiP’s optimize command, using the
recommended default calculation options1. No explicit constraints were used for
sparing of organs at risk, and the treatment plan was normalized to the median
dose inside the target volume. In this study, this set of options yielded a good
coverage of the PTV with a reasonable sparing of normal tissue and organs at
risk.
For patient 4, the calculation volume was especially large and the plan opti-
mization could not be calculated using the 32 bit version of TRiP. Because the
64 bit version could not reproduce already calculated results of smaller volumes,
it was decided to optimize the treatment plan on the regular 32 bit version of
TRiP, but using a coarser dose calculation grid. The sub-sampling was only
used in the memory-intensive optimization step, the later dose calculation was
performed using the normal CT grid for each patient.
5.2.2.3 Dose Calculation
The dose distributions resulting from each optimized treatment plan were then
calculated for the treatment planning CT as well as each of the 4D-CT motion
phases. Each calculation results in an individual dose distribution, with the dose
distribution calculated on the treatment planning CT regarded as the reference
dose distribution. The dose distributions calculated on the motion phases reflect
the deviations introduced by the organ motion.
Dose calculation was also performed using the non-4D version of TRiP. As in
the optimization, the dose command was used with the allpoints dose calculation
algorithm and lowdose biological effect calculation model. Hence, the algorithms
used in the optimization and dose calculation are comparable to each other.
In the previous chapters, to calculate a 4D dose distribution, the particle flu-
ence was accurately distributed between all motion phases to take into account
all motion effects. This information is not available in this study, hence, account-
ing for the exact motion had to be neglected. Instead, the whole treatment plan
was calculated on each of the motion phases. This approach, a “quasi-static” ir-
radiation, is comparable to a breath-hold irradiation or a very fast application of
the irradiation fields. This approach neglects the interplay pattern which would
1 allpoints dose calculation algorithm, lowdose biological effect calculation model, fletcher-reeves dose
optimization algorithm, optimization cut-off of = 10−3 and dose cut-off of g = 10−4.
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normally result from breathing motion, but still accounts for range differences
and motion of the target volume and organs at risk.
5.2.3 Dose Evaluation
With four patients, thirteen planning geometries and eight CTs used for dose
calculation, over 400 different dose distributions have to be examined and com-
pared to each other. Instead of inspecting every dose distribution individually,
the quality of each treatment plan is evaluated using statistical dose parameters.
All dose distributions were analyzed for PTV coverage, over- and underdosage,
dose homogeneity and dose in the organs at risk. Three different types of indices
are used in this analysis: Dose Volume Histogram (DVH) parameters of the tar-
get volume and the organs at risk, a homogeneity index for the dose inside the
PTV and a conformity index for the PTV. The organs at risk considered in this
analysis are the heart, the spinal cord and the lungs.
dose volume histogram parameters In radiotherapy, the Dose Volume
Histogram (DVH) is a universally used tool to characterize the quality of a treat-
ment plan (Drzymala et al. (1991)). The cumulative DVH describes the volume
V(D) which receives at least the dose D and can be calculated either for the
whole patient or target volumes and organs at risk.
Information about over- and underdosage and homogeneity of the dose in the
target volume is evaluated by calculating the fraction of the volume receiving
95% or 107% of the prescribed dose (V95%, V107%).
Other indices can be derived from the DVH and have been proven significant
in determining the quality of a treatment plan. In this study, the minimum and
maximum dose in the volume (DMin, DMax) as well as the mean and the median
dose in the volume (DMean, DMedian) have been calculated. Using these indices,
deviation from the planned dose can be evaluated as well as high dose regions
in organs at risk.
homogeneity index In addition to the V95% and V107% indices, the Homo-
geneity Index (HI) is used to determine the homogeneity of the dose distribution
inside the PTV. It is calculated from the dose difference between the highest and
the lowest dose inside the PTV. Small high- and low-dose regions are excluded
and instead of using DMax and DMin, D5% and D95% are used (Richter (2012)):
HI =
D5% −D95%
DP
(42)
To calculate D5% and D95%, the dose percentiles with the 5% highest and low-
est dose are removed. D5% is the maximum dose remaining, D95% is the mini-
mum dose remaining. The dose prescribed to the PTV (DP) is used to normalize
the dose values.
In a homogeneous dose distribution, the difference between the highest and
lowest dose in the PTV is smaller, therefore the resulting HI is smaller.
conformity index In addition to the previous indices, the conformity in-
dex (CI) is a measure of the the conformality of the treatment plan. In the
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implementation used in this study, it compares the dose deposited inside the
PTV to the dose deposited inside the whole body (Steidl (2011)). It is defined as
CI (PTV) =
R
PTV D(~x)d~xR
D(~x)d~x
(43)
The integral in the numerator (
R
PTV) evaluates only the dose inside the PTV;
the integral in the denominator covers the whole patient.
An ideal plan has a high CI (closer to 100%), and all dose is deposited inside
the target volume. When a higher fraction of the dose is deposited in the normal
tissue, this value decreases.
organs at risk For each of the evaluated organs at risk, a different dose
index was used. Because there is no absolute dose prescribed to the treatment
plans, no definitive dose limits can be established. Instead, the most suitable
predictors for adverse effects was employed for each organ at risk.
For the lungs, the relevant clinical end point is symptomatic pneumonitis. Be-
ing a parallel organ, the dose response is gradual and depending on both the
dose level and affected volume (Marks et al. (2010a)). Studies have identified the
highest predictive power when using volume indices, hence, the V20% was used
to describe the dose to each lung (Marks et al. (2010b)).
For the spinal cord, the relevant clinical end point is myelopathy. The spinal
cord is a serial organ and therefore susceptible to damage from small volumes
of high doses. Here, the maximum dose DMax has a high predictive power.
For the heart, pericarditis is the relevant clinical end point. Here, the mean
dose DMean to the heart muscle has the highest predictive power.
5.3 results
In this section, two sets of results are presented. First, the optimal planning
geometries are presented for each patient. Then, the viability of the dose calcu-
lation and analysis for use in an organ motion case is presented.
5.3.1 Optimal Treatment Planning Geometries
For each of the patients, optimal treatment planning geometries are presented.
In an optimal treatment plan, the dose coverage of the PTV is high and homoge-
neous; at the same time, the dose to the organs at risk must be reasonably small.
Because of the limited capabilities of the heavy ion gantry at the introduction,
two optimal treatment planning geometries are determined: One single-field ge-
ometry for the initially usable gantry angles and one two-field geometry using
gantry angles which should become available later.
First, the results of the dose optimization based on the treatment planning CTs
are presented. After that, the dose calculation on the motion 4D-CT is evaluated.
5.3.1.1 Planning CT Results
As a reference for the quality of the treatment plan, the results of the dose op-
timization and calculation based on the treatment planning CT are evaluated
first. The evaluation encompasses the coverage of the PTV including over- and
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underdosage, as well as the dose to organs at risk (lungs, spinal cord and heart
muscle). Only the most important indices are shown in Fig. 60, detailed results
are found in the appendix in section B.1 on page 143.
ptv coverage Coverage of the PTV was assessed using V95%(PTV), the Con-
formity Index (CI) and Homogeneity Index (HI) of the PTV. Independent of the
patient, the coverage was better in treatment plans using two irradiation fields.
V95%(PTV) is > 94% for all one-field geometries, > 98% for all two-field geome-
tries. All treatment plans show high conformality (CI(PTV) values > 0.82 for
all one-field geometries and > 0.90 for all two-field geometries) and high ho-
mogeneity (HI(PTV) < 9.5% for all one-field geometries, < 6% for all two-field
geometries).
Every treatment plan exhibited good PTV coverage, high dose conformity and
good homogeneity. Treatment plans using two fields had a small advantage over
plans using only one field.
ptv hot spots Overdose regions (“hot spots”) inside the PTV were assessed
using V107%(PTV) and DMax(PTV). The size of the volume subject to overdose
was similar in all patients, with V107%(PTV) < 1.2% for all one-field plans and <
0.3% for all two-field plans. In all patients and planning geometries, DMax(PTV)
< 120% DP except for patient 4 (geometry 2 (122%) and geometry 11 (133%)).
In general, only small volumes received a moderate amount of overdose. Again,
two-field treatment plans performed slightly better, with smaller overdose re-
gions. The dose maximum was similar in all geometries, and no pronounced
difference between one- and two-field geometries were found.
ptv cold spots Underdose regions (“cold spots”) inside the PTV were as-
sessed using V95%(PTV) and DMin(PTV). The size of the volume subject to un-
derdosage was dependent on the number of fields and the patient. For one-field
treatment plans, DMin(PTV) was as low as 40%, irrespective of the patient. For
two-field treatment plans, it depends on the patient: For patient 1, DMin(PTV) >
85%, patient 2 > 70%, patient 3: > 80%. For patient 4, DMin(PTV) > 70%, except
for geometry 9 with DMin(PTV) = 52%.
In general, one-field geometries showed more pronounced underdose regions
than two-field geometries. Additionally, patient 4, with a larger PTV and a
higher fraction of lung tissue inside the PTV, the treatment plan exhibited more
cold spots.
dose normalization Large regions with over- or underdosage, or regions
of extremely high or low doses inside the PTV, as well as errors in the normal-
ization of the dose can lead to a deviation in either median or mean dose of the
PTV. In all patients and all plan geometries, DMedian(PTV) and DMean(PTV) were
98 - 100%. No severe dose deviations were found in any plan and each treatment
plan was well normalized.
organs at risk For the organs at risk, V20% of the individual lungs, as
well as DMax(Spinal Cord) and DMean(Heart) were evaluated. For patients 1, 2
and 4, V20(Left Lung) < 22%, V20(Right Lung) < 20%. For patient 3, this was
even smaller, with V20(Lung) < 5% for both sides. For all patients, DMax(Spinal
Cord) was between 0 and 78% planned dose (DP). For an assumed planned
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Figure 60: Treatment Planning Results: Selected parameters of the resulting dose distri-
butions, calculated on the treatment planning CTs. All treatment plans are
viable treatment options; generally speaking, the two-field geometries (5 to
13) result in better treatment plans compared to one-field geometries (1 to 4).
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dose of 60 Gy (RBE), the tolerable dose to the spinal cord corresponds to 83%,
so all treatment plans are safe for treatment. The heart muscle and PTV are
overlapping in patients 1, 2 and 4, this region was not explicitly spared. For
these patients, DMean(Heart) ranged from 0 to 37%, depending on patient and
geometry. For patient 3, DMean(Heart) < 1%. For the assumed planned dose of
60 Gy (RBE), the tolerable dose corresponds to 43%, which was achieved in all
treatment plans.
summary With regard to the static planning CT, every generated treatment
plan is of high quality in terms of target coverage and achieves a high level of
organ at risk sparing. Some underdose regions are expected, mainly because of
the lung tissue included inside of the PTV, but all of the treatment plans can
potentially be used for treatment. In the static case, treatment plans with two
irradiation fields were performing better than treatment plans with only one
field.
5.3.1.2 4D-CT Quasistatic Calculation Results
In this section, the results of the quasistatic dose calculations are presented.
Again, only the most important dose indices are shown in Fig. 61, the detailed
results can be found in the appendix in section B.1 on page 143. For each dose
index and planning geometry, the range of the index values of all motion phases
are presented in a box plot.
ptv coverage For all patients and planning geometries, V95(PTV) is reduced
in contrast to the planning CT, in some cases down to 50%. The difference be-
tween single and dual field geometries has vanished. Instead, individual beam
geometries perform better than others, geometries 1, 2, 9, 10 and 11 are uni-
versally good in each patient. There is a large difference between individual
patients: For patient 1, V95(PTV) is 60-90%, patient 2: 50-90%, patient 3: 80-98%
and patient 4: 60-95%.
Similarly, the Conformity Index (CI) is reduced. As for the V95, geometries
1, 2, 9, 10 and 11 are still above 65% in all patients. For patient 1, CI is 35-80%,
patient 2: 40-80%, patient 3: 65-85% and patient 4: 50-85%.
The dose distribution is more inhomogeneous, which is reflected in the Ho-
mogeneity Index (HI). It is largely dependent on the patient. For patient 1, HI is
25-50%, patient 2: 15-80%, patient 3: 5-25%, patient 4: 5-25% (except for geome-
try 3 with up to 70%).
ptv hot spots Differences in water-equivalent path lengths can also lead
increased dose in overlapping treatment fields. Treatment plans with only one
treatment field are less susceptible to overdoses.
In comparison to the planning CTs, V107(PTV) is increased, although still be-
low 5% in most planning geometries. Geometry 5, 12 and 13 are exhibit high-
dose regions in up to 18% of the target volume.
For patient 1, V107(PTV) is 1 - 7%, (except for geometry 5: 18%), patient 2: 1 -
5%, (geometry 5: 10%), patient 3: 1 - 5%, (geometry 5: 15%), patient 4: 1 - 5%.
The maximum dose (DMax) has a median value between 110% and 125%
planned dose DP for most geometries. Only for patient 4 and geometry 11, a
max dose DMax of 140% DP is reached.
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Figure 61: Quasistatic Calculation Results: Selected parameters of the resulting dose
distributions, calculated on the 4D-CTs. All treatment plans have a reduced
target volume coverage, depending on the patient and treatment geometry.
The difference between one- and two-field geometries is reduced. Doses to
organs at risk do not vary for most patients and geometries.
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Regarding V107(PTV) and DMax, planning geometries with only one irradia-
tion field only show small deviations from the planning CT results. Treatment
plans with two fields show an increase of DMax due to overlapping fields.
ptv cold spots In comparison with the treatment planning CT calculations,
the minimum dose (DMin(PTV)) is decreased: For patient 1: 0-30% planned dose
DP, patient 2: 0-40% DP, patient 3: 20-80% DP, patient 4: 10 - 60% DP.
Of course, cold spots are a direct result of the organ motion inside of the PTV.
This is expected and the reason for the introduction of the ITV and PTV margins.
A cold spot inside the PTV can be tolerated as long as the CTV is still properly
irradiated.
dose normalization Larger volumes of over- or underdosage or extreme
deviations from the planned dose affect the median and mean dose applied to
the PTV. In this study, the median dose DMedian is 96 - 102% planned dose for
all patients, the mean dose DMean 90 - 102% planned dose.
DMean is reduced by up to 10% for patients 1 and 2, and by up to 3% for
patients 3 and 4. This result can be explained by larger low dose regions inside
the lung tissue.
organs at risk All organs at risk have a very similar radiation exposure
in comparison to the planning CT; the organ motion has almost no influence.
Hence, the results for lung, heart and spinal cord dose from the static calculation
are still valid.
There is only one exception in the case of patient 2, geometry 8. Here, a shift
in the position of the heart muscle reduces the water-equivalent path length for
one irradiation field, as seen in Fig. 67 on page 120. Here, the dose to the spinal
cord (DMax(Spinal Cord)) is dependent on the motion phase. This phenomenon
will be discussed later in context of the sensitivity of the algorithm.
summary As expected, all plan quality indices are degraded, which is due
to the free-breathing treatment planning CT not exactly matching any particular
motion phase. Depending on the slice position of the free-breathing CT, the
image data is acquired in different motion phases.
The distinction in plan quality between one-field and two-field geometries is
reduced, instead, individual geometries (1, 2, 9, 10, 11) provide a good coverage
of the PTV, with V95> 80%.
Doses to the organs at risk are similar to the treatment planning CT calcula-
tions, with the exception of one treatment geometry in patient 2, where a small
change in the water-equivalent path length increases the dose to the spinal cord
in some motion phases.
5.3.1.3 Optimal Treatment Geometries
Using the results of the quasi-static calculations, optimal treatment plans can
now be recommended. First, a general treatment planning strategy viable for
all patients is discussed. Then, the optimal treatment plans for each individual
patient are presented.
optimal treatment plans for all patients Based on the V95(PTV)
and Conformity Index, the planning geometries 1, 2, 9, 10 and 11 all performed
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reliably in each patient with a good coverage of the PTV. All treatment plans ex-
hibit a high plan quality, with V107(PTV) below 2.5% and DMin(PTV) comparable
to other treatment plans.
The difference between the treatment plans is found in the resulting dose to
organs at risk. Geometries 1 and 2 are single irradiation fields from anterior and
posterior, respectively, with almost no dose to the lungs (V20(Lung) below 5%).
Instead, dose is deposited in the heart muscle (DMean(Heart) up to 35% in Geom-
etry 1) or in the spinal cord (DMax(Spinal Cord) up to 75% in Geometry 2). These
geometries could give an advantage in patients with respiratory preconditions.
Geometries 9, 10 and 11 are all from posterior and using two treatment fields,
which reduces the dose to the heart muscle (DMean < 16%) and the spinal cord,
depending on the geometry. However, the dose to the lungs is increased, either
to both lungs (Geometry 9, V20(Lung) < 13%) or mainly to one side (Geometry
10, V20(Left Lung) < 23%; Geometry 11, V20(Right Lung) < 18%). Geometry 9
features the best compromise between both lungs and dose to the spinal cord
(DMax(Spinal Cord) < 65%).
All treatment plans result in a good target volume coverage in each patient
and tolerable doses to the organs at risk. Individual patient predispositions can
be accounted for by choosing a treatment plan which spares the corresponding
organ.
individual optimal treatment plans While the treatment planning
geometries 1, 2, 9, 10 and 11 are universally good treatment options in all pa-
tients alike, it is desirable to know which treatment plan is optimal for each
individual patient and their respective target volume position and size. To find
this optimal treatment plan, the treatment plans with the best coverage of the
PTV, indicated by a high V95 and Conformity Index, were selected. Out of this
selection, the treatment plan which best spared the organs at risk was chosen as
optimal treatment plan. For each patient, a one-field and a two-field treatment
plan was selected.
optimal treatment plan for patient 1 For patient 1, geometries 1, 2,
6, 9, 10 and 11 yield plans with good coverage (V95(PTV) > 80%, CI > 70%).
None of the treatment plans show signs of severe overdosage (V107 > 4% only
in geometries 5, 12 and 13).
Out of the one-field geometries, the selection between Geometry 1 and 2 is
a trade-off between higher dose to the heart muscle or the spinal cord. Ge-
ometry 1 yields 29% DMean(Heart), 20% DMax(Spinal Cord); Geometry 2 yields
9% DMean(Heart), 68% DMax(Spinal Cord). In both cases, V20(Lung) < 1%. To
reduce the risk of damage to the spinal cord, Geometry 1 is preferred.
Out of the selected two-field geometries, all plans yield a similar dose to the
lungs and heart muscle (V20(Lung) < 7%, DMean(Heart) < 10%. The largest
difference is found in the dose to the spinal cord, with 39% DMax(Spinal Cord)
as the minimum value in Geometry 10. Therefore, this geometry is preferred.
The optimal treatment plans for patient 1 are Geometries 1 and 10, as shown
in Fig. 62. This treatment plan might even be optimized by weighting the fields
differently or a combination of 1 and 10 to spare the spinal cord even further.
optimal treatment plan for patient 2 For patient 2, geometries 1, 2,
7, 9 and 11 yield plans with good coverage (V95(PTV) > 80%, CI > 70%). None
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(a) Geometry 1 (b) Geometry 10
Figure 62: Optimal Treatment Plans for Patient 1: Both Geometry 1 and 10 reduce the
dose to the spinal cord while yielding a high PTV coverage. A combination
of geometry 1 and 10 could further improve the resulting dose distribution.
(a) Geometry 1 (b) Geometry 9
Figure 63: Optimal Treatment Plans for Patient 2: Geometries 1 and 9 yield the highest
PTV coverage and lowest dose to the spinal cord. The results are similar to
Patient 1.
of the treatment plans show signs of severe overdosage (V107 > 4% only in
geometries 5 and 8).
As with the previous patient, the selection between geometries 1 and 2 is
a trade-off between higher dose to the heart muscle or the spinal cord. Ge-
ometry 1 yields 18% DMean(Heart), 22% DMax(Spinal Cord); Geometry 2 yields
4% DMean(Heart), 69% DMax(Spinal Cord). In both cases, V20(Lung) < 2%. To
reduce the risk of damage to the spinal cord, Geometry 1 is preferred.
Out of the selected two-field geometries, all plans yield a similar dose to the
lungs and heart muscle (V20(Lung) < 12%, DMean(Heart) < 12%. The largest
difference is found in the dose to the spinal cord, with 49% DMax(Spinal Cord)
as the minimum value in geometry 9. Therefore, this geometry is preferred.
The optimal treatment plans for patient 2 are geometries 1 and 9, as shown
in Fig. 63. This patient is very similar to patient 1 in terms of PTV size and
localization and has similar treatment planning results.
optimal treatment plan for patient 3 Patient 3 is different from the
first two patients, with a smaller, more cranial and less mobile PTV, which re-
sults in a better coverage in the quasi-static dose calculations. In this patient,
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(a) Geometry 1 (b) Geometry 5
Figure 64: Optimal Treatment Plans for Patient 3: The cranial position of the PTV re-
duces the dose to the lungs and the heart muscle. Geometries 1 and 5 yield
the highest PTV coverage with the smallest dose to the spinal cord.
geometries 1, 2, 5, 6, 9, 10, 11, 12 and 13 result in plans with very good cover-
age (V95(PTV) > 90%, CI > 70%). Some of the treatment plans show signs of
overdosage (V107 > 4% in geometries 5 and 6).
Because of the cranial position of the PTV, the dose to the heart muscle can
be neglected for all treatment plans, DMean(Heart) < 1%. Similarly, the dose
to the lungs is reduced. Therefore, the selection between Geometry 1 and 2 is
simple, in both cases, V20(Lung) < 1%. Geometry 1 yields 20% DMax(Spinal
Cord), geometry 2 72% DMax(Spinal Cord), hence, geometry 1 is preferred.
Choosing the optimal two-field geometry is less straightforward. Out of the se-
lected two-field geometries, all plans yield a similar dose to the lungs (V20(Lung)
< 4%. Again, the largest difference is found in the dose to the spinal cord, with
DMax(Spinal Cord) < 1% as the minimum value in geometry 5. Unfortunately,
this is also the treatment plan with the highest overdose volume (V107(PTV) =
13%). On the other hand, this approach reduces the dose to the spinal cord to
almost zero.
The optimal treatment plans for patient 3 are Geometries 1 and 5, as shown in
Fig. 64. While Geometry 5 allows an irradiation with almost no dose to the spinal
cord, setup uncertainties and motion might lead to overdose regions inside the
PTV. Here, the single-field treatment plan might be more robust, especially as
the intra-fractional motion is smaller and the general coverage of the PTV is
already high with just one treatment field. Indeed, the irradiation through the
shoulder section might not be practical in every patient.
optimal treatment plan for patient 4 Patient 4 is also different from
the other patients, with a caudal PTV twice as large as compared to patients 1
and 2. This can lead to a larger dose to the lung tissue. In this patient, geometries
1, 2, 7, 9, 10, 11 and 13 yield plans with very good coverage (V95(PTV) > 90%,
CI > 75%). None of the treatment plans show signs of severe overdosage (V107 <
4%).
As with patients 1 and 2, the selection between Geometry 1 and 2 is a trade-off
between higher dose to the heart muscle or the spinal cord. Geometry 1 yields
31% DMean(Heart), 24% DMax(Spinal Cord); Geometry 2 yields 13% DMean(Heart),
68% DMax(Spinal Cord). In both cases, V20(Lung) < 4%. To reduce the risk of
damage to the spinal cord, Geometry 1 is preferred.
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(a) Geometry 1 (b) Geometry 7
Figure 65: Optimal Treatment Plans for Patient 4: Geometries 1 and 7 yield a high PTV
coverage. The selection of treatment fields from anterior and posterior re-
duces the dose to the lungs significantly, as this larger target volume is situ-
ated between the lungs.
Figure 66: Coronal View of the Target Volume of Patient 4 and the dose distribution re-
sulting from geometry 1 (one field from 0◦ gantry angle): Due to the size and
position of the PTV, lateral treatment fields increase the dose to the lung sig-
nificantly. Hence, treatment fields from anterior and posterior are preferred.
Out of the selected two-field geometries, all plans yield a similar dose to the
spinal cord (DMax(Spinal Cord) < 56%). A large difference can be found be-
tween the planning geometries 9, 10, 11 and 13 (higher lung dose, V20(Lung) <
23%, lower heart dose, DMean(Heart) < 16%) and Geometry 7 (lower lung dose,
V20(Lung) < 4%, higher heart dose, DMean(Heart) = 26%). Using Geometry 7, a
small increase in heart dose yields a better sparing of lung tissue.
The optimal treatment plans for patient 4 are therefore geometries 1 and 7, as
shown in Fig. 65. The longer PTV (illustrated in Fig. 66) leads to an increased
dose to the lungs which can be mitigated by irradiating from the front and the
back of the patient, sparing the lung tissue.
5.3.2 Sensitivity of the Dose Calculation to Organ Motion
In contrast to the previous section, which concentrated on the optimal treatment
solution, this section concentrates on the sensitivity of the calculation method.
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Three examples are presented: Variation of the calculated dose to organs at risk
due to organ motion, definition of a CTV margin from quasi-static dose calcula-
tion and definition of gating window sizes from 4D dose calculation results.
5.3.2.1 Variation in Spinal Cord Dose
For most organs at risk, the calculated dose indices did not vary in between the
dose calculations based on the treatment planning CT and the 4D-CTs. This was
not the case for patient 2, geometry 8. In this case, DMax(Spinal Cord) calcu-
lated on the treatment planning CT is 17% DP. In the quasi-static calculation,
DMax(Spinal Cord) covers a range of 17% to 63% DP.
In Fig. 67, this phenomenon is explained: Because of the motion of the heart
muscle in the different motion phases, the water-equivalent path length changes
in between the treatment planning CT and individual motion phases of the 4D-
CT. Because of that, some parts of the treatment fields have a higher range
than necessary and the dose is deposited in the spinal cord. This effect is not
foreseeable from the treatment planning CT alone and can be used to increase
robustness of treatment plans.
5.3.2.2 CTV Coverage and Margins
According to ICRU reports 50, 62 and 83 (Landberg et al. (1993, 1999); Grégoire
et al. (2010)), a PTV should be created by adding a margin to the CTV, accounting
for uncertainties in patient setup and motion. It is designed in such a way, that
the respective CTV is always covered by the prescribed dose. In the previous
analysis, only the coverage of the PTV is assessed, not the coverage of the CTV.
To estimate the required internal margin from the dose calculations, it is neces-
sary to start from a CTV and add margins of different sizes to the PTV, optimize
a treatment plan and evaluate the dose inside the CTV. Due to the preliminary
scope of this study, this was not done. Instead, a CTV is calculated from the
PTV by uniformly shrinking the PTV. The resulting dose inside this CTV is then
evaluated.
The CTVs are created in steps of 2 mm (CTV 1 is PTV minus 2 mm, CTV 2 is
PTV minus 4 mm). Using the dose distributions calculated earlier, V95%(CTV) is
calculated for each of the CTV contours.
For this analysis, only the optimal treatment plans, as defined in the previous
section, are analyzed. Once the median V95(CTV) exceeds 95%, the coverage is
assumed to be a sufficient. In Fig. 68, the results of the evaluation are presented.
For patient 1, the optimal plan geometries were 1 and 10. For this patient,
a margin of 6 mm is required to reach sufficient coverage(V95(CTV 3) > 95%).
Similarly, for patient 2 (plan geometries 1 and 9), a margin of 6 mm is required.
For patient 3, the initial coverage of the PTV is already higher. For this patient
(plan geometries 1 and 5), only a margin of 2 mm is required (V95(CTV 1) >
95%). For patient 4 (plan geometries 1 and 7), a margin of 4 mm is sufficient
(V95(CTV 2) > 95%).
An isotropic margin of 6 mm is therefore sufficient for the optimal plan geome-
tries of all patients. An increased margin of 8 mm results in a V95(CTV) > 95%
for all recommended geometries (1, 2, 9, 10 and 11) in all patients.
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(a) Static Planning CT
(b) 4D-CT In75%
(c) 4D-CT Ex0%
Figure 67: Sensitivity of the Algorithm to Organ Motion: Overshoot into the spinal cord,
observed in patient 2, plan geometry 8: The dose to the spinal cord is small
in the planning CT (a). Due to movement of the heart muscle, visible in
the 4D-CT (b), (c), parts of the treatment field overshoot into the spinal cord,
leading to higher doses. Depending on the motion phase, the maximum dose
changes.
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(b) CTV 1 (PTV - 2 mm)
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(c) CTV 2 (PTV - 4 mm)
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(d) CTV 3 (PTV - 6 mm)
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(e) CTV 4 (PTV - 8 mm)
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(f) CTV 5 (PTV - 10 mm)
Figure 68: CTV Coverage and Margins: An artificial CTV is created from the PTV which
is used to estimate the necessary internal margin. For patients 1 and 2, a
margin of 6 mm is necessary to reach the same V95% as in the treatment
planning calculation. For patient 2, a margin of 2 mm is sufficient, for patient
4, a margin of 4 mm is necessary.
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(a) V95%(PTV) for Patient 2, Geometry 5
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(b) DMax(Spinal Cord) for Patient 2, Geometry 8
Figure 69: Gating Window Definition: Results of the quasi-static dose calculations as a
function of the 4D-CT motion phase. This information can be used to define
the size of a gating window.
5.3.2.3 Gating Window Definition
Finally, a preliminary investigation into the definition of gating window sizes
was started. While the quasistatic calculation is not able to predict interplay
effects as a result of organ motion, it can give a hint at which motion phases
result in a reduced PTV coverage or increased dose to an organ at risk. This
information can be used to base a decision for or against gating, and to define a
gating window size.
To find an optimal gating window, one treatment plan is selected for an indi-
vidual patient. Then, a desired dose parameter which describes the treatment
plan quality or dose to an organ at risk (V95%(PTV) or DMax(Spinal Cord)) is
calculated as a function of the motion phase. If there is a large variation of this
parameter as a function of motion phase, gating can be beneficial for the patient
and the gating window should be chosen to encompass the motion phases with
high PTV coverage or low organ at risk dose.
Two examples based on the results of patient 2 are illustrated in Fig. 69. In
Fig. 69a, the V95%(PTV) values for planning geometry 5 exhibit a dependence on
the motion phase, the values oscillate between 45% to 80%. A gating window
between In75% and Ex70% could increase the V95%(PTV) to between 75% to 80%.
In Fig. 69b, DMax(Spinal Cord) is presented for planning geometry 8. Without
gating, the maximum dose in the spinal cord could reach up to 63% prescribed
dose DP. With a gating window between In25% and In50%, the max dose could
be reduced to 17% DP.
Using gating, critical motion phases can be avoided and optimal gating win-
dows can improve sparing of organs at risk and cover of the target volume. The
quasistatic dose calculation can be used as a basis to define the gating windows.
5.4 summary
In October 2012, the HIT Heavy Ion Gantry was introduced, offering new treat-
ment planning options. This treatment planning study explored the feasibility of
using the gantry for the treatment of esophageal cancer patients. Using the data
sets of four patients with different target volumes, the robustness of 13 different
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planning geometries were tested. The tested plan geometries reflect the initial
and projected capabilities of the gantry.
For each patient, a free-breathing treatment planning CT and a co-registered
4D-CT with seven motion phases was available. Using the treatment planning
CTs, treatment plans were optimized, with all treatment plans passing accep-
tance criteria as a suitable patient treatment plan.
The resulting dose distributions of each treatment plan were then calculated
on each individual motion phase of the 4D-CT. In contrast to a proper 4D dose
calculation, the beam was not split up and divided over the motion phase, in-
stead, the whole treatment plan was calculated on one phase. This quasi-static
approach made the calculation possible despite the lack of breathing curves and
removes a lot of complexity from the calculations. On the other hand, this re-
moves the interplay effects from the calculated dose distributions.
For each patient and treatment plan combination, the quasi-static calculations
showed an expected decrease in target volume coverage. In most cases, doses
to the organs at risk were unaffected, with the exception of one treatment plan
where the dose to the spinal cord was highly sensitive to organ motion.
In total, five treatment planning geometries were found which universally re-
sulted in a high target volume coverage and low doses to organs at risk for each
patient. Additionally, two optimal treatment plans were found for each patient:
One optimal treatment plan using just one treatment field, reflecting the initial
capabilities of the heavy ion gantry, and one optimal treatment plan using two
treatment fields, reflecting the projected capabilities of the heavy ion gantry.
While treatment plans with two irradiation fields showed better target volume
coverage in the treatment planning calculation using the static treatment plan-
ning CT, they were not found to perform better than the single-field treatment
plans when organ motion was considered.
In addition to investigating the optimal treatment plans, the feasibility of using
the quasi-static dose calculation to account for the effects of organ motion was
tested. The preliminary study concluded that this method is sensitive to organ
motion and was useful in detecting changes in target volume coverage and doses
to organs at risk. It was shown to be sensitive enough to estimate the size of ITV
margins and gating window, increasing the target coverage and reducing the
dose to organs at risk.
5.5 discussion
While this treatment planning study resulted in several recommendations with
regard to esophageal irradiations using the HIT Heavy Ion Gantry, it should be
treated as a preliminary study due to the omission of several motion effects. In
the previous chapters, the particle fluence was accurately distributed between
all motion phases to include interplay effects. This calculation is sensitive to the
breathing pattern, starting phase and accelerator performance, all of which was
not included. In addition, only one treatment planning CT and a co-registered
4D-CT was used in the study, both of which were created on the same day.
Hence, inter-fractional motion and setup inaccuracies were not part of this study.
Including these motion effects could alter the optimal treatment planning strat-
egy. Especially the difference in dose distributions between this quasi-static cal-
culation and a full 4D dose calculation should be examined in a follow-up study.
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It should include a patient data set with more CTs to estimate the inter-fractional
variability as well as measured or estimated breathing patterns.
Aside from these shortcomings, the quasi-static approach still accounts for
range differences and the motion of the target volume and has been shown to be
sensitive to motion effects.
Future studies should include refined treatment planning geometries. With
the HIT Heavy Ion Gantry now in operation, all available gantry angles can now
be included into the study. Additionally, treatment plans with three or more
irradiation fields could be included.
Regarding the treatment planning process, the organs at risk were not specifi-
cally spared in this study. While all treatment plans feature a suitable sparing of
organs at risk, this dose could be further reduced in favor of re-irradiation pos-
sibilities. The robustness of such treatment plans could be the focus of further
studies.
6
D I S C U S S I O N
In 2009, the Heidelberg Ion-Beam Therapy Center (HIT) started treatment of the
first patients, most of them suffering from head and neck cancer. Treatment of
the first hepatocellular carcinoma (HCC) patients with stereotactic body radio-
therapy (SBRT) in 2011 and the introduction of the heavy ion gantry in 2012
presents new challenges and offers new treatment options.
Treatment of moving organs requires the employment of adequate motion
mitigation techniques and evaluation of the irradiation, for which a new work
flow was introduced. In this thesis, the additions to the work flow for the SBRT
of HCC were presented, including the treatment of the first beam-gated patient
at HIT and the calculation of 4D dose distributions, contributing to a safe and
reliable treatment.
Calculation of 4D dose distributions not only require a precise understanding
of organ motion, but also of the dynamics of the irradiation process. To provide
this, an analysis and simulation of the HIT accelerator timing structure was
presented and verified using patient treatment records and experimental data.
This offers an improved 4D dose calculation and is currently used to simulate
the HIT accelerator.
Finally, the introduction of the heavy ion gantry provides new degrees of
freedom for treatment planning, which was investigated in a treatment planning
study for esophageal carcinoma. This study demonstrated the efficacy of the
heavy ion gantry for the treatment of esophageal cancer and demonstrated the
sensitivity of a quasi-static dose calculation to organ motion.
introduction of a new work flow for liver irradiations
While the introduction of SBRT for the treatment of HCC was a success (Haber-
mehl et al. (2013); Richter et al. (2014)) and the irradiation of moving organs is
now performed routinely at HIT, the work involved in the preparation, data ac-
quisition and evaluation necessary for each patient is substantial. It is in theory
possible to calculate simulated dose distributions directly after treatment plan-
ning and to reconstruct dose distributions after each treatment fraction. In real-
ity, dose calculations were finished when the patient was already treated. This is
due to a very time-consuming data acquisition and evaluation process, in which
the breathing curves, the irradiation logs, the CTs, vector fields and contours
must be exported, calculated and converted into the proper input files needed
for TRiP-4D. In addition, at the time of writing, the standard implementation
of TRiP-4D was only available on the computer cluster at GSI, which required
a transfer of the data to Darmstadt for calculation and return to Heidelberg for
evaluation. Accelerating this process would substantially increase the relevance
of these calculations, enabling treatment planners and physicians to adapt the
treatment.
Some steps of the data preparation and conversion have been automated using
python scripts and dynamic TRiP executables. While this certainly simplified the
work during this thesis, it was not user-friendly enough to be used by clinical
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personnel. To meet this requirement, an integration into a more user-friendly
framework (MeVisLab by MeVis Medical Solutions AG, Bremen, Germany) was
initiated, but not completed.
Currently, relevant treatment data is acquired from several different sources,
like the treatment control system (TCS) and the ANZAI AZ-733V gating interface,
which have to be synchronized manually. This data acquisition during the pa-
tient treatment could be further improved by a close integration of the EtherCAT
system. The EtherCAT system is a part of the accelerator control system (ACS) al-
ready in place at HIT and provides all relevant accelerator data simultaneously
and in real time, including the ANZAI AZ-733V breathing motion signal, and
could become the exclusive source for data acquisition.
With integrated automation, further features could be implemented, like au-
tomatic dose calculation on the daily CT used for image guidance. Current fast
dose calculation developments, like the FRoG framework (Mein et al. (2018)),
might enable fast re-planning in the future.
Using the ANZAI AZ-733V system to monitor the organ motion only gives
limited information, as it operates only with a load cell in one position on the
chest wall. Changes in the correlation between this surrogate signal and the
internal motion is not detectable with this set-up, and should be augmented with
regular imaging of internal markers (Seppenwoolde et al. (2011)) or ultrasound
imaging (O’Shea et al. (2016)).
Gating was successfully introduced as a motion mitigation technique in this
work flow. One of the main characteristics of this mitigation technique is the long
duration of the treatment, especially when patient compliance is low. To increase
the speed of the treatment, other motion mitigation techniques, like rescanning
and tumor tracking should be investigated and implemented. Further, imple-
mentation of deep-inspiration breath hold techniques instead of free breathing
has been shown to reduce residual motion and irradiation times in treatment of
hepatocellular carcinoma (Boda-Heggemann et al. (2016)).
Treatment planning with the HIT treatment planning system (TPS) syngo®
RT Planning is currently limited to 3D dose calculation. Other TPS are capable
of 4D dose calculation and can be used to create more robust treatment plans,
including rescanning. It would be desirable to be able to import more robust
treatment plans into the HIT TPS.
analysis and modeling of the hit accelerator cycle
In this thesis, an improved version of the accelerator simulation was presented,
which takes the specific properties and variability of the HICAT accelerator into
account. The quality of the prediction was demonstrated in various analyses
of beam data and validated experimentally. However, deviations between the
simulation and the measurements have been identified.
With the implementation of the intensity feedback system (Schömers et al.
(2011); Schömers (2013)), the variability of the irradiation decreased, revealing
subtle deviations between the simulation an the actual behavior of the accelera-
tor. The reasons for this discrepancy may be in the data acquisition and process-
ing, or it may be from accelerator properties which were not implemented yet.
This includes effects like spill pauses (short interruptions of the beam extraction
in treatment plans with disjunctive fluence patterns), interlocks (longer interrup-
tions introduced by errors encountered during treatment) and deviations in the
discussion 127
spill structure from the ideal (finite rise time and deviation from the nominal
intensity). Also, the reduction of beam intensity at low beam energies has not
been implemented, although all measurements have been carried out at higher
energies, evading this effect in this study.
Along with the desire to implement current properties of the HICAT accel-
erator, new features should become available in the simulation as they are im-
plemented in the actual accelerator. This encompasses plan-specific intensity
control (Schömers et al. (2013)), which adjusts the beam intensity for each raster
point, and re-acceleration, which will enable the accelerator to change the beam
energy using the remaining particles in the synchrotron. Introduction of dif-
ferent accelerators or accelerator modes could be used to study the influence
of accelerator properties on treatment plan robustness. Introduction of proton,
helium and oxygen ion beams should be simple to implement and offer the
flexibility to conduct comparative treatment planning studies. Gating is not yet
implemented in the current implementation, because it requires the knowledge
of the treatment plan, breathing motion curve and gating window, but could be
added to future implementations.
The base data set used in the simulation is compiled from multiple sources
of the accelerator control system and treatment control system. Gathering all
the information is a time-consuming task and must be repeated each time a fea-
ture of the accelerator is changed, or else the simulation will become outdated.
A solution to this challenge could be the implementation of specially devised
treatment plans which automatically irradiate a wide range of the accelerator
parameter space. The resulting irradiation records could be evaluated automati-
cally, extracting the parameters necessary for the simulation. This approach may
even improve the quality of the simulation by removing some of the complexity.
Experimental verification of the simulation software was performed in a mov-
ing water phantom, which is already a very sensitive test of the dose calculation
quality. However, measurements anthropomorphic phantoms can be used to re-
veal the clinical impact of organ motion and verify the dose calculation accuracy.
Anthropomorphic abdominal phantoms have already been used to validate the
accuracy of image registration, including dosimetric measurements (Liao et al.
(2017)). Similar pelvis phantoms are developed at DKFZ, including MRI and
PET contrast enhancements for improved imaging (Johnen et al. (2018, 2019)).
4d treatment planning study for esophageal cancer
This treatment planning study found optimal treatment plans for carbon-ion
boosts of esophageal cancer. However, due to the difference between the free-
breathing treatment planning CT and the motion phases of the 4D-CT, the PTV
coverage calculated for the 4D-CTs was reduced in most patients. The analysis
showed that additional margins could be used to increase the target coverage,
however, this approach also increases the dose to the organs at risk. Hence, fur-
ther motion mitigation methods should be introduced, including deep-inspiration
breath hold, rescanning techniques and beam gating.
Due to the limited data set, effects of inter-fractional motion could not be
taken into account. Effects of anatomical variability and tumor response, for
example volume reduction, will change radiological path lengths and PTV cov-
erage. Daily image guided radiotherapy (IGRT) and adaptive planning strategies
are advised for the treatment of esophageal carcinoma (Han et al. (2012)).
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In the study, optimal treatment plans for each patient were selected from thir-
teen fixed geometry templates. Treatment plans could be further improved by
fine-tuning the treatment geometries to better fit the patient anatomy and by in-
troducing treatment geometries with more treatment fields. Further, prioritizing
the optimization for increased coverage of the target volume or better sparing of
organs at risk could increase the treatment plan quality.
Closely related, the role of the organs at risk is not entirely understood. Pul-
monary toxicity is a major problem and the dose must be as low as reasonably
achievable (Lee et al. (2003)). Further, even low-dose volumes of sufficient sizes
are an important risk factor (Wang et al. (2006)). On the other hand, increased
sparing of the lungs comes at the cost of higher heart dose, as seen in this study
and by Zhang et al. (2008). This increases the risk for reduced myocardial per-
fusion (Gayed et al. (2006)) and reduced heart volume (Haj Mohammad et al.
(2015)). Currently, the significance of cardiac toxicity is not yet fully understood
in esophageal cancer therapy, mainly due to the limited prognosis of esophageal
cancer patients (Beukema et al. (2015)). For the final treatment decision, these
options must be weighed, however, compared to conventional therapy, carbon-
ion irradiation will likely reduce the dose to the heart and lungs, reducing the
adverse effects.
Due to the lack of motion information, intra-fractional motion could not be
properly included in the dose calculation, leading to the quasi-static dose cal-
culation approach seen in this study. This way, the interplay effect between the
scanning motion of the ion beam and the organ motion is not properly taken into
account (Phillips et al. (1992); Bert et al. (2008)). To quantify the impact of the
interplay effect on the proposed treatment plans, the study could be extended to
patients with more available data, such as breathing curves and additional CTs
over the course of the treatment. Using a proper 4D dose calculation and 4D-CTs
from different treatment days, the robustness of treatment plans with respect to
intra- and inter-fractional motion could be quantified.
Diaphragm motion and the gas-filling of the stomach have already been shown
to impact target volume coverage (Zhang et al. (2008)) and need to be taken into
account. As a mitigation measure, asymmetrical margins have been proposed
(Zhao et al. (2007)). The calculations performed in this analysis offer a way
to determine the impact of organ motion on the target coverage and estimate
necessary margin and gating window sizes. By improving the calculation speed,
it could become a tool to help during the treatment planning process, estimate
the robustness of a patient plan and quickly select the optimal treatment.
7
C O N C L U S I O N
In this thesis, a new work flow and data acquisition strategy were presented for
the treatment of hepatocellular carcinoma (HCC) using stereotactic body radio-
therapy (SBRT) at the Heidelberg Ion-Beam Therapy Center (HIT). Initially, thir-
teen patients were treated, including the first patient treatment using respiratory
beam gating. Based on the data sets acquired from each patient, simulated and
reconstructed 4D dose distributions can now be calculated. The implemented
work flow is used for treatment of HCC and other SBRT treatments at HIT.
To improve the accelerator timing prediction, the properties of the HIT syn-
chrotron cycle were investigated, revealing energy-dependent and stochastic as-
pects as well as day-to-day beam intensity fluctuations. A simulation was imple-
mented based on a realistic energy-dependent model of the synchrotron cycle,
the stochastic daily intensity fluctuations were implemented as a randomly se-
lected beam intensity. The accuracy of the resulting irradiation sequences was
verified using treatment records. Experimental verification of a patient treatment
plan was performed in a moving water phantom, where a total dose deviation of
(1.0±7.3)% was determined. The simulation software has been used for research
done by other colleagues of the work group.
To assess the potential of the HIT heavy-ion gantry, introduced into the clini-
cal routine in late 2012, a treatment planning study was presented. In the study,
optimal plan geometries for a carbon ion boost for the treatment of esophageal
carcinoma were determined for four patient cases and a selection of thirteen dif-
ferent planning geometries. Using a quasi-static dose calculation approach, the
effects of intra-fractional organ motion were taken into account. The resulting
dose distributions can potentially be used to define volume margins and gating
window sizes.
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A N A LY S I S A N D M O D E L I N G O F T H E H I T A C C E L E R AT O R
C Y C L E
a.1 example of a simulated lmdout file
Simulated beam delivery sequence for the VX-Vorbestrahlung treatment plan:
!comment This file was created by makeLmdout
!modality CVS
!fileversion 1.0
!date 20130919
!patient_name patient
!comment Offset, timeunit and items are specific for CVS files
!offset 0
!timeunit 1
!items T NP BS ES EOP E F I
0 0 0 0 0 0 0 0
25000 0 1 0 0 0 0 0
26690 1 1 0 0 0 0 0
28311 2 1 0 0 0 0 0
29885 3 1 0 0 0 0 0
31455 4 1 0 0 0 0 0
33033 5 1 0 0 0 0 0
34603 6 1 0 0 0 0 0
36163 7 1 0 0 0 0 0
37728 8 1 0 0 0 0 0
39298 9 1 0 0 0 0 0
40865 10 1 0 0 0 0 0
[...]
77515468 5925 11 10 5 0 0 0
77528759 5926 11 10 5 0 0 0
77542825 5927 11 10 5 0 0 0
77559500 5928 11 10 5 0 0 0
77559501 5928 11 10 6 0 0 0
77559502 5928 11 11 6 0 0 0
T: Time in microseconds, NP: NextPoint (raster point index), BS: BeginSlice
(start of a beam extraction), ES: EndSlice (end of a beam extraction), EOP: End-
OfPlane (change of energy)
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a.2 additional results
a.2.1 Results of the Broadcast Pause Correction
In the initial implementation of the simulation software, a discrepancy between
the simulated and reconstructed beam delivery sequences became apparent. The
length of the pause between two consecutive irradiations was under-estimated
by approximately 400 milliseconds. For easier readability, this was not discussed
in detail in the main body of the thesis and all results presented already use the
corrected pause length (see section 4.3.1.3, page 74). For comparison and to
see the validity of the corrections, here are the results of the first, un-corrected
simulation calculations.
Fig. 70 shows the results of Analysis I using the initial version of the simulation
software, showing a discrepancy between the simulated pause times TPause and
the observed pause times1. In this first analysis, the median duration of all
pauses larger than 2 seconds in the 2012 data set is 4.48 s (“Measurement”),
while the simulation has a median value of 4.01 s. Likewise, in the 2013 data set,
the median pause duration is 4.43 s, while the simulation yields a median value
of 4.02 s.
This difference between the simulated and measured pause lengths led to the
investigation presented in section 4.2.2.3, page 52. This investigation found that
the additional pause can be attributed mainly to the broadcast delay introduced
by the accelerator control system (ACS) in the beginning and the end of each
synchrotron cycle. In addition to the broadcast delay, which is contributes ap-
proximately 350 milliseconds of pause time, the time needed to start the beam
extraction adds another 50 milliseconds.
The simulation software was corrected by adding an additional 400 ms pause
to each acceleration cycle. To test the validity of this additional pause, Analysis
II was performed with both versions of the simulation software. In Fig. 71, both
analyses are presented next to each other, with the uncorrected simulation on
the left and the corrected simulation on the right. Further, Table 4 contains the
median root mean square time difference.
Data Set Uncorrected Corrected
2012 3.73 s 3.40 s
2013 1.34 s 0.72 s
Table 4: Median Root Mean Square Deviation in seconds for the uncorrected and cor-
rected version of the simulation software.
In summary, the additional pause reduces the deviation between the simu-
lated and the recorded beam delivery sequences, improving the accuracy of the
simulation. The investigation and results of the analysis legitimize the imple-
mentation of the broadcast pause correction in the simulation software.
1 Compare to Fig. 36, page 73.
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Figure 70: Results of Analysis I (Timing Spectra Analysis) of the first simulations of the
VX-Vorbestrahlung treatment plan. In this analysis, a discrepancy of 400 ms
was found between the measured (left) and simulated (right) beam delivery
sequences. This led to the investigation of the accelerator pause times and
inclusion of the broadcast delay time into the simulation.
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Figure 71: Results of Analysis II (Root Mean Square Deviation) using the uncorrected
(left) and corrected (right) simulation software. Smaller values correspond
to a better agreement between simulation and measured beam delivery se-
quences. By including the broadcast delay into the simulation, the results
are improved. This is also reflected by the median Root-Mean-Square values
presented in Table 4.
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a.2.2 Sensitivity of the Measured Doses to Phase Deviation
a.2.2.1 Phase Shift Between Simulated and Reconstructed Dose Distributions
In the analysis comparing the simulated dose distributions to the dose distri-
bution reconstructed from irradiation records, a difference was found between
the 2012 and 2013 data set, which is mainly attributed to the introduction of
the Dynamic Intensity Control (DIC) in early 2013. Before, the beam intensity
varied immensely from day to day, leading to low repeatability of the irradia-
tion. Because of the large variation in the timing of the irradiation, the resulting
dose distribution is very independent of the starting phase of the motion, which
was also found in Fig. 43 on page 82. With the introduction of the DIC, beam
intensities are more stable and irradiations show higher repeatability. Dose dis-
tributions are now dependent on the starting phase of the motion.
In the analysis, only the comparison with all phases (Fig. 44 on page 83) and
the φ = 30◦ starting phase (Fig. 45, page 84) were shown, proving the motion
starting phase dependence of the 2013 data set and showing a phase shift of 30◦.
Here, additional results for Analysis IV for the 2013 data set are presented,
showing that a motion starting phase of φ = 30◦ is the best fit for the simu-
lated dose distributions. In Figs. 72, 73 and 74, the simulated dose distributions
(shown as box plots) were calculated with starting phases φ = 0◦, 30◦ and 60◦,
respectively. The dose distributions reconstructed from beam records (shown as
blue circles) were calculated with a motion starting phase of φ = 0◦.
Both in the upper plots of the dose values and the Kolmogorov-Smirnov
test below, the highest agreement between the simulation and reconstruction
is achieved with a simulated motion starting phase of φ = 30◦. Reasons for
this phase deviation may be found in the irradiation records, as the phase shift
vanishes in the experimental verification.
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Figure 72: Reconstructed dose values for the 2013 data set, using start phase φ = 0◦ for
the simulated dose distributions. Above: Simulated data (box plots), recon-
structed data (blue circles); below: Kolmogorov-Smirnov p values.
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Figure 73: Reconstructed dose values for the 2013 data set, using start phase φ = 30◦ for
the simulated dose distributions. Above: Simulated data (box plots), recon-
structed data (blue circles); below: Kolmogorov-Smirnov p values.
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Figure 74: Reconstructed dose values for the 2013 data set, using start phase φ = 60◦ for
the simulated dose distributions. Above: Simulated data (box plots), recon-
structed data (blue circles); below: Kolmogorov-Smirnov p values.
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a.2.2.2 Experiment: Phase Dependence of the VX-Vorbestrahlung Treatment Plan
The experimental verification of the simulation software was performed in 2013,
after the introduction of the Dynamic Intensity Control (DIC). Based on the
analysis of the irradiation records, a dependence on the starting motion phase φ
is expected in this experiment.
Using the VX-Vorbestrahlung treatment plan, three un-interrupted irradiations
were recorded with a motion starting phase of φ ≈ 60◦. The results of these mea-
surements were compared to simulated dose distributions with starting phases
from φ = 0◦ to 330◦.
In the analysis, only the result for motion starting phase φ = 60◦ was pre-
sented (Fig. 52 on page 92). Here, additional results are shown for phases
φ = 30◦, 60◦ and 90◦ in Figs. 75, 76 and 77. Additionally, a dose calculation
using 12 starting phases (φ = 0◦, 30◦, . . . , 330◦) is presented in Fig 78. In the
figures, the measured doses are represented as red circles, while the simulated
dose values are represented as box plots. The specified p values are calculated
using the Kolmogorov-Smirnov (KS) test.
Out of the data sets, the data set with the simulated motion starting phase
φ = 60◦ shows the highest agreement, also indicated by the highest p values. In
addition, the comparison with the sum of multiple starting phases in Fig 78 has
a lower agreement.
For the relatively short VX-Vorbestrahlung treatment plan, which has an irradi-
ation time of 70 to 100 seconds, the motion starting phase is a crucial property.
In the experimental verification, the phase shift observed in the analysis of irra-
diation records has vanished.
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Figure 75: Measured dose values for the VX-Vorbestrahlung treatment plan, using all
dose distributions with motion starting phase φ ≈ 60◦. Simulated dose dis-
tributions were calculated using motion starting phase φ = 30◦. Above: Sim-
ulated doses (box plots), measured doses (red circles); below: Kolmogorov-
Smirnov p values.
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Figure 76: Measured dose values for the VX-Vorbestrahlung treatment plan, using all
dose distributions with motion starting phase φ ≈ 60◦. Simulated dose dis-
tributions were calculated using motion starting phase φ = 60◦. Above: Sim-
ulated doses (box plots), measured doses (red circles); below: Kolmogorov-
Smirnov p values.
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Figure 77: Measured dose values for the VX-Vorbestrahlung treatment plan, using all
dose distributions with motion starting phase φ ≈ 60◦. Simulated dose dis-
tributions were calculated using motion starting phase φ = 90◦. Above: Sim-
ulated doses (box plots), measured doses (red circles); below: Kolmogorov-
Smirnov p values.
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Figure 78: Measured dose values for the VX-Vorbestrahlung treatment plan, using all
dose distributions with motion starting phase φ ≈ 60◦. Simulated dose dis-
tributions were calculated using multiple motion starting phases φ = 0◦, 30◦,
. . . , 330◦. Above: Simulated doses (box plots), measured doses (red circles);
below: Kolmogorov-Smirnov p values.
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a.2.2.3 Experiment: Phase Dependence of the Patient Treatment Plan
In addition to the relatively short VX-Vorbestrahlung treatment plan with an ir-
radiation time of 70 to 100 seconds, a patient treatment plan used for the treat-
ment of hepatocellular carcinoma was irradiated for the experimental verifica-
tion. This treatment plan has a higher dose per fraction and takes approximately
nine minutes to irradiate.
Three un-interrupted irradiations with a motion starting phase φ ≈ 180◦ were
measured and compared to simulated dose distributions. In the analysis, only
the comparison with a simulated dose distribution with starting phase φ = 180◦
was presented (Fig. 53, page 92). To illustrate the reduced dependence on the
motion starting phase experienced with longer treatment plans, this result is
compared to a calculation using multiple motion phases.
In Fig. 79, the results of the comparison with only the φ = 180◦ motion starting
phase are repeated. The dose calculation has an accuracy of ∆MeanD = (0.045±
0.331) Gy or (1.0± 7.3)%.
In comparison, Fig. 80 shows the results of a dose calculation with multiple
motion starting phases φ = 0◦, 30◦, . . . , 330◦. Here, the dose calculation accu-
racy is ∆MeanD = (0.024± 0.409) Gy or (0.5± 9.0)%. This result shows a larger
deviation of the dose values, but is still acceptable.
With longer treatment plans, small deviations of individual raster point irradi-
ation times will add up. Because significant parts of the patient dose is irradiated
at the end of the treatment, this deviation translates to larger phase deviations,
reducing the dependence on the starting phase.
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Figure 79: Resulting doses for the patient treatment plan for all measurements with a
starting phase of φ ≈ 180◦ and no interlocks (red dots). The simulated doses
(box plot) were calculated with a starting phase of φ = 180◦. Dose calculation
accuracy ∆MeanD = (0.045± 0.331) Gy or (1.0± 7.3)%.
A.2 additional results 141
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
0
1
2
3
4
5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Pinpoint
Ab
so
lu
te
 D
os
e 
[G
y]
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
0.00
0.25
0.50
0.75
1.00
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Pinpoint
p−
Va
lu
e
Figure 80: Resulting doses for the patient treatment plan for all measurements with a
starting phase of φ ≈ 180◦ and no interlocks (red dots). The simulated doses
(box plot) were calculated with a multiple starting phases of φ = 0◦, 30◦, . . . ,
330◦. Dose calculation accuracy ∆MeanD = (0.024± 0.409) Gy or (0.5± 9.0)%.

B
4D T R E AT M E N T P L A N N I N G S T U D Y F O R E S O P H A G E A L
C A N C E R
b.1 detailed results
To improve readability, only the most relevant graphs were included in chapter 5
(page 99. Additional data is presented on the following pages.
In the graphs presented in Fig. 81 to 84, the resulting dose index for the treat-
ment planning CT is presented on the left, the respective results for the qua-
sistatic dose calculation are presented on the right. Fig. 81 presents the indices
associated with PTV coverage (V95%, Conformity Index, Homogeneity Index).
Figs. 82 and 83 present the indices associated with PTV over- and underdosage
(V107%, DMax, DMin, DMedian, DMean) and the mean dose to the heart muscle.
Fig. 84 presents the indices associated with the lung and spinal cord dose (V20%
Lung, DMax Spinal Cord).
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Figure 81: PTV Coverage (V95%, Conformity Index, Homogeneity Index)
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Figure 82: PTV Over- and Underdosage (V107%, DMax, DMin)
146 4d treatment planning study for esophageal cancer
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Figure 83: PTV Over- and Underdosage (Median Dose, Mean Dose), DMean to the Heart
Muscle
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Figure 84: Organs at Risk (V20% Lung, DMax Spinal Dose
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Notre nature est dans le mouvement;
le repos entier est la mort.
— Blaise Pascal
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